



Supplement to

Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

INDEX

To Volume 57

1997

December 15, 1997
Index Issue
Volume 57 • Number 24
PP. 5623-5673
ISSN 0008-5472 • CNREA 8

Notice to Members of the American Association for Cancer Research (AACR)

Officers for 1997-1998

President: Donald S. Coffey, Johns Hopkins University School of Medicine, Baltimore, MD 21287-2101
President-Elect: Webster K. Cavenee, Ludwig Institute for Cancer Research, La Jolla, CA 92093-0660
Treasurer: Bayard D. Clarkson, Memorial Sloan-Kettering Cancer Center, New York, NY 10021
Executive Director: Margaret Foti, AACR, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483

Annual Dues

The annual dues of active members of the AACR are \$175, \$90 of which may be applied to a subscription to *Cancer Research*. Corresponding members of the Association will be charged an appropriate fee to offset postage costs. Payment of dues and changes of address of members of the Association should be sent promptly to: Member Services, AACR, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Telephone: (215) 440-9300; FAX: (215) 440-9313.

Back Issues and Single Copy Sales of the Journal

Copies of back stock of the journal *Cancer Research* may be ordered from AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202 [Telephone: (800) 633-4931 or (205) 995-1567; FAX: (205) 995-1588]. As long as supplies permit, single copies of *Cancer Research* will be sold at \$30 per copy for regular and Supplement issues, plus \$4 shipping for orders outside the U.S. The annual *Proceedings of the American Association for Cancer Research* is available at \$45 per copy, plus \$6 shipping for orders outside the U.S.

Advertisements in *Cancer Research*

Advertisement insertion orders and copy must be received approximately 5 weeks prior to the date of the issue in which the advertisement is to be published. The journal is mailed approximately 5 days preceding the date of issue. Inquiries about advertising should be directed to: M. J. Mrvica Associates, Inc., 2 West Taunton Avenue, Berlin, NJ 08009 [Telephone: (609) 768-9360; FAX: (609) 753-0064].

Historical Cover Themes

Readers are invited to submit themes (events, persons, institutions) for consideration for the illustrated covers of *Cancer Research*. Correspondence regarding suggested cover themes, or other matters regarding covers, should be addressed to the Cover Editor, AACR Publications Department.

Submission of Manuscripts

Manuscripts should be sent to the attention of: Dr. Carlo M. Croce, Editor-in-Chief, AACR Publications Department, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Telephone: (215) 440-9300. If accepted, they will be listed under one of ten categories in the Table of Contents. Please specify in a covering letter which category applies to your submission: biochemistry and biophysics, carcinogenesis, clinical investigations, endocrinology, epidemiology and prevention, experimental therapeutics, immunology, molecular biology and genetics, tumor biology, and virology. (Final categorization in the Table of Contents is at the discretion of the Editor-in-Chief.) Consult the "Instructions for Authors" printed in the January 1 issue of the journal for other submission requirements. Reprints of the "Instructions" are available upon request.

Manuscript Processing Fee

Journal policy requires that a manuscript processing fee of \$75 be assessed for each paper to defray the expenses incurred in the editorial review process. Each manuscript submitted for publication should be accompanied by a check (drawn on a U.S. bank) for \$75 in U.S. currency, payable to AACR, Inc., or credit card information (VISA, Mastercard, or American Express) should be supplied. Note: If an author resubmits a manuscript that our Editors previously found unacceptable for publication, it is journal policy to consider it a new submission, assign it a new manuscript number, and charge the author another \$75 handling fee to cover the cost of review.

Page Charges

Accepted manuscripts will be published with the understanding that the author(s) will pay a charge of \$75 per printed page. Under exceptional circumstances, when no source of grant or other support exists, the author(s) may apply to Dr. Carlo M. Croce, Editor-in-Chief, at the time of submission, for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

Copyright and Copyright Clearance Center

The Copyright Revision Act (PL 94-553), which became effective January 1, 1978, states that the copyright of a work is vested in the author from the moment of creation. Therefore, all authors who wish to publish in *Cancer Research* must formally transfer copyright to the proprietor of the journal, AACR, Inc. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation, distribution, sale, and display.

Authors who prepared their articles as part of their official duties as employees of the U. S. Federal Government are not required to transfer copyright to the American Association for Cancer Research, Inc., since these articles are considered to be in the public domain. However, it is necessary for these authors to sign the appropriate section of the transfer form. In the case of articles supported by federal grants or contracts, copyright transfer to AACR, Inc., is required. The federal government may retain a nonexclusive license to publish or republish such material.

Copies of articles for which AACR, Inc. owns the copyright may be made for personal or internal use, provided that the copier pay the per-copy fee of \$4 through the Copyright Clearance Center, Inc. This Center is a nonprofit organization through which individuals and institutions may reimburse a copyright owner for photocopying journal articles beyond what is defined as "fair use" in Sections 107 and 108 of the Copyright Revision Act of 1978. Those who wish to photocopy *Cancer Research* articles may report the number of copies they have made, together with the fee code 0008-5472/97 \$04.00, to: Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923; (508) 750-8400. Remittances may be sent to the Center at the time of reporting or the Center will bill the user on a monthly basis. Deposit accounts and prepayment plans may also be arranged.

Between June 1978 and August 1983, a fee code appeared on the first page of all articles for which *Cancer Research* owned the copyright. For those issues, it is understood that any articles which did not carry this code are in the public domain.

Cancer Research is abstracted or indexed in *Biological Abstracts*, *Chemical Abstracts*, *Index Medicus*, *MEDLINE*, *Current Contents*, and *Reference Update*. This journal is printed on acid-free paper.

No responsibility is accepted by the Editors, by AACR, Inc., or by Cadmus Journal Services for the opinions expressed by contributors or for the content of the advertisements.

Cancer Research (ISSN 0008-5472) is published twice a month by the American Association for Cancer Research, Inc., Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483 for \$90 annually for members and \$460 for individual nonmembers. *Cancer Research* is only available to institutions as a combined subscription with *Clinical Cancer Research*. The combined 1997 institutional subscription price of \$685 includes a subscription to *Clinical Cancer Research*. Periodicals postage paid at Philadelphia, PA and additional mailing offices. POSTMASTER: Send address changes to AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202. Copyright 1997 by the American Association for Cancer Research, Inc. Printed in the U.S.A.



Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

American Association for Cancer Research, Inc.

Publications Staff Managing Editor

Margaret Foti
Assistant Managing Editor
Mary Anne Mennite
Manager, Editorial Services
Heide M. Pusztay
Staff Editors
Michael J. Beveridge
Kathleen C. Assenmacher
Pamela R. Arnold
Laurie B. Baker
Ronald M. Vitale

Staff Assistant
Mary Ellen Pirring
Administrative Coordinator
Holly M. Haskins

Senior Editorial Assistant
Theresa A. Griffith

Editorial Assistants
Valerie L. Samuel
Andrea Conrad
Cecilia Gallo

Marketing Coordinator
Robert B. O'Malley

Administrative Staff
Executive Director
Margaret Foti

Director of Administration
Adam D. Blistein

Controller
Joan D. Ritchie

Coordinator, Financial
Operations

George L. Moore
Manager, Meetings and Exhibits

Jeffrey M. Ruben

Meeting Planner
Carole L. Kanoff

Public Information Coordinator
Jenny Anne Horst-Martz

Assistant to the Executive
Director

Ruth E. Fortson
Membership Development

Coordinator
Robin E. Felder

Administrative Assistant
Margaret A. Pickels

Systems Specialist
Lydia I. Rodriguez

Secretary
Malika L. Wright

Editorial Assistant
Diana F. Certo

Office Clerk
James J. Waters

Data Entry Clerk
Robert A. Simms II

Editor-in-Chief

Carlo M. Croce

Associate Editors

Stuart A. Aaronson
David S. Alberts
Carmen J. Allegra
Frederick R. Appelbaum
Leonard H. Augenlicht
Silvia Bacchetti
William M. Baird
Allan Balmain
J. Carl Barrett
Renato Baserga
Stephen B. Baylin
William T. Beck
Nathan A. Berger
Joseph R. Bertino
Diane F. Birt
Mina J. Bissell
Clara D. Bloomfield
Ronald H. Blum
Gianni Bonadonna
Rodrigo Bravo
Edward Bresnick
Garrett M. Brodeur
Paul A. Bunn, Jr.
C. Patrick Burns
Fernando Cabanillas
Bruno Calabretta
Eli Canaani
Robert L. Capizzi
Webster K. Cavenee
Ann F. Chambers
Bruce D. Cheson
David Colcher
Robert L. Comis
Allan H. Conney
Neal G. Copeland
Pelayo Correa
Suzanne Cory
William M. Crist
Riccardo Dalla-Favera
Mary B. Daly

Nancy E. Davidson
Benoit de Crombrughe
Albert B. Deisseroth
Luigi M. DeLuca
Eugene R. DeSombre
Vincent T. DeVita, Jr.
T. Michael Dexter
Ralph E. Durand
Alan Eastman
Merrill J. Egorin
Gertrude B. Eliot
Leonard C. Erickson
Nelson Fausto
Eric R. Fearon
Andrew P. Feinberg
Olivera J. Finn
Robert A. Floyd
Antonio T. Fojo
Judah Folkman
Kenneth A. Foon
Albert J. Fornace, Jr.
Joseph F. Fraumeni, Jr.
Stephen H. Friend
Zvi Y. Fuks
Minoru Fukuda
Philip Furmanski
Eugene W. Gerner
Eli Glatstein
David W. Golde
Joe W. Gray
J. W. Grisham
Lorraine J. Gudas
F. Peter Guengerich
Sen-itiro Hakomori
Stanley R. Hamilton
Curtis C. Harris
Stephen S. Hecht
Carl-Henrik Heldin
Ingegard Hellström
Brian E. Henderson

Richard B. Hochberg
Wu Ki Hong
Tasuku Honjo
H. Robert Horvitz
Janet A. Houghton
Kay Huebner
Mark A. Israel
Elaine S. Jaffe
Rakesh K. Jain
Peter A. Jones
V. Craig Jordan
Fred F. Kadlubar
Michael B. Kastan
John H. Kersey
Young S. Kim
Kenneth W. Kinzler
Hynda K. Kleinman
Alfred G. Knudson, Jr.
Richard D. Kolodner
Laurence N. Kolonel
Peter H. Krammer
David P. Lane
Edmund C. Lattime
John S. Lazo
Victor A. Levin
Jay A. Levy
Victor Ling
Lance A. Liotta
Martin Lipkin
Marc E. Lippman
Gerald Litwack
Leroy F. Liu
David M. Livingston
Lawrence A. Loeb
Dan L. Longo
Reuben Lotan
David B. Ludlum
Lynn M. Matrisian
W. Gillies McKenna
Beatrice Mintz

James B. Mitchell
Malcolm S. Mitchell
Ruth J. Muschel
Yusuke Nakamura
Susan L. Naylor
Kenneth Nilsson
Susumu Nishimura
Jeffrey A. Norton
Kenneth Olden
Allen I. Oliff
Richard J. O'Reilly
Robert F. Ozols
Michael A. Palladino, Jr.
Luis F. Parada
Drew M. Pardoll
Anthony E. Pegg
Pier Giuseppe Pelicci
Angel Pellicer
Bice Perussia
Lester J. Peters
Gordon L. Phillips
Cecil B. Pickett
Jacalyn H. Pierce
Jennifer A. Pietsenpol
Yves G. Pommier
Bruce A. J. Ponder
Theresa P. Pretlow
Vito Quaranta
Frank J. Rauscher III
John C. Reed
Richard A. Rifkin
Leslie L. Robison
Igor B. Roninson
Eric K. Rowinsky
Howard I. Scher
Robert T. Schimke
J. Schlessinger
Manfred Schwab
Jerry W. Shay
David Sidransky

Joseph V. Simone
Francis M. Sirotnak
Anna Marie Skalka
Michael B. Sporn
Martha R. Stampfer
Eric J. Stanbridge
Patricia S. Steeg
Glenn Steele, Jr.
Gary S. Stein
Gary D. Stoner
Takashi Sugimura
Saraswati Sukumar
Paul Talalay
Tadatsugu Taniguchi
Steven R. Tannenbaum
Masaaki Terada
Kenneth D. Tew
Donald J. Tindall
Thea D. Tlsty
Jeffrey M. Trent
Giorgio Trinchieri
Takashi Tsuruo
Axel Ullrich
George F. Vande Woude
Peter W. Vaupel
Giancarlo Vecchio
Peter K. Vogt
Daniel D. Von Hoff
Cheryl Walker
Michael D. Waterfield
Lee W. Wattenberg
Ralph R. Weichselbaum
Bengt Westermark
Raymond L. White
Alice S. Whittemore
Max S. Wicha
Wendell Wierenga
Roger Wiseman
Sheldon Wolff
Harald zur Hausen

Cover Editorial Board

Sidney Weinhouse,
Cover Editor

Hugh J. Creech
Clark W. Heath, Jr.

Edwin A. Mirand
Raymond W. Ruddon

Takashi Sugimura
John H. Weisburger

Cancer Research is sponsored by the American Association for Cancer Research, Inc. Publication costs are also met by a grant from the Elsa U. Pardee Foundation. Accelerated mailing of all AACR journals to AACR members in Japan is supported by a generous grant from the Banyu Pharmaceutical Company, Tsukuba, Japan.

Subscription Information

Cancer Research is published twice a month, one volume per year, by the American Association for Cancer Research (AACR), Inc. Subscriptions include the *Proceedings of the American Association for Cancer Research*, issued in March of each year. Except for members of the AACR, all subscriptions are payable in advance to AACR, Subscription Office, P.O. Box 11806, Birmingham, AL 35202 [Telephone: (800) 633-4931 or (205) 995-1567; FAX: (205) 995-1588], to which all business communications, remittances (in United States currency or its equivalent), and subscription orders should be sent. In Japan, send orders and inquiries to (sole agent): USACO Corporation, Tsutsumi Bldg., 13-12, Shimabashi 1-chome, Minato-ku, Tokyo 105, Japan; Tel. (03) 502-6471. Individuals who are not AACR members may subscribe to Volume 57 (1997) of *Cancer Research* at the rate of \$460 U.S./\$550 foreign. *Cancer Research* is only available to institutions as a combined subscription with *Clinical Cancer Research*. The combined 1997 institutional subscription price of \$685 U.S./\$815 foreign includes \$170 U.S./\$210 foreign for a subscription to *Clinical Cancer Research*. (Foreign subscription cost includes cost of surface mail. For faster delivery, expedited mailing rates are available by contacting the AACR Publications Department.) Canadian subscribers should add 7% GST. Changes of address notification should be sent 60 days in advance and include both old and new addresses. Member subscribers should send address changes to: AACR Member Services, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Nonmember subscribers should send changes of address to: AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202. Copies of the journal which are undeliverable because of address changes will be destroyed.



Cancer Research

VOLUME 57 • NUMBER 24 • INDEX ISSUE • CNREA 8 • PP. 5623-5673

CONTENTS

INDEX TO VOLUME 57

- 5623 Author Index
- 5641 Subject Index
- i Contents of Volume 57
- xvii Cover Illustrations for Volume 57

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Officers

President, Donald S. Coffey
President-Elect, Webster K. Cavenee
Treasurer, Bayard D. Clarkson
Past President, Louise C. Strong
Executive Director, Margaret Foti

Board of Directors

Until 1998
Clara Derber Bloomfield
Michael M. Gottesman
Ann R. Kennedy
Frederick P. Li

Until 1999
Susan P. C. Cole
Eric R. Fearon
Stephen H. Friend
Waun Ki Hong

Until 2000
William T. Beck
O. Michael Colvin
Lynn M. Matrisian
Joseph V. Simone

AUTHOR INDEX*

Volume 57

A

Aalders, M., 4811
Aaltonen, L. A., 5017
Abbruzzese, J. L., 3929, 4309
Abdo, M., 3798
Abdollahi, A., 2029
Abe, M., 1335, 3168
Abe, R., 3920
Abe, T., 1851
Abedi, M. R., 1523
Abken, H., 1704
Aboagye, E. O., 3314
Abolhoda, A., 152
Abraham, J. M., 2350, 2543
Abrahams, P. J., 4384
Abul-Hajj, Y. J., 2341
Aburatani, H., 2151
Acharya, S., 206
Adair, G. M., 4048
Adam, L., 1023
Adami, F., 4940
Adams, D. M., 4333
Adler, G., 3135
Adlercreutz, H., 2916
Advani, S., 4340
Aebi, S., 1841, 3253
Agadir, A., 3444
Agani, F., 4474, 5328
Agarwal, R., 415
Agarwal, S., 1039, 1855
Agarwal, S. K., 4682, 5446
Agell, N., 55
Aggarwal, B. B., 3084
Aghajanian, C., 5426
Agnarsson, B. A., 1222
Agostini, C., 4940
Aguzzi, A., 4889
Ahmad, I., 1915
Ahmad, M., 615
Ahmadian, M., 2256, 3154, 3664
Ahmed, M. M., 5360
Ahnen, D. J., 267, 2452, 2909
Ahrendt, S., 5356
Ahrendt, S. A., 2888
Ahrenkiel, V., 3660
Ahrent, S., 1
Ahuja, N., 3370
Aizawa, S., 646
Akahani, S., 5272
Akai, H., 1281
Akama, T. O., 3294
Akanni, A. O., 2341
Akasaka, H., 7
Akasaka, T., 7
Akinaga, S., 1495
Akiyama, M., 94
Akiyama, N., 3548
Akiyama, S.-I., 5475
Akiyama, T., 1495
Akiyama, Y., 3920, 5243
Akiyoshi, T., 28, 1335, 4465
Aklilu, F., 4517
Akman, S. A., 2394
Aktas, E., 2916
Albelda, S. M., 466
Albert, I., 4624
Alberta, J. A., 4141
Albertini, R. J., 1188
Alberts, D. S., 2909
Albin, N., 1660

Albores-Saavedra, J., 5360
Albrecht, S., 2085
Albright, K. D., 2657
Aldape, K. D., 3635
Alderete, B., 842
Alderete, B. E., 5254
Aldrian, C., 1776
Alexander, D. L., 4498
Alexander, N., 3180
Alfieri, A. A., 3956
Ali-Osman, F., 2933
Allam, M., 2615
Allegretto, E. A., 2642
Alley, M. C., 3895
Allgayer, H., 1394
Allione, F., 5469
Allouche, M., 686
Allred, D. C., 5505
Al-Nabulsi, I., 156
Alnemri, E. S., 43, 615
Altman, N. H., 900
Alvarez, S., 4091
Amaya, H., 1043
Ambros, R. A., 2760
Amin, K. M., 466
Amino, N., 3792
Amorosi, A., 4523
Amoroso, B., 1066
Amos, C. I., 1859, 3653
Anachkova, B. B., 2252
Anaraki, F., 332
Andersen, T. I., 2474
Anderson, B. W., 87
Anderson, C. J., 659
Anderson, E., 4987
Anderson, G., 3798
Anderson, J. P., 3653
Anderson, M., 1344
Anderson, M. W., 1
Andersson, L. C., 3016
Andis, S. L., 1116
Andoh, N., 1281
Andreansky, S., 1502
Andreola, F., 2835
Andres-Barquin, P. J., 215
Andreutti-Zaugg, C., 3288
Andrew, S. E., 5143
Andrews, L. E., 1137
Angeletti, C. A., 2121
Angers, E. G., 4803
Anholt, H., 1481
Anichini, A., 5534
Annessi, G., 747
Aoki, K., 5022
Appella, E., 4348
Appleton, S., 3697
Arap, W., 1250
Arbeit, J., 1294
Arber, N., 1569
Archer, G. E., 1510
Archer, M. C., 3685
Arlett, C. F., 4600
Arnold, L., 4838
Arranz, E., 4217
Arrigo, A.-P., 2661
Arteaga, C. L., 970
Arthur, J. R., 4257
Artigas, C., 1098
Aruga, A., 3230
Aruga, E., 3230
Arús, C., 407

Arver, B. W., 2474
Arwert, F., 2244
Asa, S. L., 5446
Asada, M., 1073, 1895
Asai, N., 2870
Asano, M., 2151
Asano, Y., 3395
Asculai, S., 1625
Ashar, H. R., 2276
Ashmore, S. M., 4196
Ashworth, A., 5485
Askenazy, N., 1452
Asou, H., 4545
Attardo, G., 4803
Aubrecht, J., 4378
Augenlicht, L. H., 1769
Augustus, M., 4455
Aurelio, O. N., 2827
Aust, G., 1798
Autzen, P., 4427
Auvinen, M., 3016
Avruch, J., 4177
Avrutskaya, A. V., 3784
Awazu, S., 5305

B

Baas, F., 3537
Babic, R., 1394
Bachman, N. J., 38
Bachmann, F., 988
Bachs, O., 55
Backway, K. L., 2446
Bacus, S. S., 5217
Bader, S. A., 2256
Badie, C., 4600
Bae, D. G., 3733
Bae, I., 4285
Baens, M., 564
Baffa, R., 504, 3010
Bagnall, K., 5564
Bagnato, A., 1306
Baguley, B. C., 284, 2172
Baird, A., 1447
Baird, W. M., 415
Baker, A., 5162
Baker, S. M., 5143
Bakker, A., 2485
Baldi, A., 3381
Baldi, F., 3381
Bali, D., 3653
Baliva, G., 747
Ballal, K., 3407
Ballato, G., 2341
Ballesteros, M. F., 234
Balmas, K., 1387
Balsara, B. R., 2116
Banáth, J. P., 5528
Band, V., 5584
Bande, C. I., 3532
Bander, N. H., 2362, 3629
Bandera, C. A., 513
Bang, Y.-J., 2856
Baniyash, M., 2434
Bankert, R. B., 2937
Banni, S., 5067
Bänziger, R., 988
Barba, I., 407
Barbacci, E. G., 4838
Barbanti-Brodano, G., 4153, 4493
Barbin, A., 375, 1695
Barcos, M., 678
Bard, J.-J., 1364
Bardi, A., 1144
Bare, J. W., 2369
Bar-Eli, M., 2295
Barendsward, E., 2181
Barkardottir, R. B., 1222
Barleon, B., 5421
Barletta, J. M., 48
Baron, P. L., 2961
Barrett, J. C., 537, 2687, 2986, 3949, 4667, 4736
Barrett, M. T., 2619
Barrington, R. E., 600
Barrios, R. J., 4687
Barroso, A., 4217
Bartel, P., 4177
Barth, R. F., 1129, 4333
Barth, R. J., Jr., 2569
Bartholomew, J. S., 937
Bartke, I., 3149
Barzaga, E., 4570
Barzan, L., 2366
Baserga, R., 3079, 3264
Baskaran, R., 3253
Basset, P., 5226
Bassilian, S., 4242
Basso, U., 4940
Basu, A., 229
Basu, S., 943
Bates, A. S., 2703
Batova, A., 832
Battey, J. F., 290
Baulida, J., 240
Baumgard, M., 4177
Baust, C., 1460
Bavelloni, A., 2137
Bawa, S., 2715
Baylin, S. B., 837, 1678, 3126, 3370
Beard, S. E., 1575
Beardsley, G. P., 1116
Beauchamp, R. D., 169, 1638
Beauchemin, N., 2781
Bechich, M. J., 3830
Beck, L. A., 1537
Beck, W. T., 5004
Becker, K., 3335
Becker, W., 5309
Beckett, M. A., 1270, 4340
Bedi, A., 2550
Bednarski, K., 4803
Bedossa, P., 516, 1986
Beer, D. G., 5571
Beerli, R. R., 3804
Beesley, J. S., 850
Beger, H. G., 1634
Behbakht, K., 513
Behm, F. G., 4042
Behr, T. M., 5309
Behrens, C., 3154, 3664
Bekesi, J. G., 4795
Belanger, A., 3494
Belch, A. R., 930
Belfi, C. A., 5112
Bell, D. A., 5493
Bell, D. W., 4057
Bell, R., 4177
Bell, R. H., Jr., 1475
Bellacosa, A., 5480
Bellantone, R., 5406

* For title of article and coauthors, see listing in Contents of Volume 57 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 57

- Beldegrun, A., 5189
 Beldegrun, A. S., 495
 Bellemann, M. E., 3415
 Bellet, D., 516
 Belleudi, F., 5498
 Belli, F., 5534
 Bellnier, D. A., 4000
 Bellone, M., 2564
 Belpoggi, F., 1695
 Ben-Bassat, H., 3741
 Benchimol, S., 3765
 Bender, C. M., 5336
 Bendik, I., 3669
 Benedict, M., 4956
 Benedict, W. F., 1217
 Benítez, J., 4217
 Benito, A., 1320
 Benjamin, I., 513
 Bennett, C. B., 1970
 Bennett, E. P., 4744
 Bennett, L. M., 3121
 Bennett, S. E., 2956
 Bennett, W. P., 426, 1435
 Benson, A., 1769
 Bentley, S. A., 1547
 Bentz, M., 4608
 Ben-Yehuda, D., 2434, 5610
 Benz, C. C., 3723
 Beraldi, E., 1584
 Berberich, S. J., 5013
 Berchuck, A., 4736
 Berean, K., 5258
 Berg, K., 1481
 Berg, R. J. W., 581, 1238
 Berger, J., 4158
 Berger, M. S., 1250, 3526
 Berger, N. A., 1425, 2157, 5112
 Berger, S. J., 5112
 Berger, S. L., 3693
 Bergeron, R. J., 5521
 Berggren, M., 4965
 Berkowitz, R. S., 387
 Bermingham-McDonogh, O., 3526
 Bermudes, D., 4537
 Bernacki, R. J., 5521
 Bernstein, L., 3678
 Berry, S., 4177
 Berry, T. D., 75
 Berson, A., 5221
 Bertagnoli, M. M., 5045
 Berthelemy, M., 3360
 Berthold, F., 2085
 Bertin, N., 396
 Bertino, J. R., 2193
 Bertness, V., 4408
 Bertolette, D. C., III, 881
 Bertrand, R., 2615
 Bertwistle, D., 5485
 Bessho, F., 3772
 Bettaieb, A., 5300
 Bevilacqua, G., 2121
 Bewley, J. R., 1116
 Bezabeh, T., 3398
 Bhalla, K., 1109, 3115
 Bhatia, K. G., 2508
 Bhattacharya-Chatterjee, M., 728
 Bianco, A. R., 5107
 Bianco, R., 5107
 Bibeau, L., 4803
 Bible, K. C., 3375
 Bicknell, J. E., 2703
 Bicknell, R., 136, 570, 963, 1814, 5281
 Bidart, J.-M., 516
 Biden, K., 2350
 Bièche, I., 516
 Biel, M. A., 1678
 Biemann, J. A., 537
 Biesterveld, E. J., 2256
 Bigner, D. D., 1510, 2933, 4130, 4187
 Bigner, S. H., 2933, 4187
 Bigoni, R., 1144
 Bigsby, R. M., 865
 Bilbe, G., 5386
 Bilinski, R. T., 5045
 Billadeau, D., 2268
 Billaud, M., 391
 Billi, A. M., 2137
 Binasci, M., 1710
 Binderup, L., 4091
 Biondi, A., 2879
 Bioulac-Sage, P., 1986
 Birch, J. M., 3245
 Birchenall-Roberts, M. C., 881, 2668
 Birck, A., 3660
 Birnbaum, D., 5469
 Birrer, M. J., 2112, 3046
 Bischoff, E. D., 162
 Bishop, G. A., 1758, 3941
 Bitto, T., 370
 Bjerknes, M., 355
 Bjørge, T., 3989
 Björkstrand, B., 1523
 Black, K., 4098
 Black, P. M., 4141
 Blagosklonny, M. V., 130, 320
 Blair, A., 3728
 Blair, S. L., 152
 Blamble, D. A., 234
 Blanco, G., 5517
 Blank, E. W., 1103
 Blank, K., 753
 Blankenstein, R. A., 2109
 Blask, D. E., 1909
 Blay, J., 2602
 Blazes, M. S., 3935
 Blöchl-Daum, B., 2598
 Block, N. L., 773, 778
 Blok, L. J., 4075
 Bluestone, J., 4036
 Bluethmann, H., 94
 Blum, J., 3664
 Blumenstein, B. A., 1194
 Blumenthal, R. D., 5309
 Bocker, T., 4739, 4749
 Bockmühl, U., 5213
 Bodmer, W. F., 5017
 Boehm, M. F., 162
 Boeters, L., 3812
 Bogert, C., 2909
 Bogomolny, F., 3657
 Bohlen, H., 1704
 Boige, V., 1986
 Boiocchi, M., 2366
 Boissier, S., 3890
 Boivin, S., 1695
 Boland, C. R., 3949
 Bolen, J. B., 5221
 Bollag, W., 1460
 Bolodeoku, J., 3140
 Boman, B., 4838
 Bonacum, J., 5356
 Bonder, C. S., 476
 Bondy, M. L., 1673
 Bonfanti, M., 1442
 Bongcam-Rudloff, E., 5598
 Bookstein, R., 5221
 Boolbol, S. K., 5045
 Boothman, D. A., 206, 5557
 Borg, A., 1222, 1244, 2474
 Borgen, P. L., 3657
 Borkowski, A., 426
 Borner, C., 1405
 Bornet, F., 225
 Boros, L. G., 4242
 Borst, P., 3537
 Bortolin, M., 4940
 Borysiewicz, L. K., 2943, 4855
 Bosch, F. X., 4692
 Bosco, M. C., 2468
 Bose, S., 3935
 Bosserhoff, A.-K., 3149
 Bosslet, K., 2440
 Bostwick, D. G., 524, 3532
 Böttinger, E. P., 5564
 Bouayadi, K., 110
 Bourgeois, S., 720
 Bova, G. S., 35, 2350, 4455, 4707, 4997
 Bove, K. E., 1690
 Bowden, E. T., 5028
 Bowler, W. B., 5386
 Bowlin, T. L., 4803
 Boyadjiev, S. A., 1188
 Boyce, B. F., 3194
 Boyd, J., 513, 3657
 Boyett, J. M., 4042
 Boyle, C. C., 2404
 Boyle, J. M., 4153
 Boysen, B., 3486
 Bozik, M. E., 304
 Brabant, G., 2501
 Bradburn, M., 5281
 Bradbury, E. M., 1151
 Bradley, A., 5143
 Bradley, G., 3708
 Brady, F., 2172
 Brailly, S., 857
 Branda, M. T., 3517
 Branda, R. F., 2586
 Brandes, J. L., 4242
 Branham, W. S., 1903
 Branston, N. M., 4196
 Braslawsky, G. R., 100
 Brass, N., 2290
 Braun, S., 3511
 Bravo, J., 3728
 Brecher, M. E., 1547
 Bregni, M., 5534
 Breier, G., 3852, 3860
 Breit, S., 2916
 Brendel, K., 2909
 Brenner, W., 5009
 Brent, T. P., 3672
 Briand, P., 585
 Briebl, M. M., 5162
 Brien, T. P., 2760
 Bright, R. K., 995
 Brilliant, M. H., 5226
 Brinkmann, A. O., 4075
 Brinkschmidt, C., 481
 Bristow, R. G., 3765
 Brix, G., 3415, 4777
 Brogini, M., 870, 1442
 Brognara, C. B., 1387
 Bronner, C. E., 5143
 Bronson, D., 209
 Brooks, J. D., 35
 Brown, C. C., 2843
 Brown, G., 2172
 Brown, J., 100
 Brown, J. M., 672, 2313, 2922, 4703
 Brown, J. R., 1625
 Brown, P. H., 3046, 4652
 Brown, S. M., 466
 Brownlee, H. A., 3121
 Broxmeyer, H. E., 3511
 Bruce, J. N., 4183
 Bruce, K., 2336
 Bruchovsky, N., 1584
 Brüggemann, S. K., 2676
 Bruner, J. M., 1673
 Brünner, N., 3486
 Brunner, T., 1007
 Bruns, C., 956
 Buchegger, F., 447, 1312
 Büchler, M., 3135
 Buchsbaum, D. J., 4325
 Buckman, R., 2388
 Budman, D. R., 714
 Buettner, R., 3149
 Bugni, J. M., 590
 Bühring, H.-J., 696
 Bui, L. A., 2865
 Bujard, M., 2331
 Buller, R. E., 1047
 Bullinger, L., 4608
 Bultrich, F., 1144
 Burchell, B., 284
 Burczak, J., 2378
 Bureaud, N., 4249
 Burg, G., 5073
 Burgaud, J.-L., 3079
 Burger, M. M., 988
 Burgman, P., 2847
 Burke, L. M., 1435
 Burke, M. D., 3026
 Burlingame, A. L., 1137
 Burns, A. L., 1039, 1855, 4682, 5446
 Burt, D. J., 937
 Burt, M., 152
 Burt, R. W., 2909
 Buscail, L., 956
 Buschfort, C., 651
 Butterfield, L. H., 2865
 Buttitta, F., 2121
 Buttyan, R., 2362
 Bye, S., 1188
 Byrd, L. L., 68

C

- Caan, B., 75
 Cady, B., 1259
 Caffrey, T., 4744
 Caffrey, T. C., 1206
 Cai, Y., 2522
 Cairns, P., 2888, 4183, 4997, 5356
 Cajander, J., 549
 Cajot, J.-F., 2593
 Calabretta, B., 1180
 Calberg-Bacq, C.-M., 5590
 Calcagnile, A. S., 747
 Callery, P. S., 234
 Calmels, S., 3365
 Calsou, P., 4600
 Calzolari, A., 4523
 Cama, A., 4523
 Camalier, R. F., 3895
 Campagnoni, A. T., 4098
 Campaign, J. A., 1447
 Campbell, J. W., 304
 Campbell, M. J., 4545

* For title of article and coauthors, see listing in Contents of Volume 57 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 57

- Campleman, S., 2839
 Canaani, E., 2879
 Cannistra, S. A., 1228
 Cao, C-X., 4029
 Cao, Y-a., 5584
 Capereil-Grant, A., 865
 Capranico, G., 1710
 Capron, F., 1986
 Caputi, M., 3381
 Carbone, A., 5406
 Carbone, R., 799, 5498
 Cardi, G., 3517
 Carducci, M. A., 1537
 Carey, L. A., 5605
 Carey, T., 3055
 Carey, T. E., 38, 824
 Carlberg, M., 543
 Carlomagno, F., 391
 Carlson, P., 2203
 Caron, S., 5017
 Carothers, A. M., 440
 Carpenter, G., 240
 Carpten, J. D., 4707
 Carrasquillo, J. A., 1955, 2754
 Carroll, R. S., 4141
 Carroll, W., 3055
 Carson, D. D., 5148
 Carstens, C-P., 5117
 Carter, C. A., 3895
 Carter, D., 3079
 Carter, K. C., 4455
 Caruso, L., 3693
 Casazza, A. M., 100
 Cascante, M., 4242
 Casero, R. A., Jr., 199
 Casorati, G., 1922
 Cassel, S. L., 3562
 Castedo, M., 62
 Castellano, M., 4868
 Castoldi, G., 1144
 Catt, K. J., 1306
 Cavazzini, P., 1144
 Cavenee, W. K., 1250, 4082, 4171
 Cazaux, C., 110
 Cebrián, M., 3728
 Celis, E., 4348, 4465
 Celis, J. E., 4111
 Cenni, B., 3253
 Ceriani, R. L., 1103
 Cerottini, J-C., 735
 Cerutti, A., 4940
 Chada, K. K., 2276
 Chadburn, A., 5045
 Chae, C-B., 3733
 Chakraborty, M., 728
 Chamness, G. C., 5505
 Champ, M., 225
 Chan, B. M. C., 3812
 Chan, H. S. L., 2325
 Chan, L. C., 117
 Chandraratna, R. A. S., 2642, 4931
 Chandrasekharappa, S. C., 1039, 1855, 2238, 4682, 5446
 Chang, A. E., 3230
 Chang, G. T. G., 4075
 Chang, J., 2856
 Chang, J-S., 5465
 Chang, K-S., 1868
 Chang, L., 1020
 Chang, M. Y., 466
 Chang, S-L., 2341
 Chang, T. K. H., 1946
 Chang, Y., 3520
 Chao, T-S. O., 3168
 Chapeaurouge, A., 1137
 Chaplin, D. J., 948, 1829, 5261
 Chapman, J. M., 2961
 Chapman, V. M., 1250
 Charlesworth, M. C., 2651
 Charnaux, N., 857
 Charytonowicz, E., 1217
 Chastre, E., 1776
 Chatterjee, S., 5112
 Chatterjee, S. K., 728
 Chau, M. S., 5168
 Chauffert, B., 2661
 Chehab, N. H., 3693
 Chella, A., 2121
 Chen, A. C., 4642
 Chen, A. Y., 1529, 2865
 Chen, C-F., 4225
 Chen, C-J., 3471
 Chen, D. J., 2847
 Chen, F-A., 2937
 Chen, H., 3154, 4593
 Chen, J., 2474
 Chen, K., 3511
 Chen, L., 4830
 Chen, L-C., 2369
 Chen, M-W., 2362
 Chen, P-L., 4225
 Chen, S. J., 117
 Chen, S-F., 279
 Chen, T., 3772
 Chen, V. J., 1116
 Chen, X., 1889
 Chen, Y., 4225
 Chen, Z., 1614
 Chen, Z-q., 2013
 Chenevix-Trench, G., 2085
 Cheng, C., 3180
 Cheng, H., 152, 355
 Cheng, L., 1673
 Cheng, W., 5179
 Cheng, X., 5258
 Chengang, J., 937
 Cherman, L., 4098
 Cherney, B. W., 2508
 Chhajlani, V., 4348
 Chi, D. D. J., 1371
 Chiang, C-S., 3899
 Chiantore, M. V., 2835, 4460
 Chiao, C., 2986
 Chiao, P. J., 3929
 Chiappetta, C., 2547
 Chien, J. Y., 5509
 Childers, S. R., 156
 Chin, D., 5217
 Chisari, F. V., 3606
 Chishima, T., 2042
 Chisholm, V., 4593
 Chiu, C-H., 4267
 Chmura, S. J., 1270, 4340
 Cho, K. R., 3935, 4692
 Choi, S. H., 3772
 Choi, Y., 678
 Chopra, D. P., 3688
 Chou, J., 1502
 Choudhuri, R., 1814
 Chow, S., 2446
 Christen, R. D., 1841, 2657, 3253
 Christenson, B., 1523
 Christians, F. C., 2007
 Chu, G., 68
 Chu, X-Y., 1934
 Chung, L. W. K., 1868
 Ciardiello, F., 5107
 Cimino, G., 2879
 Cimoli, F., 4523
 Cimpola, A., 4803
 Cirafici, A. M., 391
 Civin, C. I., 837
 Clapper, M. L., 2749
 Clark, G. M., 5505
 Clark, S. J., 2229
 Clarke, J., 2884
 Clarke, R., 3486
 Clarke, R. B., 4987
 Clarkin, K. C., 1171
 Claro, A., 2474
 Clausen, H., 634, 4744
 Clauser, K. R., 1137
 Clayman, G., 4722
 Clayton, R. N., 2703
 Cleutjens, K., 314
 Clezardin, P., 396, 3890
 Clifford, C. K., 3979
 Clift, S. M., 1537
 Clipson, L., 812
 Cnaan, A., 4578
 Coates, A., 75
 Coates, M. M., 2007
 Cocco, L., 2137
 Cochran, C., 2710
 Coetzee, G. A., 1063
 Coffey, R. J., Jr., 3180
 Coffing, S. L., 415
 Cogen, P. H., 2369
 Cohen, A. M., 2181
 Cohen, L. K., 1537
 Cohen, M. B., 1758, 3941
 Cohen-Jonathan, E., 1364
 Colburn, N. H., 3569
 Cole, D. J., 5320
 Cole, S. P. C., 2325, 4451
 Coleman, A. E., 4585
 Coleman, W. B., 1807
 Collector, M. I., 837
 Colletta, G., 2071
 Collins, F. S., 1039, 1855, 2238, 4682, 4707, 5446
 Collins, N. K., 3121
 Collins, V. P., 2611
 Columbano, A., 795
 Colville-Nash, P. R., 1625
 Colvin, O. M., 2933
 Comstock, G. W., 5493
 Condon, P. J., 532
 Conlon, W., 3798
 Conn, M., 3594
 Conney, A. H., 2419, 2623
 Connolly, D. C., 4692
 Conrad, A. J., 1371
 Conway, K., 1157
 Cooley, J. M., 5521
 Corcoran, J., 5557
 Cordon-Cardo, C., 1217, 2789
 Cornelissen-Steijger, P. D. M., 4384
 Corner, G., 1769
 Cornetta, K., 3511
 Corona, R., 747
 Corti, A., 1922
 Cosgrove, J. M., 3084
 Cost, G. J., 926
 Costa, M., 5060
 Costalas, J., 5480
 Costello, J. F., 1250
 Cotticelli, M. G., 504
 Cottrell, J., 2350
 Cottrell, S. E., 5017
 Coutu, P. H., 300
 Coucke, P., 1312
 Coucke, P. A., 4023
 Couderc, B., 1364
 Coughlin, C. M., 2460
 Coulter, F., 5469
 Coulter, K., 3436
 Courjal, F., 4360, 4368
 Cowan, K. H., 5441
 Cox, G. W., 2468
 Crabtree, J. S., 5446
 Cranston, D., 136, 5281
 Cremer, T., 481, 2331
 Crépin, M., 1023
 Crew, J. P., 5281
 Criel, A., 564
 Croce, C. M., 229, 504, 799, 1144, 1166, 2035, 2121, 2378, 2879, 4493, 5207, 5452
 Crompton, M. R., 5485
 Crossland, S., 5485
 Cucurella, M-G., 407
 Cui, H., 4469
 Cukor, B., 1259
 Cummings, O. W., 4221
 Cundari, E., 1722
 Cuneo, A., 1144
 Cunha, G., 3594
 Cunningham, A., 4838
 Cunningham, J., 1673
 Cuny, M., 4360
 Curiel, D. T., 1447, 4325
 Curtiss, S., 4082
 Cussenot, O., 1058
 Custer, M., 5320
 Cuthbert, J. A., 3498
 Cuzin, B., 3890

D

- Dabelsteen, E., 634
 Dachs, G. U., 570
 D'Agostino, R., Jr., 2394
 Dahia, P. L. M., 310, 4710, 5017
 Dairkee, S. H., 1590
 Dalbagni, G., 1217
 Dale, A-L. B., 2474
 Daly, J. M., 3804
 Daly, M., 5480
 Daly-Schweitzer, N., 1364
 D'Amato, R. J., 81
 D'Ambrosio, C., 3264
 Damert, A., 3860
 D'Amico, C., 4523
 Dang, C. V., 4905
 Dangel, J. E., 5480
 Dangler, C. A., 3972
 Dangles, V., 3360
 Daniels, E., 2781
 Dannenberg, A. J., 1081, 2890
 Dannull, J., 495
 Danska, J. S., 4408
 Dapunt, O., 3818
 Darcy, K., 5067
 Dark, G. G., 1829
 Darling, J. L., 4196
 Darrow, T. L., 1561
 Darzynkiewicz, Z., 803
 David, L., 634
 David-Pfeuty, T., 4482
 Davidson, B. L., 5550
 Davie, J. R., 147
 Davies, P. J. A., 162
 Davies, R., 1288
 Davis, B. M., 5093
 Davis, M. A., 1699
 Davis, T., 3779, 4177, 5221

* For title of article and coauthors, see listing in Contents of Volume 57 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 57

- Davis, T. W., 206
 Dawson, B. J., 2007
 Dawson, M. I., 4931
 Daxenbichler, G., 3818, 4158
 Dean, C., 4063
 Debatin, K.-M., 3823, 4956
 Debelenko, L. V., 1039, 1855, 2238, 4682, 5446
 Debernardis, D., 870
 DeBlasio, A., 1750
 Decaudin, D., 62
 Decker, H.-J., 5009
 Décorps, M., 407
 Deeley, R. G., 2325
 De Feudis, P., 870
 de Franciscis, V., 391
 De Frank, J., 5435
 Deftos, L. J., 900
 De Gregorio, L., 2121
 de Gruijl, F. R., 581, 1238
 de Haas, M., 3537
 Dehal, S. S., 3402
 de Jong, P. C., 2109
 deKernion, J. B., 495, 5189
 de Laat, A., 1238
 Delaporte, C., 4301
 Delesque, N., 956
 Delgado, R., 5360
 Delia, D., 1895
 Dellabona, P., 1922
 Delmas, P. D., 3890
 Delohery, T., 1569
 De Luca, A., 3381
 De Luca, L. M., 2835, 4460
 De Marchis, L., 4523
 DeMuys, J.-M., 4803
 Deng, J., 4722
 Denissenko, M. F., 4727
 Denk, C., 1460
 Denko, N. C., 4703
 Denmeade, S. R., 4924
 Denning, M. F., 3180
 Denny, W. A., 2172
 DeNobile, J. W., 4478
 Dent, G., 1547
 Deo, Y. M., 696, 4008
 Dereuddre, S., 4301
 Derguini, F., 4642
 Deroanne, C. F., 5590
 D'Errico, M., 747
 Deutsch, W. A., 5457
 Dev, R., 5509
 Devaney, K. O., 824
 De Vita, G., 391
 de Vree, W. J. A., 2555
 de Vries, A., 581, 1238
 de Vries, T. J., 3223
 deWolf, W., 5189
 Dexter, D. L., 279
 Dhingra, K., 4992
 Diasio, R. B., 1660
 Díaz-Guillén, M. A., 4217
 Di Castro, V., 1306
 Diccianni, M. B., 832
 Diegelman, P., 5521
 Diehl, V., 1704
 Dienes, H. P., 2048
 Diep, A., 3678
 Dierkesmann, R., 2440
 Diermann, J., 4739
 Dietel, M., 2331, 5213
 Dietmaier, W., 4749
 Di Filippo, F., 1554
 Di Fiore, P. P., 240, 799, 5498
 DiFranco, E. M., 1039
 di Isernia, G., 5107
 Dijkmans, L. M., 2244
 Dilber, M. S., 1523
 Di Leonardo, A., 1013
 Dillner, J., 3989
 Dimitrakopoulou-Strauss, A., 3415
 Dimond, E., 4478
 Dimichev, A., 24
 D'Incalci, M., 870, 1442
 Di Nicola, M., 5534
 Dionne, C. A., 176
 DiOrio, C., 4838
 DiPaolo, J. A., 4200
 Dipple, A., 415
 Dissette, V. B., 2865
 Di Stasi, S. M., 875
 Dittadi, R., 1066
 Ditter, M., 1776
 Dive, C., 1939
 Dlugosz, A. A., 3180
 Dobrovic, A., 3347
 Doerfler, W., 3001
 Dogliotti, E., 747
 Döhner, H., 4608
 Doki, Y., 1569
 Dolan, E., 2933
 Dolci, S., 875
 Dolman, C. S., 4948
 Domann, F. E., Jr., 5550
 Dome, J. S., 5605
 Dong, J.-T., 846
 Dong, Q., 1855, 2933
 Dong, S., 117
 Dong, Z., 2873, 4414
 Donghi, R., 1895
 Donker, T. H., 2109
 Donnini, S., 1814
 Dorie, M. J., 2922
 Dorjsuren, D., 5137
 Dosemeci, M., 2839
 Doty, J., 4838
 Dougherty, G. J., 3899
 Dougherty, T. J., 4000
 Douglas, J. T., 1447
 Douglass, E. C., 1859
 Dove, W. F., 812, 1999
 Down, L. M., 4868
 Dowsett, M., 3723
 Doyen, N., 4600
 Doyle, L. A., 5460
 Doyle, T. W., 100
 Drabkin, H., 1
 Drabkin, H. A., 1344
 Draetta, G., 1259
 Dragan, Y., 1438
 Dragan, Y. P., 3451
 Dragani, T. A., 4164
 Dralle, H., 1798, 2501
 Dranoff, G., 1537, 2569
 Dreier, T., 4948
 Dreyling, M. H., 4608
 Dricu, A., 543
 Drinkwater, N. R., 590
 Driouch, K., 1058
 Dritschilo, A., 24, 1412, 3881
 Drobetsky, E. A., 3390
 Drobnjak, M., 1217
 Druck, T., 504, 1166, 1180
 Drumm, D., 1955, 2754
 Drummond, J. T., 2933
 DuBois, R. N., 169, 1638
 Dubrez, L., 686
 Duchaud, E., 1722
 du Manoir, S., 2116, 2331, 4585
 Dumanski, J. P., 2611
 Dummer, R., 5073
 Duncan, J. R., 659
 Dunlop, M. G., 5017
 Dunn, R. M., 5309
 Dunn, S. E., 2687, 4667
 Dunstan, C. R., 3194
 Duranton, B., 573
 Duray, P. H., 995
 Durham, S., 5258
 Dykes, D. J., 3895
 Dynan, W. S., 1412
 Dziubinski, M. L., 978
- E**
- Eberlein, T. J., 5122
 Ebetino, F. H., 3890
 Ebihara, Y., 2100
 Eccles, D., 5017
 Economou, J. S., 2865
 Ecsedy, J. A., 1580
 Edelman, W., 3972
 Edmiston, K. H., 4432
 Edmonds, B., 3697
 Edwards, C. L., 4309
 Edwards, S., 75
 Egenter, C., 2860
 Egilmez, N. K., 2937
 Egle, A., 3331
 Egorin, M. J., 234
 Eguchi, K., 4913
 Eguchi, M., 1895
 Eguchi, Y., 1835
 Eichler, H. G., 2598
 Eichler, H.-G., 362
 Eichler, W., 1798
 Eisinger, F., 5469
 Ekimoto, H., 5041
 Ekstrand, B. C., 382
 Ekström, C., 2048
 Ekström, T. J., 2048
 El-Bayoumy, K., 3644, 4757
 El-Deiry, W. S., 130, 320
 Elder, J. T., 3055
 El-Deredy, W., 4196
 Elfman, F., 3594
 El-Gawly, H., 4811
 Elia, L., 2879
 Ellenson, L. H., 3935
 Elliott, K., 3258
 Ellis, E. M., 4257
 Ellis, L., 5221
 Ellsworth, L., 2909
 El-Naggar, A., 5221
 Elo, J. P., 3356
 El-Obeid, A., 5598
 Elshami, A. A., 466
 El-Sohehy, A., 3685
 Elson, A., 1664
 Elstner, E., 4545
 Eltom, S. E., 4498
 Emdin, S. O., 549
 Emerman, J. T., 1124
 Emmert-Buck, M. R., 995, 1039, 1855, 2238, 4682, 5446
 Emond, M. J., 2619
 Endo, M., 921
 Endo, T., 1073
 Eng, C., 310, 500, 4710, 5017
 Engeland, A., 3989
 Engelhardt, J. F., 5550
 Engelmann, H., 891
 Engels, K., 1794
- F**
- Facco, M., 4940
 Factor, V. M., 2089
 Faenza, I., 2137
 Fagin, J. A., 1690
 Fahl, W. E., 5117
 Fairman, J., 3779
 Falchetti, M., 4523
 Falck, J., 4451
 Fallon, M. T., 3532
 Fan, H., 4876
 Fan, J., 2193
 Fan, S., 4285
 Fan, Y., 1673, 3511
 Fang, G., 3115
 Fanger, M. W., 4008
 Farinosi, R., 1710
 Farley, D., 5386
 Farrell, C., 3798
 Farrell, W. E., 2703
 Fasco, M. J., 2589
 Faught, W. J., 4447
 Favre, G., 1364, 1846
 Fay, M. P., 3979
 Fearon, E. R., 382
 Federici, M. G., 3657
 Feigelson, H. S., 1063
 Feinberg, A. P., 48, 926, 3131
 Feitelson, M. A., 426
 Felding-Habermann, B., 1554
 Felix, D., 3886
 Féménia, F., 3360
 Feng, S., 5369
 Fenig, E., 1750
 Ferguson-Smith, M. A., 4585
 Fernandes-Alnemri, T., 43, 615
 Fernández-Luna, J. L., 1320
 Fernandez-Salguero, P. M., 2835

AUTHOR INDEX TO VOLUME 57

- Ferrandina, G., 4309, 5406
 Ferrara, N., 4593
 Ferrell, R. E., 4191
 Ferrone, S., 1554
 Festing, M. F. W., 1288, 2832
 Fetni, R., 3390
 Fetsch, P., 995
 Feucht, H. E., 891
 Feunteun, J., 828
 Fey, G. H., 2035
 Fiander, A. N., 4855
 Field, J. K., 4070
 Figlin, R., 5189
 Fike, J. R., 2694
 Filep, J. J., 1915
 Finch, R. A., 5238
 Finegold, M. J., 4687
 Fingar, V. H., 4551
 Fink, D., 1841, 3253
 Fink, T., 3135
 Finkelstein, S. D., 304, 2485
 Finn, C. C., 1537
 Finn, T., 2909
 Finn, T. S., 2452
 Fiore, M., 1722
 Fiorino, A., 4164
 Firestone, R. A., 100
 Fishel, R., 206, 2378, 3010, 3765, 4739, 4749
 Fisher, D. E., 1664
 Fisher, J., 4008
 Fisher, P. B., 18
 Fisher, R., 1859
 Fisher, R. J., 2013
 Fishman, D., 5410
 Fisk, B., 87
 Fitzgerald, E. B., 202
 Fitzgerald, P., 2642
 Fitzpatrick, D. R., 3200
 Place, A., 5073
 Flanders, K. C., 2543
 Flavell, D. J., 4824
 Flavell, R. A., 5232, 5238
 Flavell, S. U., 4824
 Fléjou, J. F., 1986
 Floore, A. N., 3478
 Flores, J. F., 5336
 Flotte, E. R., 1502
 Flynn, E., 81
 Fogel-Petrovic, M., 5521
 Foiles, P. G., 259
 Fojo, A. T., 1516
 Fojo, T., 130, 5086
 Fonatsch, C., 3914
 Fong, A. Z. C., 337
 Fong, K. M., 400, 2256, 3664
 Fons, P., 110
 Fontana, J. A., 5129
 Foon, K. A., 728
 Foray, N., 4600
 Forbey, K., 1
 Fornace, A. J., Jr., 4285, 5434
 Fortier, A. H., 1329
 Foster, B. A., 3325
 Fotsis, T., 2916
 Foty, R. A., 5033
 Fouchet, P., 1986
 Foulhé, N., 407
 Fountain, J. W., 1, 5336
 Fourkour, A., 3223
 Fournier, G., 1058
 Fox, J. G., 3972
 Fox, S., 963
 Frandsen, T., 3486
 Frank, C. J., 824
 Frank, D., 4177
 Frank, S., 2638
 Frank, T., 2350, 2543
 Frankel, A., 2388
 Franklin, J. C., 1915
 Franklin, W. A., 1, 1344
 Frappart, L., 396, 3890
 Fraser, N. W., 466
 Frawley, L. S., 4447
 Frazier, M., 5221
 Frazier, M. L., 3653
 Fré, S., 5498
 Frederick, L., 842, 5254
 Freedman, L. S., 3979
 Freedman, R. S., 4309
 Freemantle, C. N., 1625
 Freije, D., 4707
 Frelinger, J. A., 1547
 French, J., 4667
 Frend, A. J., 3300
 Frey, R. S., 628
 Freyaldenhoven, B. S., 123
 Freyaldenhoven, M. P., 123
 Fridman, R., 3159
 Friedel, G., 2440
 Friedl, P., 2061
 Friedl, W., 4739
 Friedman, A. H., 4130, 4187
 Friedman, H. S., 2933, 4187
 Friedman, S. L., 4474
 Friend, S., 4285
 Friesen, C., 3823, 4956
 Friesen, P. D., 43
 Friess, H., 3135
 Frische, K., 3214
 Frisk, T., 4710
 Fritz, G., 454
 Fritz, P., 2440
 Fritzell, J. A., 5143
 Frizelle, S. P., 1007
 Froment, O., 1695
 Fromentin, A., 2661
 Frommer, M., 2229
 Fruitwala, M. M., 5360
 Frydman, B., 620
 Frye, C., 4177, 5221
 Fryer, B. H., 2452
 Fu, T., 881, 2668
 Fu, T.-B., 504
 Fucci, M., 747
 Fuchs, A., 3084
 Fuchs, C., 1098
 Fuchs, E. J., 2550
 Fueyo, A., 4882
 Fuggle, S., 136, 5281
 Fujie, T., 4465
 Fujii, G., 5221
 Fujiki, F., 94
 Fujimoto, J., 5579
 Fujita, M., 5379
 Fujita, M. Q., 3860
 Fujita, N., 3040
 Fujita, T., 3145
 Fujiwara, H., 2216, 4036
 Fukasawa, K., 2151
 Fukuchi-Shimogori, T., 5041
 Fukuda, K., 1233, 2081
 Fukuda, M., 5201
 Fukuhara, S., 7
 Fukushima, S., 4765
 Fukutani, K., 246
 Fulci, G., 1922
 Fulda, S., 3823, 4956
 Fults, D. W., 842
 Fung, H., 3101
 Fuqua, S. A. W., 1244, 3486
 Furihata, C., 1416
 Furihata, K., 4167
 Furuhata, T., 3281
 Furukawa, K., 1073
 Furuke, K., 4916
 Furuse, M., 4714
 Furusho, K., 5243
 Furuya, K. N., 3708
 Fusco, A., 391
 Futakuchi, M., 195
 Futreal, P. A., 3121
- ## G
- Gabr, A., 4811
 Gabrielli, B. G., 4868
 Gabrielson, E., 2116
 Gadbois, D. M., 1151, 3174
 Gaddy, J., 3511
 Gahrton, G., 1523
 Gaida, G. M., 808
 Gaidarov, I., 240
 Gajate, C., 1320
 Gal, A., 1823
 Gahli, U., 332
 Galitzki, L., 5410
 Gallagher, J. A., 5386
 Gallegos, A., 4965
 Gallie, B. L., 2325
 Gallinger, S., 355
 Galli-Stampino, L., 3214
 Gallo, J. M., 3063
 Galluser, M., 573
 Galmiche, M. C., 447
 Ganesh, A., 3765
 Ganeshaguru, K., 943
 Gangopadhyay, A., 4432
 Gansauge, F., 1634
 Gansauge, S., 1634
 Gao, A. C., 846
 Gao, Q., 5584
 Gao, Y., 5460
 Gardiner, K., 3914
 Gariboldi, M., 4164
 Garkavtsev, I., 1255
 Garrido, C., 2661
 Garrido, F., 937
 Garrison, D. A., 1371
 Garvin, A. J., 1429
 Gascoyne, R., 1605
 Gasdaska, J. R., 4965
 Gasparotto, D., 2366
 Gasser, T. C., 2860
 Gastl, G., 3818
 Gately, S. T., 5277
 Gates, S. B., 1116
 Gatter, K. C., 1794
 Gau, J.-T., 3830
 Gaullier, J.-M., 1481
 Gauthier, S., 3494
 Gazdar, A. F., 2256, 2373, 3154, 3664
 Gazit, A., 2434, 3741
 Gebert, J., 4739
 Gebrim, L. H., 378
 Gee, P., 1575
 Geisen, C., 1460
 Geiser, C. F., 1859
 Geley, S., 62, 3331
 Gell, D., 4600
 Gellert, K., 2331
 Gelman, I. H., 2304
 Gelmann, E. P., 4455
 Gemma, A., 1435
 Gemmill, R., 1
 Gemmill, R. M., 1344
 Gendler, S. J., 3520
 Gentz, R., 3084
 George, D. L., 3562
 Georgii, A., 2501
 Geradts, J., 3126
 Gerald, T. M., 5129
 Gerhäuser, C., 272, 3424, 3429
 Germain, G., 2933
 Gerson, S. L., 4817, 5093
 Gervasi, D. C., 3159
 Gespach, C., 1776
 Getts, L. A., 2029
 Geurts, J. M. W., 13
 Gho, Y. S., 3733
 Ghosh, P., 3569
 Giaccia, A. J., 4200, 4703
 Giaccone, G., 2256
 Giannakakou, P., 130
 Giannantonio, A., 875
 Giannarelli, D., 1554
 Gianni, A. M., 5534
 Giannobile, W. V., 4141
 Giardiello, F. M., 199
 Gibbs, J. P., 5509
 Gibbs, M., 1194
 Gibson, K. M., 4316
 Giffard, R. G., 4200
 Gilbertson, R. J., 3272
 Gillespie, G. Y., 1502
 Gilliard, G., 2630
 Gillies, S. D., 4948
 Gilmer, T. M., 1962
 Gilmour, R. S., 2137
 Gilmour, S. K., 2104
 Gingrich, J. R., 3325, 4687
 Gioeli, D., 1157
 Gion, M., 1066
 Giordano, A., 3381, 4063
 Giordano, G. G., 3381
 Giovangrandi, Y., 516
 Giovannucci, E., 1098
 Glaab, W. E., 3949
 Glaspy, J. A., 2865
 Glassman, A. B., 1487
 Glazer, P. M., 3079, 5143
 Gleave, M. E., 1584
 Gleiberman, A. S., 5217
 Glendening, J. M., 5336
 Glenville, S., 937
 Glickman, B., 4393
 Glover, R. A., 1758, 3941
 Gnant, M., 2598
 Gobbel, G. T., 2694
 Godwin, A. K., 2029, 5480
 Goedegebuure, P. S., 5122
 Goel, A. S., 3111
 Goeze, A., 2331
 Goggins, M., 1005, 1731
 Goi, K., 1895
 Golde, D. W., 2529
 Goldmacher, V. S., 176
 Goldman, C. K., 1447
 Goldman, H., 808
 Goldsmith, S., 38
 Goldstein, A. M., 4637
 Goldstraw, P., 5207
 Gollin, S. M., 304
 Gollnick, S. O., 3904
 Goltzman, D., 4517
 Gomes, I., 3168

- Gomi, A., 5292
 Gonzalez, F. J., 2835
 Gonzalgo, M. L., 594, 5336
 Goodhardt, M., 4600
 Goodison, S., 3140
 Goodlad, R. A., 4507
 Goodman, J. H., 1129
 Goodman, M. T., 5077
 Goodman, O. B., Jr., 240
 Goodman, S. N., 1731
 Goodmanson, M., 2651
 Goodrow, T., 2710
 Goodrow, T. L., 5226
 Goodwin, E. H., 2164, 3963
 Goossens, K., 1086
 Goral, M. A., 2104
 Gordon, A. J. E., 3390
 Gordon, N. H., 1425, 4817
 Gordon, R., 4082
 Gorelik, E., 332
 Gorham, H., 3140
 Görög, J.-P., 2860
 Goss, P., 209
 Gossé, F., 573
 Gossett, L. S., 1116
 Goto, M., 3145
 Gou, F. V., 2668
 Gould, K. A., 812
 Gourley, L., 3653
 Graber, M. W., 2961
 Graeber, T. G., 4200
 Graham, M. A., 3314
 Gramatzki, M., 696
 Grana, G., 5480
 Grant, D. S., 2130
 Gratz, S., 5309
 Grau, A. M., 3929
 Graus-Porta, D., 3804
 Gravitt, K. R., 87
 Gray-Bablin, J., 604
 Graziano, R. F., 4008
 Greaves, M., 2879
 Greaves, M. J., 4153
 Greco, V., 1013
 Greco, W. R., 4000
 Green, D. R., 1007
 Greenberg, N. M., 3325, 4687
 Greenberg, S. J., 678
 Greenblatt, M. S., 426
 Greenfield, R. S., 100
 Greenlee, W. F., 1264, 3026
 Greenspan, D. L., 4692
 Gregel, C. M., 3335
 Greil, R., 3331
 Greim, R., 2035
 Greiner, A., 3944
 Gremm, B., 1460
 Grénman, R., 2281
 Gress, T. M., 3135
 Griffiths, J. R., 3314
 Griffiths, L., 570
 Grignani, F., 799
 Grignon, D. J., 3688
 Grimm, M. S., 1124
 Grisham, J. W., 1807
 Groden, J., 488
 Groffen, J., 32
 Grogan, L., 4478
 Grogan, T. M., 2325
 Groger, A. M., 3381
 Grönberg, H., 4707
 Gronwald, J., 481
 Groopman, J. D., 641
 Gross, N., 1387
 Gross, P. H., 2909
 Grossman, A. B., 310
 Grossman, H. B., 38
 Grove, M. L., 3830
 Grunberger, D., 440
 Gruol, D. J., 720
 Grützner, K. U., 1394
 Gu, L. J., 117
 Gualandi, F., 4153
 Guan, Y., 1673
 Gudas, L. J., 4642
 Gudkov, A. V., 3941, 5217
 Guengerich, F. P., 4757
 Guha, A., 4141
 Guidos, C. J., 4408
 Guillen, J. M., 2909
 Guillou, L., 4023
 Guillouf, C., 1722
 Guillouzo, A., 3649
 Guise, T. A., 3194
 Guldberg, P., 3660
 Gullestad, H. P., 404
 Gulley, M. L., 4123
 Gumbs, A. A., 3079
 Gumpper, K. L., 5221
 Gunn, J. R., 2569
 Guo, K., 351
 Guo, N.-h., 1735
 Guo, X., 4642
 Gupta, E., 5100
 Gupta, G., 2508
 Gupta, P. K., 1188
 Guru, S. C., 1039, 1855, 2238, 4682, 5446
 Gutierrez, M. I., 2508
 Gutman, M., 2295
 Guvakova, M. A., 2606
 Guyre, P. M., 4008
- H**
- Haas, M., 1841
 Haas, S., 2721
 Haataja, L., 32
 Haba, T., 5379
 Habeck, L. L., 1116
 Haber, D. A., 1429
 Haber, M., 5399
 Haberkorn, U., 3415
 Hadaczek, P., 481, 504
 Haddad, G., 2325
 Haddad, R., 4615
 Hafeli, U., 3063
 Haffty, B. G., 3079
 Hagemeijer, A., 564
 Hagenmüller, F., 2354
 Hagevik, S., 3121
 Hagiwara, H., 1851
 Hagiwara, K., 1435
 Hahn, M., 2638
 Hahn, P., 3398
 Hahn, S. A., 1731, 3126
 Hahner, L., 1344
 Haile, R. W., 3678
 Hainaut, P., 3365
 Haines, D. C., 2843, 5564
 Hajiro-Nakanishi, K., 1981
 Hajitou, A., 5590
 Håkansson, S., 2474
 Häkkinen, L., 2281
 Hakomori, S.-i., 3092
 Hakulinen, T., 3989
 Halachmi, N., 2888, 4997
 Halachmi, S., 4997
 Halazonetis, T. D., 3693
 Haldar, S., 229
 Halder, T., 3238
 Hallahan, D. E., 2096, 4205
 Haller, D., 1769
 Halling, B. P., 4551
 Hamada, H., 461, 4279
 Hamaguchi, M., 5416
 Hamaoka, T., 2216, 4036
 Hamby, C. V., 1554
 Hamdy, F. C., 4427
 Hamel, E., 81, 3429
 Hamelin, R., 300
 Hamid, R., 253, 3465
 Hamilton, A. D., 1846
 Hamilton, R. L., 304
 Hamilton, S. R., 199, 3370, 4221
 Hamilton, T. C., 850, 1050, 2029
 Hamlin, B. C., 1030
 Hammann, A., 2661
 Hampl, J., 2638
 Hampl, M., 2638
 Hampton, G. M., 4082, 4171
 Hamstra, D., 5571
 Han, E. K.-H., 1569
 Han, H.-j., 3281
 Han, J.-w., 176
 Hanada, R., 907, 3772
 Hanahan, D., 1294, 3860
 Hanawalt, P., 1650
 Hancock, J. F., 5399
 Handa, H., 3145
 Handa, K., 3092
 Handa, S., 1882
 Hande, P. M., 2081
 Hangan, D., 3812
 Hankin, J. H., 4787, 5077
 Hanna, N. N., 4205
 Hänseler, E., 3841
 Hansen, K. L., 5221
 Hansen, L., 3180
 Hansen, M. F., 106
 Hansford, L. M., 5399
 Haque, M., 4460
 Hara, A., 246
 Harada, A., 94
 Harada, N., 1634
 Hard, G. C., 2623
 Hardman, R. A., 2687
 Härkönen, M., 1276
 Härkönen, P., 3356
 Harpaz, N., 2350
 Harper, J. C., 4221
 Harris, A. L., 136, 570, 963, 1794, 5281
 Harris, C. C., 426, 1435
 Harris, S. R., 3924
 Harrison, J., 2229
 Harrison, P. R., 3886
 Hart, P. H., 476
 Hart, S. M., 943
 Harte, R. J. A., 2172
 Hartman, N. R., 815
 Hartmann, B. L., 3331
 Hartwell, L., 4437
 Hartzstark, Z., 3741
 Harvey, R. G., 415
 Hasebe, O., 5201
 Hasegawa, M., 2493
 Hasegawa, R., 195
 Hashida, M., 2681
 Hassan, H., 4744
 Haston, C. K., 5286
 Hattier, T., 4177
 Hauda, K. M., 1537
 Haugen-Strano, A., 3121
 Hausner, P., 4478
 Havre, P. A., 3079
 Hawighorst, H., 4777
 Hawley, R. G., 337
 Hawley, T. S., 337
 Hawthorne, M., 272
 Hay, J., 5258
 Hayashi, S.-i., 1981
 Hayashi, Y., 907, 3772
 Hayashizaki, Y., 3294
 Haydon, P. S., 4551
 Hayes, A. K., 4736
 Hayes, J. D., 4257
 Hayes, R. B., 2839
 Hayes, T. E., 215
 Hayward, N. K., 4868, 5336
 He, D., 1868
 He, J., 1717
 He, L., 4469
 He, L.-Z., 943
 He, W., 1329
 He, Y., 3993
 Heaney, J. A., 3517
 Hebrink, D., 842
 Hecht, S. S., 259, 2873
 Heckel, D., 2290
 Hedborg, F., 4469
 Hedican, C., 5605
 Hedley, D. W., 2446
 Heerd, B. G., 1769
 Heerd, P., 152
 Hegde, P. V., 702
 Heideman, R. L., 4042
 Heijnen, I. A. F. M., 696
 Heim, S., 404
 Heilmann, R., 4340
 Hein, R., 3149
 Heine-Suñer, D., 4217
 Heinrich, U., 3944
 Heintz, N. H., 3101
 Heinz, R., 4718
 Heiss, M. M., 1394
 Heisterkamp, N., 32
 Hejlik, D. P., 3779
 Helbich, T., 2598
 Helbing, C. C., 1255
 Held, W. A., 1250, 3294, 4615
 Heldin, N.-E., 1798
 Helie, M., 382
 Hellström, I., 100, 4530
 Hellström, K. E., 100, 4530
 Helzlsouer, K. J., 5493
 Hemminki, A., 5017
 Henderson, A. J., 100
 Henderson, B. E., 1020, 1063, 3678
 Henderson, B. W., 3904, 4000
 Henderson, D. R., 2559
 Henderson, G. A., 2559
 Hendricks, D. T., 2112
 Hendry, W. J., III, 1903
 Hengstler, J. G., 454
 Henion, T., 332
 Henk, B., 2085
 Henkels, K. M., 4488
 Henkin, J., 3585
 Henne-Bruns, D., 3106
 Hennekens, C. H., 1098
 Heppner, C., 4682, 5446
 Heppner, K. J., 169, 1638
 Herlyn, M., 1873, 3258, 3835
 Herman, J. G., 837, 3126, 3370, 4997
 Hernandez, M.-C., 215

AUTHOR INDEX TO VOLUME 57

- Herr, I., 3823
Herrington, C. S., 4210
Herrlich, P., 4889
Herrmann, S., 2216
Hershenson, M. B., 3168
Herzog, C., 5421
Hess, S., 891
Hess, S. M., 3635
Heyman, R. A., 162, 2642, 4931
Heyns, W., 1086
Hiai, H., 2904
Hickman, J. A., 1939, 2404
Hickson, I. D., 1794
Hiddemann, W., 4608
Higashi, Y., 1981
Higgins, T., 51
Higgs, P. I., 130
Higgy, N. A., 378
Hilger-Eversheim, K., 3001
Hilgers, W., 3126
Hill, D. L., 3444
Hill, R. P., 3765
Hill, S. A., 1829, 5261
Hilliker, C. E., Jr., 1344
Hilsenbeck, S. G., 600, 5505
Hino, O., 4673
Hipfner, D. R., 2325
Hippo, Y., 2151
Hirai, H., 3548
Hirohashi, S., 4913
Hirose, K., 94
Hirose, M., 195
Hirota, H., 5112
Hirsch, T., 62
Hiwasa, T., 4578
Hixson, L. J., 2909
Hiyama, E., 326
Hiyama, K., 326
Ho, C-T., 2623
Ho, I-C., 5051
Hoang, J-M., 300
Hoang-Vu, C., 1798
Hochhauser, D., 2193
Hochwald, S., 152
Hocker, J. E., 5399
Hodemaekers, H., 4384
Hodgson, S. V., 5017
Hoener, B-A., 2839
Hoffbrand, A. V., 943
Hoffman, R. M., 2042
Hoffman, S., 5493
Hoffmann, J., 3847
Hoffmann, J-S., 110
Hofmann, W. J., 2048
Hofstead, S. J., 100
Hogan, J. K., 4177
Hogg, D., 209
Höglund, M., 2765
Hohenfellner, R., 5009
Holinski-Feder, E., 4739
Holland, J. F., 4795
Hollingshead, M. G., 3895
Hollingsworth, M. A., 1206, 4744
Holmquist, G. P., 2394
Holst-Hansen, C., 3486
Holt, P. R., 1569
Holtgreve-Grez, H., 481
Hölttä, E., 3016
Hong, J-H., 3899
Hong, W. K., 400, 4931
Hongyo, T., 2081, 5379
Honkanen, N., 1276
Honn, K. V., 2522
Hoon, D. S. B., 1371
Horii, A., 1630, 1851
Horne, C. H. W., 4427
Hornung, U., 2993
Horsman, M. R., 3314
Hortobagyi, G., 4992
Hoskin, D. W., 2602
Hoskin, P. J., 5261
Hosokawa, Y., 5305
Hostager, B. S., 1758, 3941
Houghton, A. N., 2529
Houghton, P., 2933
Howell, A., 4987
Howell, S. B., 1841, 2657, 3253
Hruban, R. H., 1731, 2140, 3126
Hsieh, J-T., 1868
Hsieh, M-L., 2651
Hsu, C. K. A., 5129
Hsu, H-C., 5179
Hsu, M-Y., 3835
Hu, B., 2865
Hu, M., 3577
Hu, N., 4123
Hu, R., 4177, 5221
Hu, S-X., 1217, 3339
Huan, S., 209
Huang, A., 4876
Huang, C., 2873, 4414
Huang, H-J. S., 1250
Huang, H-Y., 5493
Huang, L., 3993
Huang, M-T., 1468, 2623
Huang, P., 3407
Huang, S., 2295, 4682, 5446
Huang, T. H-M., 1030
Huang, T-S., 2974
Huang, Y., 3115, 3640, 5258
Huang, Z., 2589
Hubbard, F. C., 5226
Huber, C., 5009
Huberman, E., 2732
Hudson, E. A., 5391
Huebner, K., 504, 1166, 1180, 2121, 5207
Huff, V., 1859
Hughes, S. J., 5571
Hukku, B., 576
Hume, S. P., 2172
Hundley, J. E., 600
Hung, M-C., 4722
Hunt, K. K., 4722
Hunter, D. J., 1098
Hunter, S. B., 3532
Hunter, T., 5168
Hunter, T. C., 1188
Hursting, S. D., 2843
Hurt, J. C., 68
Hussain, A., 5129
Hwang, J., 1516
Hyder, S. M., 2547
Hylind, L. M., 199
Hyman, T., 2732
Hynes, N. E., 3804
Hyytinen, E., 314
I
Iacovoni, J. S., 123
Iannetoni, M. D., 5571
Iannolo, G., 240, 5498
Ibrado, A. M., 1109, 3115
Ibrahim, N., 5100
Ichihashi, M., 370
Ichikawa, D., 3092
Ichinose, M., 1416
Ichioka, K., 2904
Ide, H., 5022
Ideta, T., 4862
Iezzi, G., 2564
Igarashi, K., 5041
Iggo, R., 3288
Iinuma, S., 2200
Iizuka, Y., 3506
Ikeda, H., 4578
Ikeda, K., 2799
Ikeda, M., 4557
Iliakis, G., 1654
Iliev, D., 5221
Imada, K., 5452
Imai, K., 1981, 2055
Imaida, K., 195
Imaoka, S., 921
Inamoto, T., 4916
Inaoka, T., 5386
Incarbone, M., 2121
Ingvarsson, S., 1222
Inman, J. K., 1735
Inohara, H., 5272
Inomoto, T., 5542
Inoue, A., 3772
Inoue, H., 504, 1081, 2151, 2890
Inoue, J-i., 3145
Inoue, M., 610, 1863, 2055
Inouye, M., 1468
Ioannides, C. G., 87
Iozzo, R. V., 2130
Ip, C., 5067
Irimura, T., 3612
Isaacs, J. S., 2986
Isaacs, J. T., 846, 1054, 4924
Isaacs, S. D., 4707
Isaacs, W. B., 2741, 4707, 4997
Isaksson, M., 4530
Ishida, H., 94
Ishida, T., 2151
Ishii, I., 5041
Ishikawa, D., 1882
Ishikawa, H., 1863
Ishikawa, T., 646, 2415, 5292
Ishiko, T., 3640
Ishioka, C., 1895
Ishizuka, T., 3548
Isogai, M., 4460
Isola, J., 314, 1222, 1597
Israel, L., 1023
Israel, M. A., 215
Issa, J-P. J., 837, 1678, 3370
Ito, M., 3294
Ito, N., 195
Ito, S., 1035, 2870
Ito, T., 1416
Itoh, M., 326
Iversen, P. O., 476
Iwamura, T., 1206, 4744
Iwanuma, Y., 2937
Iwao, T., 326
Iwashita, T., 2870
Iwata, K. K., 4838
Iwata, S., 1895
Iwata, Y., 2870
Izquierdo, M., 407
J
Jablonska, S., 4214
Jackman, J., 4285
Jackson, L. E., 5485
Jackson-Cook, C. K., 4699
Jacobs, A. L., 5148
Jacoby, L. B., 4889
Jacoby, R. F., 812
Jacquemier, J., 5469
Jacquemin-Sablon, A., 4301
Jaffee, E. M., 1537
Jaffrézou, J-P., 5300
Jahnke, V., 5213
Jaiswal, A. K., 440
Jaken, S., 3101
Jakesz, R., 2598
Jakubczak, J. L., 3606, 5564
Jalkanen, S., 2281
James, C. D., 842, 5254
James, R., 3697
Jammulapati, S., 4177
Jan, K., 2827
Janecki, T., 3779, 4177
Jang, A., 3765
Jänkälä, H., 1276
Jankun, J., 559
Jannot, C. B., 3804
Janoff, A. S., 1915
Jansen, B., 362, 2598
Janssen, Y. M. W., 3101
Janz, S., 4585
Jarrard, D. F., 35
Järvinen, H., 5017
Jasser, S., 5221
Jauch, A., 481
Jefcoate, C. R., 4498
Jeffers, M., 5391
Jeggio, P., 4600
Jelinek, D., 2268
Jellum, E., 3989
Jen, J., 4997, 5356
Jenkins, R. B., 524, 842, 5254
Jenkins, T. D., 5542
Jenkins, W. T., 5155
Jensen, M. R., 2089
Jensen, P. B., 4451
Jensen, R. T., 290, 2238, 4682
Jensen, T., 3214
Jessup, J. M., 808, 4432
Jhanwar, S. C., 4057
Ji, H., 759
Ji, W., 3339
Jia, T., 759
Jiang, B-H., 5328
Jiang, C., 267, 5605
Jiang, F., 2860
Jiang, J., 4795
Jiang, S., 1475
Jilani, S. M., 2865
Jin, C., 404
Jin, S., 576
Jin, Y., 404
Jing, Y., 1668
Jirik, F. R., 5143
Jirus, S., 3486
Jochimsen, A. G., 1353
Joel, D. D., 1129
Joenje, H., 2244
Joensuu, H., 2281
Johannsson, O., 1222
Johansson, B., 2765
Johnson, C. S., 3759
Johnson, J. P., 2295
Johnson, K. R., 2741
Johnson, M. R., 1660
Johnson, R. L., 2369
Johnson, S. P., 2933
Johnson, S. W., 850, 1050
Johnson, T. M., 3055
Johnston, R. N., 1255
Johnston, S. R. D., 3723
Jolivet, A., 857

AUTHOR INDEX TO VOLUME 57

- Jones, A. S., 4070
 Jones, D., 5505
 Jones, J. A., 2657
 Jones, P. A., 594, 5336
 Jones, R., 426
 Jones, T., 2172
 Jonsson, N., 404
 Joon, D. L., 2493
 Jordan, V. C., 1438, 3071
 Joseph, B. K., 759
 Joseph, I. B. J. K., 1054
 Jove, R., 978
 Juan, G., 803
 Judah, D. J., 4257
 Juhl, H., 3106
 Juijn, J. A., 3537
 Jukkola, A., 5517
 Julian, J., 5148
 Jung, B., 3554
 Jung, M., 24, 576, 1412
 Just, J. J., 1194
 Just, K., 2331
- K**
- Kaboo, R., 495
 Kacinski, B. M., 209
 Kadhim, S. A., 4803
 Kadow, K. F., 100
 Kähkönen, M., 1597
 Kaina, B., 454, 2721, 3335
 Kaisary, A. V., 3189
 Kaiser, L., 2373
 Kaiser, L. R., 466
 Kakehi, Y., 742
 Kaklamanis, L., 1794
 Kakolyris, S., 1794
 Kalbacher, H., 3238
 Kalden, J. R., 696
 Kalhorn, T. F., 4229
 Kalimo, K., 2281
 Kalla, J., 3944
 Kallakury, B. V. S., 2760
 Kallassy, M., 4731
 Kallioniemi, A., 1597
 Kallioniemi, O.-P., 314, 1222, 1597
 Kalthoff, H., 3106
 Kaluza, B., 3149
 Kamata, N., 1895
 Kamataki, T., 641
 Kaminsky, L. S., 2589
 Kamoto, T., 2904
 Kan, M., 5369
 Kanai, F., 461, 4279
 Kanai, Y., 4913
 Kancharla, S. R., 4325
 Kandikonda, S., 4378
 Kane, M. F., 808
 Kaneda, N., 5305
 Kaneko, T., 2200
 Kang, L., 3657
 Kang, X., 202
 Kangas, A., 3016
 Kangas, L., 3016
 Kanner, S. B., 1962
 Kanno, H., 1035
 Kanno, N., 2575
 Kantoci, D., 4316
 Kao, C.-Y., 2089
 Kao, G. D., 753
 Kaplan, L., 3079
 Kaplan, M. I., 4048, 5557
 Kaplan, O., 1452
 Kappes, H., 2721
 Karayiannakis, A. J., 3189
 Karger, A., 1460
 Karhu, R., 1222, 1597
 Kari, F. W., 2687, 4667
 Karlic, H., 4718
 Karnaoukhova, L., 4393
 Karner-Hansch, J., 4739
 Kärre, K., 4348
 Kasai, H., 2410
 Kashima, T., 4098
 Kashiwagi, K., 5041
 Kastan, M. B., 3386, 4474
 Kastury, K., 504, 1166, 1180
 Kataoka, A., 5243
 Katayose, Y., 5441
 Kato, D., 3145
 Kato, H., 2100
 Kato, T., 3640, 5037
 Kato, Y., 1851, 1934, 3040, 3506
 Katsuki, M., 641
 Katsuyama, T., 4167, 5201
 Kattan, M. W., 4687
 Katyal, S. L., 795
 Katz, A. E., 18, 2362
 Katzenberger, T., 3944
 Kaufmann, M., 3140, 3149, 3723
 Kaufmann, S. H., 1678, 3375
 Kaufmann, W. K., 68
 Kavanagh, J. J., 4309
 Kawabata, K., 2681, 3644
 Kawabe, T., 5475
 Kawagoe, H., 2516
 Kawaguchi, T., 2081
 Kawai, T., 1241
 Kawakami, M., 94, 2321, 4167
 Kawakami, Y., 202
 Kawano, Y., 5037
 Kawata, A., 678
 Kawazoe, N., 3097
 Ke, Y., 1435
 Keating, M. J., 1487
 Keck, R. W., 559
 Kedersha, N. L., 176
 Keen, J. H., 240
 Keerie, A.-J., 3300
 Keir, S., 2933
 Keitz, B., 3798
 Keler, T., 4008
 Keller, J., 2394
 Kelley, M. R., 5457
 Kelloff, G., 3717
 Kelloff, G. J., 420, 1301, 5489
 Kellokumpu, I., 5017
 Kelly, P. J., 3272
 Kelner, M. J., 279
 Kelsey, A. M., 3245
 Kelson, A. B., 3314
 Kemp, B. L., 400
 Kennedy, L. J., 1823
 Kennedy, T., 1344
 Kensler, T. W., 2806
 Keohavong, P., 2485
 Kerangueven, F., 5469
 Kerbel, R. S., 2388
 Kern, S., 4082
 Kern, S. E., 1005, 1731, 2140, 3126
 Kerr, L. R., 1124
 Kestell, P., 284
 Kester, M. B., 1039, 1855, 4682, 5446
 Ketterer, B., 3649
 Keyomarsi, K., 604
 Khan, M. A., 1435
 Khan, S. H., 1013
 Khater, C., 1050
 Kidd, L. C. R., 3457
 Kidder, G. M., 1523
 Kiefer, M. C., 1758
 Kiessling, R., 4348
 Kikkawa, F., 5416
 Kikutani, H., 2569
 Kim, C. N., 3115
 Kim, C. Y., 4200
 Kim, D., 2856
 Kim, H., 355
 Kim, H. T., 4652
 Kim, H.-R. C., 5272
 Kim, M., 5441
 Kim, M. J., 5465
 Kim, M.-K., 1955
 Kim, N.-H., 1569
 Kim, S., 1889, 3629
 Kim, S. K., 400
 Kim, S. Y., 38
 Kim, S.-J., 2668, 2856
 Kim, W. S., 2856
 Kim, Y.-T., 4692
 Kimura, H., 2799
 Kimura, Y., 3281
 Kinar, Y., 2732
 King, B. L., 209
 King, H. D., 100
 King, P., 5356
 King, S. A., 513
 Kinghorn, A. D., 3424
 Kingston, D. G. I., 130
 Kiningham, K. K., 5265
 Kinoshita, H., 742
 Kinzler, K. W., 2578
 Kirichenko, A. V., 1929
 Kiritoshi, A., 3305
 Kirkin, A. F., 3238, 3660
 Kirsch, D. G., 4474
 Kirsch, I. R., 4408, 4478
 Kiselyov, A. S., 415
 Kishi, T., 3548
 Kishimoto, T., 1335, 4765
 Kisro, J., 2676
 Kissel, J., 3415
 Kitaeva, M. N., 4478
 Kitamura, N., 1206
 Kitaoka, A., 1043
 Kitoh, K., 3208
 Kitoh, T., 5243
 Kivistö, K. T., 2440
 Kærn, J., 3818
 Klauber, N., 81
 Klee, G. G., 2651
 Kleihues, P., 382
 Klein, C. E., 2061
 Klein, M. G., 1569
 Kleinberger-Doron, N., 2434, 3741
 Kleinman, G., 382
 Klein-Szanto, A. J. P., 2104, 5226
 Klemi, P., 2281
 Klineberg, E., 5391
 Kloppenborg, K. I. M., 3478
 Kluth, B., 891
 Knapp, D. J., 1007
 Knapstein, P. G., 4777
 Knipe, J., 100
 Knof, A., 4777
 Knopp, M. V., 4777
 Knowles, R. G., 3300
 Knubovets, T., 1452
 Knudsen, B., 3629
 Kobata, A., 1073
 Kobayashi, H., 1955, 2754
 Kobayashi, K., 4913
 Kobayashi, M., 1644
 Kobayashi, S., 3395
 Kobayashi, T., 4898
 Kobayashi, Y., 1281
 Koç, O. N., 5093
 Koch, A., 2085
 Koch, C. J., 5155
 Kodagoda, D. R., 3664
 Kodali, S., 387
 Kodama, T., 326, 2151
 Koeffler, H. P., 913, 4545
 Koelble, K., 4739
 Koester, S. K., 600
 Kofler, R., 62, 3331
 Kohama, T., 610
 Kohler, W., 1116
 Kohn, K. W., 4029, 4285
 Kohn, K., 4557
 Kohno, T., 907
 Kohsaki, H., 921
 Koi, M., 3949
 Koike, C., 3612
 Koike, K., 5475
 Koike, M., 4545
 Koishi, S., 5243
 Koivisto, P., 314
 Kojima, Y., 2575
 Kok, H., 2474
 Kokkinakis, D. M., 5360
 Kokubo, T., 5386
 Kokura, S., 2200
 Koli, K. M., 970
 Kolodner, R., 808
 Kolodner, R. D., 3949
 Kolonel, L. N., 1020, 1063, 4787, 5077
 Komarova, E. A., 5217
 Komminoth, P., 4710
 Kona-Horstmann, M., 2354
 Kondo, K., 1035
 Kondo, M., 2200, 4898
 Kondratyev, A., 24
 Kong, D., 2543
 Kong, X.-T., 3772
 Konishi, Y., 1281
 Konno, H., 3294
 Kononen, J., 314
 Koochekpour, S., 5391
 Kool, M., 3537
 Kopras, E., 1475
 Korourian, S., 2884
 Kos, M., 3331
 Koskela, P., 3989
 Koski, K. M., 2832
 Kosmeder, J. W., 3424, 3429
 Koster, J. F., 2555
 Kottickal, L. V., 3779
 Koulu, L., 2281
 Koutcher, J. A., 3956
 Kovacs, M. S., 672
 Koyanagi, N., 3208
 Kraemer, K. H., 4637
 Kraft, A., 5348
 Krajewska, M., 1605
 Krajewski, S., 1605
 Krämer, A., 5117
 Kramer, D. L., 5521
 Kramer, H., 3649
 Krammer, P. H., 4956
 Kratzke, R. A., 1007
 Kraus, J., 2085
 Krauss, J. C., 4849
 Kreidberg, J., 1429
 Kreis, W., 714

AUTHOR INDEX TO VOLUME 57

- Kremer, B., 3106
 Kremer, C., 3852
 Kremer, H., 500
 Kress, S., 1264
 Krill, C. E., 1859
 Krill, D., 3830
 Krishna, R., 5246
 Kroemer, G., 62
 Kroemer, H. K., 2440
 Krohne, G., 2061
 Krueger, A., 1050
 Krüger, U., 3106
 Krummen, L., 4593
 Krutzsch, H. C., 1735
 Kruyt, F. A. E., 2244
 Kruzelock, R. P., 106
 Krystal, G. W., 2203
 Kube, D., 1704
 Kubiak, R., 396
 Kubo, T., 2216
 Kubota, M., 5243
 Kucharczuk, J. C., 466
 Kucheralapati, R., 3972
 Kudelka, A. P., 87, 4309
 Kuettel, M. R., 576
 Kufe, D. W., 1270, 4205, 4340
 Kuida, K., 4578
 Kuin, A., 4811
 Kullmann, F., 3554, 4749
 Kuma, K., 3792
 Kumar, A., 3111
 Kun, L., 3238
 Kun, L. E., 4042
 Kunath, T., 2781
 Kung, J. T., 4123
 Kunkel, T. A., 2956, 3949
 Kuo, M. T., 5292
 Kupfer, D., 3402
 Kurachi, H., 5379
 Kurdoglu, B., 1091
 Kurimoto, M., 4557
 Kurita, A., 5305
 Kuroda, Y., 5037
 Kuroki, T., 921
 Kurooka, M., 2081
 Kurosumi, M., 1981
 Kurth, L. A., 4162
 Kushnir, T., 1452
 Kuukasjärvi, T., 1597
 Kuwano, M., 5475
 Kwon, E. D., 3325
 Kwon, T. J., 400
 Kwon, Y. K., 4141
 Kyllönen, A. P., 3356
 Kyo, S., 610, 1863
 Kyriakis, J. M., 4177
 Kyrtis, A. P., 1673
- L**
- Labrie, C., 3494
 Labrie, F., 3494
 Lacey, D., 472
 Lachyankar, M. B., 532
 Lafayette, A. R., 2586
 Lahrech, H., 407
 Lai, M. T., 3351
 Lai, P.-L., 5179
 Laiho, M., 2966
 Laine, A., 3016
 Lainé, V., 3360
 Lam, E. W. N., 5550
 Lam, K. S., 1877
 Lam, S., 2373
 Lamborn, K. R., 2694
- Lampe, J., 4889
 Lamph, W. W., 162, 4931
 Lamps, L., 169, 1638
 Lan, K.-H., 461, 4279
 Lan, Y., 4948
 Landberg, G., 549
 Landers, J. E., 3562
 Landreneau, R. J., 433
 Landry, C. F., 4098
 Landthaler, M., 3554
 Langford, L. A., 5221
 Langouët, S., 3649
 Langreck, H., 2331
 Lannutti, B. J., 5277
 Lansing, T. J., 1962
 Lapceovich, R., 1329
 Lapière, C. M., 5590
 Larsen, A. K., 818
 Larsen, S. S., 585
 Larson, A. A., 4082, 4171
 Larson, J. S., 3351
 Larson, R. S., 2341
 Larsson, C., 500, 4710
 Larsson, E., 2048
 Larsson, O., 543
 Lasch, S. J., 100
 Latil, A., 1058
 Lau, R., 2865
 Laub, P. B., 850
 Laue, S., 1798
 Laughlin, K. M., 5155
 Laurent, G., 5300
 Laurent-Puig, P., 1986
 Lautenberger, J. A., 2013
 Laux, D. E., 1030
 Lavigne, J. A., 5493
 Lavin, M. F., 3600
 Lavin, P., 1259
 Lawrence, T. S., 1699
 Lazar, V., 516
 Lazenby, A. J., 1537
 Lazo, J. S., 4191, 4236
 Lazzereschi, D., 2071
 Lazzeri, C., 5452
 Le, N., 1955, 2754
 Le, X., 1868
 Leadon, S. A., 3784
 Leavitt, A., 4177
 Leavitt, W. W., 1903
 LeBien, T. W., 2268
 Leboldus, L., 3398
 Lebowitz, P. F., 708
 Lech, J., 2419
 Ledbetter, D. H., 32
 Ledda-Columbano, G. M., 795
 Leder, P., 1664
 Lee, C., 141
 Lee, C. C. R., 4765
 Lee, C.-S., 3471
 Lee, E. Y.-H. P., 4123
 Lee, G.-H., 590, 2896
 Lee, J., 5221
 Lee, J. E., 3733, 4200
 Lee, J. J., 4992
 Lee, J. S., 400
 Lee, J.-H., 2384
 Lee, J.-Y., 926
 Lee, K., 4924
 Lee, M. J., 1575
 Lee, M. P., 3131
 Lee, P. J., 5122
 Lee, P.-H., 3471
 Lee, S. A., 24
 Lee, S. K., 3429
- Lee, T.-C., 5051
 Lee, W. M. F., 2460
 Lee, W.-H., 35, 4225, 4274, 5505
 Lee, W.-N. P., 4242
 Leek, R., 963
 Le Ferrec, E., 3649
 Leftwich, M. E., 1877
 Leggett, B., 2350
 Lehman, T. A., 5001
 Lehmann, I., 1798
 Lehnert, B. E., 1151, 2164, 3174, 3963
 Lehtinen, M., 3989
 Lei, R. Y., 4692
 Leiferman, K. M., 1537
 Leininger, J. R., 4667
 Leipold, D. D., 4316
 Lejbkiewicz, F., 2732
 LeJeune, S., 963
 Le Marchand, L., 4787
 Lenoir, G. M., 828
 Le Rhun, D., 3360
 Leszyk, J., 5460
 Levade, T., 5300
 Levenson, A. S., 3071
 Levin, V. A., 1673
 Levine, E., 3835
 Levitsky, H. I., 1537
 Levitzki, A., 2434, 3741, 5610
 Levitzki, R., 3741
 Levy, D., 3360
 Lewis, A. D., 3314
 Lewis, J. E., 206
 Ley, R. D., 3682
 Li, D., 1438
 Li, D.-M., 2124
 Li, F. P., 1859
 Li, G. C., 2847
 Li, G.-L., 2839
 Li, H., 2452, 2909, 4042
 Li, J., 3084, 3935, 4183
 Li, J.-J., 1991, 3569
 Li, L., 1487
 Li, L. Y., 2081
 Li, P.-K., 702
 Li, Q., 3370
 Li, S., 4356
 Li, W. W., 2193
 Li, X., 803, 2048
 Li, X.-G., 5100
 Li, X.-S., 5129
 Li, Y., 234, 641
 Li, Y.-X., 4023
 Li, Z., 5441
 Liang, B., 1554
 Liang, G., 594
 Liang, H., 1329, 3779
 Liang, X., 3723
 Liao, J., 1889
 Liao, S.-Y., 2827, 4171
 Lichter, P., 3135
 Lidereau, R., 516, 1058
 Lieber, M. M., 524
 Liebert, M., 38, 3055
 Lien, M. C., 3693
 Liénard, D., 735
 Light, B. W., 3759
 Lilja, H., 4924
 Lilly, M., 5348
 Lillywhite, K. J., 284
 Liloglou, T., 4070
 Lim, H. Y., 2559
 Lim, J.-t., 921
 Limoli, C. L., 4048, 5557
- Lin, H., 5221
 Lin, J., 18
 Lin, T.-P., 1841
 Lin, X., 2304
 Lin, Y., 5137
 Lin, Y. W., 5243
 Lindblom, A., 2474
 Linder, A., 2440
 Lindhofer, H., 2346
 Linehan, M., 5189
 Linehan, W. M., 995
 Linet, M., 2839
 Ling, N., 4824
 Ling, V., 2325
 Link, M. P., 832
 Linke, S. P., 1013, 1171
 Liotta, L. A., 1039, 1855, 2238, 4682, 5446
 Lipman, J., 808
 Lippman, J., 3486
 Lippman, S. M., 4992
 Lipsky, P. E., 3498
 Liskay, R. M., 5143
 Lista, F., 4408
 Liston, J. C., 1007
 Litofsky, N. S., 532
 Littlewood-Evans, A. J., 5386
 Litman, C., 3398
 Litwack, G., 43, 615
 Litz, J., 2203
 Litzky, L. A., 466, 2373
 Liu, A. A., 620
 Liu, H., 3629
 Liu, J., 272, 759, 2223
 Liu, J. M., 2951
 Liu, L., 1109, 3115, 4817
 Liu, L. F., 620
 Liu, L. Q., 5077
 Liu, P., 2268
 Liu, P. C., 513
 Liu, S.-C., 5226
 Liu, T.-J., 4722
 Liu, W., 5254
 Liu, X., 3904, 4992
 Liu, X. M., 714
 Liu, X.-m., 1487
 Liu, Y., 1650
 Liu, Y. E., 759, 3084
 LiVolsi, V. A., 513
 Ljung, B.-M., 1590
 Lo, C.-K., 1516
 Lo, K.-M., 4948
 Locker, J., 795
 LoCoco, F., 799, 2879
 Loda, M., 808, 1259, 3381
 Lode, H. N., 4948
 Loeb, L. A., 2007
 Loercher, A., 4309
 Loftus, T., 5067
 Logothetis, C., 3339
 Loignon, M., 3390
 Lokeshwar, V. B., 773, 778
 Lomax, M. I., 38
 London, S. J., 5001
 London, W. T., 2749
 Longy, M., 500, 4710, 5469
 Look, A. T., 4042
 Loosfelt, H., 857
 Lopez, A. F., 476
 López-Boado, Y. S., 4091
 López-Carrillo, L., 3728
 López-Cervantes, M., 3728
 López-Otín, C., 4091, 4882
 Lorenz, W. J., 3415

AUTHOR INDEX TO VOLUME 57

- Lorenzen, J., 1704
 Lorenzo, M. J., 5399
 Lorico, A., 5232, 5238
 Los, M., 4956
 Lotan, R., 4931, 4992
 Lotz, O., 1798
 Lou, Q., 1877
 Lou, W., 846, 4924
 Lou, Y-R., 1468, 2623
 Louason, G., 4360
 Lövgren, J., 4924
 Low, K. B., 4537
 Lowry, C. V., 2760
 Lu, B., 3723
 Lu, C., 221, 1043
 Lu, J., 267
 Lu, K. H., 387
 Lu, M., 337
 Lu, S., 4511
 Lu, W., 2839
 Lu, Y., 2325
 Lu, Y-P., 1468
 Lubahn, D. B., 1030
 Lübke, A. S., 3063
 Lübke, J., 370
 Lubensky, I. A., 1039, 1855, 2238, 4682, 5446
 Lubet, R., 420, 3717
 Lubinski, J., 481
 Luca, M., 2295
 Luchtefeld, M. A., 3653
 Ludescher, C., 3818
 Ludwig, C. U., 3669
 Lükkarinen, O., 3356
 Lukmanji, F., 4992
 Lundy, S. K., 2522
 Lunec, J., 3272
 Lunetta, K. L., 5017
 Lunn, R. M., 3471
 Luo, X., 2209, 2851
 Luongo, C., 169, 812, 1999
 Luostarinen, T., 3989
 Luthra, S. K., 2172
 Lykkesfeldt, A. E., 585
 Lyman, S., 3511
 Lynch, H. T., 828
 Lynch, P. M., 3653
 Lyu, L-C., 4787, 5077
- M**
- Ma, J., 1098
 Ma, K-N., 75
 Ma, L-W., 1481
 Ma, W-J., 5426
 Ma, W-Y., 2873, 4414
 Ma, Z. G., 117
 Maaser, K., 2061
 MacDonald, J. R., 279
 Mach, J-P., 1312
 Mach, R. H., 156
 Machein, M., 3860
 Macho, A., 62
 Mack, D., 4744
 Mackay, W., 1425
 MacKellar, W. C., 1116
 Mackenzie, P. I., 284
 MacKerell, A. D., Jr., 234
 Mackey, M. F., 2569
 MacLean, A. R., 466
 MacLeod, C. L., 1841
 Mader, R. M., 2598
 Madhukar, B. V., 865
 Madias, C., 3325
 Madike, V., 4455
- Madsen, J. W., 1329
 Madsen, M. W., 585
 Maestro, R., 2366
 Mafune, K-I., 28
 Magi-Galluzzi, C., 1259
 Magit, D., 4631
 Magnetto, S., 3890
 Magnuson, S. R., 35
 Magnuson, T., 3180
 Magrath, I. T., 2508
 Mahéo, K., 3649
 Maher, E. R., 310
 Maheswaran, S., 1429
 Mahmoud, N. N., 5045
 Mains, R. E., 5226
 Maitimu-Smeele, I., 2109
 Maity, A., 753
 Majewski, S., 4214
 Mak, T. W., 3765
 Makita, H., 246, 3644
 Makridakis, N., 1020
 Malaise, E-P., 4600
 Malfetano, J. H., 2760
 Malkinson, A. M., 2832
 Malm, J., 4924
 Malspeis, L., 3895
 Maltoni, C., 1695
 Man, A., 943
 Man, S., 2943, 4855
 Mancini, P., 5498
 Mandahl, N., 404
 Mandal, A., 4008
 Mandel, U., 634, 4744
 Mandelli, F., 2879
 Manenti, G., 2121, 4164
 Manfredi, M. G., 1580
 Mangold, G. L., 279
 Manickam, P., 1039, 1855, 2238, 4682, 5446
 Manns, M. P., 2979
 Mansat, V., 5300
 Manson, M. M., 4257
 Mant, M. J., 930
 Manzke, O., 1704
 Manzoli, L., 2137
 Mao, L., 400, 1673, 5356
 Mao, Y., 620
 Marcantonio, D., 3895
 Marcelli, S., 2933
 Marchetti, A., 2121
 Marchetti, P., 62
 Maret, A., 1364
 Margison, G. P., 366
 Mariani-Costantini, R., 4523
 Marion, M-J., 1695
 Markert, J. M., 1502
 Markie, D., 5017
 Markowitz, S. D., 4817
 Marks, P. A., 2789
 Marmé, D., 5421
 Marschalek, R., 2035
 Marsh, D. J., 500, 4710, 5017
 Marsh, J. P., 3101
 Marshall, C. J., 5485
 Marshall, D. J., 812
 Marshall, F. F., 1537, 2741
 Marshall, G. M., 5399
 Marston, N. J., 5485
 Marth, C., 3818, 4158
 Martin, E. A., 1288
 Martinez, A. J., 304
 Martinez, R., 1180
 Martínez-Dalmau, R., 1320
 Martin-Fontecha, A., 2564
- Martín-Martín, B., 1320
 Martins, H., 4393
 Martiny-Baron, G., 5421
 Marton, L. J., 620, 1999
 Martucci, C., 5045
 Maruta, H., 2478
 Marx, S. J., 1039, 1855, 2238, 4682, 5446
 Marxsen, J., 3106
 Marynen, P., 564
 Marzo, A. L., 3200
 Masala, G., 4523
 Masellis-Smith, A., 930
 Mashiba, H., 5041
 Massarelli, R., 407
 Massoud, R., 875
 Masters, G. R., 1915
 Masucci, G., 4348
 Masuda, A., 4898
 Masuda, M., 3506
 Masuda, Y., 3097
 Masutani, H., 4916
 Masuzawa, T., 5292
 Mathiak, M., 2130
 Mathiesen, T., 2611
 Matrisian, L. M., 2104
 Matsuba, C., 2151
 Matsubara, A., 5369
 Matsubara, N., 2350
 Matsui, N. M., 1137
 Matsumoto, K., 3305
 Matsumoto, K-I., 195
 Matsumoto, N., 5022
 Matsumoto, T., 3145
 Matsumoto, Y., 1050, 5086
 Matsumura, M., 1043
 Matsuno, F., 678
 Matsuoka, M., 4862
 Matsushima, K., 94
 Matsuura, Y., 326
 Matsuyama, K., 1043, 2200
 Matsuzuka, F., 3792
 Matthews, J. C., 2172
 Mauceri, H. J., 4205, 4340
 Maurel, P., 1946
 Maurer, F. G., 3804
 Maxwell, R. J., 3314
 Mayer, L. D., 5246
 Mayhew, E., 1915
 Maynard, R., 3126
 Mayo, L. D., 5013
 Mayo, M. S., 4325
 Mayr, A., 4158
 Mazar, A., 3585
 Mazoyer, S., 828
 McAfee, J. G., 2754
 McAllister, K. A., 3121
 McBride, W. H., 2865, 3899
 McClatchey, K. D., 824
 McClay, E. F., 2657
 McClellan, M., 2440
 McClelland, M., 3554
 McCracken, J. D., 4316
 McCue, P., 504
 McCulloch, E. A., 2446
 McCullough, K. D., 1807
 McDonald, J. M., 1859
 McDuffie, K., 5077
 McElwain, M. C., 3759
 McEntee, M. F., 4267
 McFadyen, M. C. E., 3026
 McGarrity, T. J., 3653
 McGown, G., 3245
 McGregor, F., 3886
- McIntee, E. J., 2341
 McKay, J. A., 3026
 McKay, R. D. G., 215
 McKay, R. T., 1877
 McKeehan, W. L., 5369
 McKenna, K. A., 2550
 McKenna, W. G., 753
 McKiernan, J. M., 2362
 McLachlan, J. A., 4356
 McLean, G. R., 4015
 McLendon, R. E., 4130, 4187
 McLeod, R., 4257
 McMahon, K. S., 4551
 McManis, J. S., 5521
 McMichael, M., 1475
 McMorris, T. C., 279
 Meager, A., 3084
 Medina, V., 3697
 Meduri, G., 857
 Meese, E. U., 2290
 Meflah, K., 225
 Megosh, L. C., 2630
 Mehlen, P., 2661
 Mehta, P. P., 900
 Mehta, R. G., 267, 272, 3429
 Meinjohanns, E., 3214
 Meistrich, M. L., 1091, 2493
 Meldal, M., 3214
 Melichar, B., 4309
 Melillo, G., 2468
 Melillo, R. M., 391
 Meloni, A. M., 2276
 Meltzer, S. J., 1851, 2350, 2543
 Melvin, W. S., 4242
 Melvin, W. T., 3026
 Menanteau, J., 225
 Mendelsohn, J., 1750
 Mendelsohn, L. G., 1116
 Mendoza, J., 5100
 Meng, Y. G., 4593
 Menke, A. L., 1353
 Menke, D., 672
 Menke, D. R., 2922
 Menon, A. G., 2369
 Menrad, A., 3847
 Meo, S., 1066
 Merand, Y., 3494
 Merlino, G., 3606
 Merrick, B. A., 2986
 Mertens, F., 404, 2765
 Mesnil, M., 2929
 Mestre, J. R., 1081, 2890
 Meuth, M., 3765
 Meyer, H. E., 3238
 Meyer, J. C., 5073
 Meyer, K. B., 2839
 Meyers, D. A., 4707
 Meyers, M., 206, 5557
 Meyn, M. S., 2313
 Micali, F., 875
 Micallef, M. J., 4557
 Michael, J. M., 3600
 Michalkiewicz, E., 4042
 Michel, K., 495
 Michel, S., 4931
 Mickley, L. A., 1516
 Midthune, D. N., 3979
 Mier, W., 4956
 Miglietta, L. M., 259
 Mihatsch, M. J., 2860
 Mihich, E., 4437, 5185
 Miki, K., 1416
 Miki, S., 4673
 Miki, T., 2575

AUTHOR INDEX TO VOLUME 57

- Miki, Y., 4673
Mikolajczyk, S. D., 3111
Mikovits, J. A., 881
Milchgrub, S., 2373, 3154
Milgrom, E., 857
Millar, D. S., 2229
Millar, L. S., 3111
Miller, P., 4838
Miller, P. D., 2029
Mills, G. B., 5221
Minale, L., 3751
Mincione, G., 2071
Miners, J. O., 284
Minish, T. M., 147
Minna, J. D., 400, 2256, 3154, 3664
Minoletti, F., 5207
Miquel, K., 1846
Mira-y-Lopez, R., 1668
Mirimanoff, R.-O., 1312, 4023
Mirochnitchenko, O. I., 1468
Mironov, N., 2148
Mirski, S. E. L., 4451
Misao, R., 5579
Mishra, R., 808
Mitani, H., 4673
Mitchell, J. B., 1529
Mitchell, J. T., 4177
Mitelman, F., 404, 2765
Miura, I., 7
Miura, K., 1851
Miyagi, Y., 2042
Mizukami, I., 1682
Mizukami, T., 1495
Mizutani, S., 1895
Mo, Y.-Y., 5004
Moan, J., 1481
Moch, H., 2860
Mocikat, R., 2346
Modolell, M., 1320
Modrich, P., 2933
Moeschberger, M. L., 1129
Moeslein, G., 4739
Moffat, J., 4393
Moghaddam, A., 963
Mohamed, A., 3688
Mohan, A. L., 3370
Mohar, A., 3728
Mohiuddin, M., 5360
Mok, J. E., 4692
Mok, S. C., 387
Molla, A., 5534
Mollinedo, F., 1320
Molnar-Kimber, K. L., 466
Monforte-Munoz, H., 1690
Monges, G., 1986
Monks, A., 4285
Monnat, R. J., Jr., 2956
Monsigny, M., 4249
Montague, W., 2478
Monteil, S., 1364
Montellano, F. D., 3154
Montesano, R., 1695, 2916
Montoya, S. E., 4191
Moon, R. C., 272, 3424, 3429
Moore, D. H., 1590
Moore, R., 4356
Moossa, A. R., 2042
Moran, E., 3693
Morel, F., 3649
Morelli, C., 4153
Moreno, A., 407
Morgan, A. C., 4015
Morgan, M. A., 513
Morgan, S. E., 3386
Morgan, W. F., 4048, 5557
Mori, H., 246, 3644
Mori, M., 28, 4465
Moriarty, R. M., 272, 3424, 3429
Morimoto, K., 1241
Morin, M. J., 4838
Moriwaki, S.-I., 4637
Moro, M., 1922
Morosetti, R., 913
Moroson, B. A., 1116
Morris, R. J., 2104, 3436
Morris, V. L., 3812
Mortarini, R., 5534
Morton, D. L., 1371
Moscatello, D. K., 1419
Moser, A. R., 812, 1999
Moskaluk, C. A., 2140, 3126
Mossman, B. T., 3101
Möstl, M., 4718
Mostowski, H., 2508
Mosure, K., 100
Mouritsen, S., 3214
Moustacchi, E., 1722
Moy, P., 3629
Moyer, J. D., 4838
Moyer, M. P., 4838
Mu, J., 2216, 4036
Mu, Z.-M., 1868
Mucha, J., 440
Mucke, H., 4718
Mueller, A., 5542
Mueller, N., 4862
Mueller, S. C., 5028
Mühlradt, P. F., 3344
Mukaida, N., 94
Mulder, K. M., 628
Mulders, P., 5189
Müller, C., 956, 3154
Müller, J., 2638
Müller, M., 2598
Müller, M. R., 651
Müller-Hermelink, H. K., 3944, 4608
Müller-Hermelink, H.-K., 2993
Müller-Holznier, E., 4158
Müller-Pillasch, F., 3135
Mulligan, L. M., 310
Mulligan, R. C., 1537
Multani, A. S., 1769
Mundy, G. R., 3194
Munemitsu, S., 4624
Muñoz, N., 4692
Munoz-Medellin, D., 4652
Muraca, P. J., 2760
Murakami, H., 2870
Murakami, S., 5137
Murakumo, Y., 2378, 3010
Muramatsu, M., 3294
Muraoka, R., 1043
Murata, Y., 5379
Mürdter, T. E., 2440
Murphy, E., 537
Murphy, E. C., 106
Murphy, J. R., 290
Murray, E. D., Jr., 4316
Murray, G., 5509
Murray, G. I., 3026
Muran, E., 3693
Murthy, L., 87
Murthy, L., 2547
Muscarella, P., 4242
Muschel, R. J., 753
Muscolat, C. C., 279
Musser, D. A., 3904
Musso, K., 2121
Mutoh, M., 4285
Myers, T. G., 4285
N
Nachman, A. P., 4432
Nacy, C. A., 1329
Nadzan, A. M., 162
Nagafuchi, A., 3189
Nagarajan, L., 3779
Nagasaki, H., 3920
Nagase, S., 1630
Nagashima, M., 1435
Nahm, H. S., 4687
Nair, T. S., 38
Naito, Y., 2200
Nakabayashi, H., 461
Nakachi, K., 1981
Nakada, S., 3640
Nakae, D., 1281
Nakagawa, H., 5542
Nakagawara, A., 4578
Nakahara, K., 4478
Nakajima, H., 2081
Nakajima, M., 1882
Nakajima, S., 2681
Nakajo, S., 3097
Nakamori, S., 921
Nakamura, E., 742
Nakamura, H., 2055, 2516
Nakamura, N., 5201
Nakamura, Takao, 3305
Nakamura, Tatsuya, 799
Nakamura, Toshikazu, 3305
Nakamura, Y., 921, 3281, 4578
Nakanishi, T., 4118
Nakanishi, Y., 5579
Nakashima, H., 3395
Nakashima, R., 5379
Nakatsuru, Y., 646
Nakaya, K., 3097
Nakayama, J., 2321, 5201
Nakazawa, H., 370, 4731
Nakazawa, K., 370, 4731
Nakazawa, S., 1895
Nakazawa, T., 4348
Nambu, Y., 5571
Nanda, I., 2993
Nandagiri, R., 4992
Nangia-Makker, P., 5272
Nanney, L. B., 169, 1638
Naraparaju, V. R., 295, 2187
Narayanan, L., 3079, 5143
Narayanan, P. K., 3963
Nardi, F., 2071
Narducci, M. G., 5452
Natali, P. G., 1554
Naumovski, L., 1650
Naus, C. C. G., 1523
Navarro, V., 3629
Navon, G., 1452
Nawa, A., 5416
Nawrocky, M. M., 1129
Naylor, S. L., 106
Neal, C. L., 1194
Neal, D. E., 4427
Neal, G. E., 4257
Neale, K., 5017
Nebel, S., 1841, 3253
Neders, L., 130
Neder, K., 620
Negishi, M., 4356
Negrini, M., 504, 1144, 2378, 4153, 4493
Nehmé, A., 1841, 3253
Nelson, J. B., 35
Nelson, W. G., 35, 1537
Neumaier, M., 2354
Neveu, M., 4838
Newbold, R. R., 4356
Newman, R. A., 1929
Newmark, H. L., 1468
Newton, M. A., 812
Nguyen, S. H., 35
Ni, J., 3084
Nichol, C. A., 5185
Nicklas, J. A., 2586
Nicolson, G. L., 3577
Nictro, M. R., 1554
Nieddu, M., 2035
Niehans, G. A., 1007
Nielsen, H. V., 4111
Nielsen, N. H., 549
Nielsen, P. A., 634
Niggemann, B., 2061
Nigro, J. M., 3635
Niho, Y., 3395
Ni'inuma, K., 3506
Nikiforov, Y. E., 1690
Nikitin, A. Y., 4274
Nilsson, P., 549
Nimako, M., 4855
Nir, U., 2732
Nishigaki, R., 3506
Nishimaki, J., 2100
Nishimori, H., 590, 3281
Nishimori, I., 4744
Nishimura, K., 2575
Nishimura, M., 2904
Nishimura, M. I., 5320
Nishimura, S., 2151, 2200
Nishioka, Y., 784
Nishizawa, O., 4167
Nistér, M., 5598
Nitiss, J. L., 4564
Nobori, T., 832
Nodzenski, E., 1270, 4340
Noelle, R. J., 2569
Noguchi, M., 2055
Noguchi, T., 5469
Noh, D. Y., 5465
Nokihara, H., 784
Nollau, P., 2354
Nomura, T., 1335, 2081, 2681, 5137, 5379
Nong, Z., 2048
Nonomura, N., 2575
Noordzij, A., 314
Nordenskjöld, A., 4469
Nordlinder, H., 2048
Nordqvist, A.-C. S., 2611
Norris, M. D., 5399
Norris, P. S., 1841
Nortier, H. W. R., 2109
Noss, A., 4824
Nouvian-Dooghe, Y., 4482
Nowak, J. A., 3154
Nsi-Emvo, E., 573
Nualart, F., 2529
Nuñez, G., 4956
Nuppenon, N., 1597
Nur-E-Kamal, M. S. A., 2478
Nusgens, B. V., 5590
O
Obata, M., 590
Öbek, C., 773
Oberley, L. W., 1991, 5550
O'Brian, C. A., 87

AUTHOR INDEX TO VOLUME 57

- O'Brien, T., 136, 5281
O'Brien, T. G., 2630
O'Brien, T. J., 2884
O'Connor, P. M., 4029, 4285
O'Connor, S. J., 4593
Oda, H., 646
Odegaard, E., 206
Odenhal, M., 2048
O'Dwyer, P. J., 1050
Odze, R., 5542
Oesterreich, S., 1244
Ogawa, H., 246
Ogawa, K., 590, 2896
Ogawa, M., 2216
Ogura, M., 1882
Oh, K. S., 3733
Ohashi, K., 1281
Ohashi, M., 461, 4279
Ohata, T., 1233
Ohgaki, H., 382
Ohlsson, R., 4469
Ohmori, M., 4714
Ohmura, T., 795
Ohnishi, K., 3910
Ohnishi, M., 246
Ohnishi, T., 3910
Ohno, H., 7
Ohno, S., 94
Ohshima, H., 3365
Ohshima, K., 2799
Ohta, M., 504, 1166
Ohtani, H., 1851
Ohtsubo, T., 3910
Ohtsuka, E., 2151
Ohyashiki, J. H., 2100
Ohyashiki, K., 2100
Oka, M., 1416
Okabe, M., 1495
Okada, M., 1335
Okada, S., 2410, 3612
Okada, Y., 742, 2055
Okami, K., 4997, 5356
Okamoto, M., 141, 4898
Okamoto, Y., 5037
Okamura, S., 3395
Okane, T., 4167
Okayama, A., 4862
Okazaki, Y., 3294
Oku, N., 3612
Okudaira, T., 461, 4279
Okuzumi, H., 3294
Okuma, M., 7
Okumura, K., 4714
Okunieff, P., 1529
Okuyama, A., 2575
Okuyama, Y., 3145
Old, L. J., 2181
Oldfield, E. H., 5446
Oleinick, N. L., 1717
Oliphant, A., 4177
Olive, P. L., 5528
Olschwang, S., 1986
Olson, J. M., 3526
Olsson, C. A., 2362
Olsson, H., 1222
Olufemi, S-E., 1039, 1855, 4682, 5446
O'Malley, L., 3798
Omata, M., 461, 4279
Omori, Y., 375
Onda, M., 3548
O'Neill, J. P., 1188, 2586
Ong, S. T., 2256
Ono, M., 5475
Ono, S., 4036
Oppenorth, T. J., 35
Oreffo, V. I. C., 1288
O'Reilly, M. S., 1329
O'Reilly, S., 815
Orlandini, S., 2035
Orntoft, T. F., 4111
Orr, F. W., 4105
Orringer, M. B., 5571
Orton, T. C., 4148
Osada, Y., 5022
Osana, M., 2896
Osborne, C. K., 3723, 5505
Oshalim, M., 3798
Oshima, H., 1644
Oshima, J., 2956
Oshima, M., 1644
Osman, S., 2172
Osmanian, C., 4200
Osorio, A., 4217
Østergaard, M., 4111
Östman, A., 5598
Ostrander, E. A., 1194
Ostot, J. T., 1
Ott, G., 3944, 4608
Ott, M. M., 3944
Ottavi, P., 2661
Ottini, L., 4523
Otto, V. L., 3841
Ouhit, A., 370
Ouyang, H., 1851, 2847
Owczarczak, B., 3904
Owens, A. H., Jr., 1537
Oyasu, R., 141
Ozaki, K., 921
Özdemir, E., 742
Ozols, R. F., 850
- ## P
- Paasinen-Sohns, A., 3016
Paavonen, J., 3989
Pack, S., 4682, 5446
Padberg, G. W., 500
Paganelli, G., 1922
Pagano, M., 1259, 3381
Paik, C. H., 1955, 2754
Palade, G. E., 765
Paller, A. S., 5277
Palli, D., 4523
Palmberg, C., 314
Palumbo, G. A., 2434
Palumbo, M., 1710
Pamukcu, R., 267, 2452, 2909
Panasci, L. C., 3895
Panayiotidis, P., 943
Pandey, R. K., 4000
Pang, D., 1412
Pang, S., 495
Pantazis, P., 5100
Panzer, S., 1731
Papas, T. S., 2961
Pappas, J., 2615
Papworth, J. L., 1625
Paradis, V., 516
Parangi, S., 81, 3594
Paranka, N. S., 267, 2909
Pardee, A. B., 4631
Pardoll, D. M., 1537
Parham, G. P., 2884
Park, H-S., 4507
Park, I. A., 5465
Park, K., 2856
Park, M., 4517
Park, W-S., 4682, 5446
Parkinson, D., 5189
Parkinson, K., 3886
Parmiani, G., 5534
Parmley, T. H., 2884
Parodi, S., 870
Parsonnet, J., 3620
Parsons, P. G., 4868
Parsons, R., 3935, 4183, 4187, 4710
Parzefall, J., 2993
Pasquini, P., 747
Passaniti, A., 5328
Pastan, I., 1955
Pastorino, U., 2121, 5207
Pataer, A., 2904
Patel, M., 5100
Patel, V. F., 1116
Paterlini, P., 516
Pathak, S., 1769
Pathare, P. M., 4015
Pattassery, J., 1915
Paul, C. L., 2229
Paul, R., 2741
Paulo, E. C., 1590
Pavloff, N., 1758
Pavlova, B., 4718
Pawelec, G., 3238
Pawelek, J. M., 4537
Payne, C. M., 5162
Pazik, J., 3798
Peacock, J., 3765
Pearson, A. D. J., 3272
Peaston, A. E., 5399
Pederson, L. C., 4325
Peehl, D. M., 4200
Peeler, M. O., 1638
Peeters, P., 564
Pehamberger, H., 362
Pekarsky, Y., 3914
Pelagi, M., 1922
Pellicci, P. G., 240, 799, 5498
Pellegrini, S., 2121
Pelton, P., 4889
Peng, H-Q., 209
Peng, L., 4849
Peng, Q., 1481
Pennanen, S., 1597
Pepe, S., 5107
Pepper, M. S., 2916
Perez-Stable, C., 900
Perin, A., 4940
Perkins, S. N., 2843
Pero, R., 4177
Perrault, A. R., 1654
Perrin, P., 225
Perrotti, D., 1180
Perry, R. H., 3272
Perry, W., III, 3779
Perry, W. L., III, 4177
Pershouse, M. A., 5221
Persson, B., 404
Perucho, M., 4420
Pervin, S., 728
Peter, M. E., 4956
Peters, A., 1915
Petersen, D., 32
Petersen, I., 2331, 5213
Petersen, S., 2331, 5213
Peterson, J. A., 1103
Peterson, S., 2847
Pettersson, M., 4348
Petkovich, M. P., 2835
Petrilli, N. J., 3798
Petroff, C. A., 4905
Petrukhin, L., 5480
Pettersson, H., 2611
Pettit, G. R., 1829
Petty, H. R., 1682
Peyrard, M., 2611
Pezzella, F., 5207
Pezzuto, J. M., 272, 3424, 3429
Pfeifer, G. P., 4727
Pfeifer-Ohlsson, S., 4469
Pfeilstöcker, M., 4718
Pham, H. T., 778
Pham, T. A., 4682
Phang, J. M., 2843
Phillips, D. M., 3517
Phillips, J. O., 1743
Phillips, J. W., 4048
Phillips, R., 5017
Phillips, W. P., Jr., 4817
Piantadosi, S., 1537
Piantelli, M., 5406
Piatyszek, M. A., 2373
Piazza, G. A., 267, 2452, 2909
Piccinin, S., 2366
Piccoli, C., 2929
Pickhardt, P. A., 2428
Pierotti, M. A., 2121, 4164, 5207
Pierre, F., 225
Pietsch, T., 2085
Pignatelli, M., 3189
Pike, M. C., 1020, 3678
Pike, S. E., 2508
Pilarski, L. M., 930
Piller, F., 4249
Piller, V., 4249
Pilotti, S., 2121, 5207
Pistorius, S., 2638
Pitot, H. C., 1438, 3451
Plaschke, J., 2638
Plass, C., 1250, 3294
Plate, K. H., 3852, 3860
Plowman, G., 3741
Plunkett, W., 1487, 3407
Poirier, D., 3494
Polakis, P., 4624
Pollack, A., 2493
Pollack, I. F., 304
Pollack, R. E., 5221
Pollack, V. A., 4838
Pollock, P. M., 4868
Pollock, R. E., 3577
Pomatico, G., 5107
Pommier, Y., 1529, 4029, 4564
Ponder, B. A. J., 5399
Pong, R-C., 1868
Ponta, H., 4889
Poon, R. Y. C., 5168
Popescu, N. C., 1166
Porfiri, E., 4624
Port, R., 3415
Porter, A. T., 2522
Porter, C. W., 5521
Porter, R. A., 1785
Potten, C. S., 4987
Pötter, E., 2501
Potter, J., 75
Poupon, M-F., 3360
Pourquier, P., 4564
Pourzand, C., 1405
Pousset, D., 4249
Poutanen, M., 3356
Povirk, L. F., 4699
Powell, M. E. B., 5261
Powell, S., 5435
Powell, S. M., 2350, 4221
Powis, G., 4965, 5162

- Prabhu, N. S., 320
 Pradines, A., 1846
 Prats, H., 1364
 Prendergast, G. C., 708, 3258
 Presta, L. G., 4593
 Preston, G. A., 537
 Price, C., 2879
 Price, C. M., 117
 Price, P. M., 2172
 Priel, E., 5410
 Prisco, M., 3264
 Prise, V. E., 948, 1829
 Prolla, T. A., 5143
 Protti, M. P., 2564
 Puc, J., 4183
 Puente, X. S., 4091
 Puget, N., 828
 Puigjaner, J., 4242
 Pulford, K. A. F., 4824
 Pullen, J., 832
 Pustilnik, L. R., 4838
- Q**
- Qian, J., 524
 Qian, X., 4948
 Qian, X. C., 3672
 Qian, Y., 1846
 Quesenberry, P. J., 532
 Quevedo, M. E., 5277
 Quiggle, D. D., 4316
 Quinlan, T. R., 3101
 Quintans, J., 1270, 4340
- R**
- Rabbani, S. A., 3585, 4517
 Rabes, H. M., 2358
 Rabindran, S. K., 3126
 Rácz, A., 2290
 Radetzky, S., 5309
 Raffel, C., 32, 842
 Ragsdale, S. T., 4042
 Rahm, A. K., 2452
 Rainier, S., 48
 Rajasekaran, A., 3629
 Rajewsky, M. F., 651
 Rakkar, A. N. S., 5441
 Ramadani, M., 1634
 Ramirez, G., 1419
 Randazzo, B., 466
 Ranelletti, F. O., 5406
 Ranieri, A., 2071
 Rao, C. V., 420, 1301, 2806, 3717
 Rao, K., 1
 Rao, S., 604
 Rapanotti, M. C., 2879
 Rappa, G., 5232, 5238
 Rasheed, B. K. A., 2933, 4187
 Rasio, D., 2378
 Rasku, S., 2916
 Rasmussen, H. H., 4111
 Rassool, F. V., 2256
 Ratcliffe, C., 5207
 Rathmell, W. K., 68
 Ratnam, M., 1116
 Rau, B., 1634
 Raue, F., 5309
 Raul, F., 573
 Rave-Fränk, M., 5309
 Ravn, V., 634
 Rayl, E. A., 1116
 Raz, A., 5272
 Reale, M. A., 382
 Reardon, D. A., 4042
- Recht, L. D., 532
 Reddy, B. S., 253, 420, 1301, 2806, 3465, 3717
 Reddy, P., 4652
 Reed, A. L., 2888
 Reed, J. C., 1605
 Reed, M., 2112
 Reelfs, O., 1405
 Reese, J. S., 5093
 Reh, T. A., 3526
 Rehemtulla, A., 1699, 5571
 Reich, R., 2295
 Reichard, B.-A., 926
 Reichardt, J. K. V., 1020
 Reichel, M., 2331
 Reid, B. J., 2619
 Reifengerger, G., 2581
 Reifengerger, J., 2581
 Reis, C. A., 634
 Reis, M. D., 337
 Reisfeld, R. A., 4948
 Reiss, K., 3264
 Reist, C. J., 1510
 Reiter, B. E., 585
 Reitmair, A. H., 3765
 Relf, M., 963
 Remberger, K., 2290
 Rémy, C., 407
 Ren, S., 4229
 Rennie, P. S., 1584
 Repp, R., 696
 Resau, J. H., 5391
 Reske, K., 1416
 Resnick, M. A., 1970
 Resnick, M. S., 2209
 Reubi, J. C., 1377
 Reuter, V. E., 1217
 Reyes, R., 3728
 Reyes-Mugica, M., 382
 Reynes, J.-P., 110
 Reynolds, M. M., 4838
 Rhee, S.-G., 2137
 Rhei, E., 3657
 Rhein, A., 2501
 Rhim, J. S., 576, 995, 2013
 Rhyu, M.-G., 2350
 Riabowol, K., 1255
 Ribas, A., 2865
 Rich, T. A., 1929
 Richards, C., 1769
 Richmond, A., 3032
 Richmond, P. J. M., 3189
 Richon, V. M., 2789
 Richter, J., 2860
 Rideout, W. M., III, 594
 Ridet, A., 1722
 Ried, T., 2331, 4585
 Rieger-Christ, K., 382
 Riesenberger, R., 1394
 Riethmüller, G., 891
 Rifkind, R. A., 2789
 Riganelli, D., 799
 Riggins, G. J., 2578
 Riggs, C. W., 2013
 Rigolin, G. M., 1144
 Riley, D. J., 4274
 Rimessi, P., 4153
 Rimoldi, D., 735
 Ripple, M. O., 2428
 Risau, W., 3852, 3860
 Risberg, B., 404
 Rishi, A. K., 5129
 Risinger, J. I., 3949, 4736
 Risler, L., 5509
- Risley, R., 3765
 Risteli, J., 5517
 Risteli, L., 5517
 Ristimäki, A., 1276
 Ritchie, J., 2909
 Riteco, N., 1353
 Ritland, S. R., 3520
 Rivolta, A., 2879
 Rivolta, L., 2564
 Rivoltini, L., 5320
 Rizk, N. P., 466
 Ro, J. Y., 400
 Robbins, D., 2378
 Robbins, P. F., 202
 Roberti, M. G., 1144
 Roberts, D. D., 1735
 Roberts, W. G., 765
 Robertson, N. M., 43
 Robinson, B. W. S., 3200
 Robinson, C. R., 4221
 Robinson, J. C., 2741
 Robinson, M. C., 4427
 Robledo, M., 4217
 Roboz, J., 4795
 Robson, C. N., 4427
 Röder, C., 3106
 Rodriguez, C., 4360
 Rodriguez, H., 2394
 Rodriguez, R., 2559
 Rodriguez-Bigas, M., 3798
 Rodríguez de Córdoba, S., 4217
 Roebuck, B. D., 2806
 Rogaia, D., 799
 Rogers, A. E., 2806
 Rogers, B. E., 1447
 Rogers, T., 2373
 Rohde, S., 2354
 Röijer, E., 13
 Roizman, B., 1502
 Rokhlin, O. W., 1758, 3941
 Romero, P., 735
 Ronchetti, A., 2564
 Roodman, G. D., 3194
 Roos, B. A., 900
 Roos, G., 549
 Rosato, A., 2564
 Rosen, C., 759
 Rosen, D., 504
 Rosen, D. M., 234
 Rosen, R. T., 2419
 Rosenbaum-Mitrani, S., 3741
 Rosenberg, S. A., 202
 Rosenwald, A., 3944
 Rosin, M. P., 5258
 Rosner, M. R., 3168
 Ross, A. H., 532
 Ross, B., 4063
 Ross, D., 2839
 Ross, D. D., 5460
 Ross, J. S., 2760
 Ross, R. K., 1020, 1063
 Rosselli, F., 1722
 Rossi, V., 2879
 Rossier, G., 1405
 Rostomily, R. C., 3526
 Rotaru, J. H., 1129
 Roth, S., 5017
 Roth, T., 2378
 Rothman, N., 2839
 Rothstein, J., 504
 Rowan, S., 1664
 Rowland, J. M., 1690
 Rowse, G. J., 3520
 Rozen, P., 5017
- Rozen, R., 1098
 Rozenblum, E., 1731
 Rozenfurt, E., 51
 Ruan, S., 3929
 Rubbini, S., 2137
 Rubin, E. H., 5100
 Rubin, M., 1750
 Rubin, R., 4063
 Rubin, S. C., 513
 Rubinfeld, B., 4624
 Rubini, M., 3264
 Rueda, C., 3728
 Ruiter, D. J., 3223
 Ruiz-Cabello, F., 937
 Rulong, S., 5391
 Ruscetti, F. W., 881, 2668
 Rüschhoff, J., 4739, 4749
 Russell, D. M., 3759
 Russev, G. C., 2252
 Russo, G., 5452
 Russo, I. H., 378
 Russo, J., 378
 Russo, P., 870, 2789
 Rustgi, A. K., 5542
 Ruzicka, T., 2581
 Ryan, L., 1769
 Rybak, R. J., 678
 Rychetsky, L., 1877
 Rynditch, A., 3914
 Ryu, S. H., 5465
- S**
- Sabbadini, M. G., 2564
 Sabbioni, S., 4493
 Saboorian, M. H., 3664
 Saccomanno, G., 1
 Sachar, S., 152
 Sacks, P. G., 1081, 2890
 Saeedi, M. S., 3111
 Saeki, Y., 1895
 Sager, R., 4631
 Sahin, A. A., 5148
 Sahota, A., 1188
 Sai, Y., 4118
 Saieva, C., 4523
 Saint-Laurent, N., 956
 Saito, H., 3910
 Saito, T., 375, 4898
 Saji, M., 2144
 Sakai, T., 3145
 Sakaki, Y., 1416
 Sakamoto, H., 3548
 Sakamuro, D., 708
 Sakiyama, S., 4578
 Sakr, W. A., 3688
 Saksela, O., 3016
 Sakumi, K., 2415
 Salazar-Onfray, F., 4348
 Salcini, A. E., 240
 Saleem, A., 5100
 Salemark, L., 404
 Salerno, C. T., 1007
 Salicioni, A. M., 378
 Salles, B., 4600
 Salmi, M., 2281
 Salmon, R. J., 300
 Salmon, S. E., 1877
 Salmons, M., 1442
 Salnikow, K., 5060
 Salter, R. D., 3830
 Salvatore, G., 391
 Salzberg, S., 2732
 Samaha, H., 420
 Samaha, H. S., 1301

AUTHOR INDEX TO VOLUME 57

- Sam-Lai, E., 407
 Sampson, L. K., 1743
 Samuel, S. K., 147
 Sancetta, R., 4940
 Sanchez, R., 3494
 Sandalon, Z., 2434
 Sandberg, A. A., 2276
 Sandelin, K., 2474
 Sanders, M. M., 620
 Sando, J. J., 2209
 Sandomenico, C., 5107
 Sandstedt, B., 4469, 4677
 Sano, K., 2516
 Sano, M., 195
 Santella, R. M., 3471
 Santibanez-Koref, M. F., 3245
 Santoni-Rugiu, E., 2089
 Santoro, I. M., 488
 Santoro, M., 391
 Sapp, M., 3989
 Sarantou, T., 1371
 Sard, L., 2121, 5207
 Sargent, L. M., 3451
 Sarkar, F. H., 3688
 Sarkar, S., 937, 5122
 Sartor, C. I., 978
 Sartorelli, A. C., 5232, 5238
 Sartorius, G., 2860
 Sasada, T., 4916
 Sasagawa, T., 1863
 Sasaki, H., 3548
 Sasaki, T., 4118
 Sasazuki, T., 4714
 Sasse, F., 3344
 Satake, S., 1863
 Sato, B., 4673
 Sato, H., 2055, 3920, 5028
 Sato, M., 2904
 Sato, N., 1584
 Sato, S., 1630
 Satoh, H., 1281
 Satoh, K., 246
 Sattler, G., 3451
 Satyamorthy, K., 1873
 Saunders, M. I., 5261
 Sausville, E. A., 3895, 4285, 5610
 Sauter, G., 2860
 Sawada, J.-i., 3145
 Sawada, M., 5243
 Sawai, H., 4420
 Sawczuk, I. S., 2362
 Scaffidi, C., 4956
 Scambia, G., 4309, 5406
 Scarpa, A., 2035
 Schackert, G., 2638
 Schackert, H. K., 2638
 Schackert, H.-K., 4739
 Schaeffer, U., 4777
 Schaer, J.-C., 1377
 Schäffer, A., 1597
 Schafnitzer, S., 891
 Schalling, M., 2611
 Schantz, S. P., 1081, 2890
 Schär, B. K., 3841
 Scharl, A., 2993
 Scharl, M., 2993
 Scheffer, G. L., 3537
 Scheller, H., 2354
 Scheper, R. J., 3537
 Scherbarth, S., 4105
 Scherbaum, W. A., 1798
 Scheumann, G. F. W., 2501
 Schiestl, R. H., 4378
 Schildberg, F. W., 1394
 Schiller, J., 3989
 Schirmacher, P., 2048
 Schirmer, W. J., 4242
 Schirmer, M., 3847
 Schlagbauer-Wadl, H., 362
 Schleicher, R. L., 3532
 Schleiffer, R., 573
 Schlom, J., 4570
 Schlupp, I., 2993
 Schmaltz, C., 1664
 Schmandt, N., 2085
 Schmid, M., 2993
 Schmid, P., 1371
 Schmid, S. M., 815
 Schmidberger, H., 5309
 Schmidt, C., 2378
 Schmidt, S., 5213
 Schmiegel, W., 3126
 Schmitz, A., 1986
 Schmutte, C., 3010
 Schned, A. R., 3517
 Schneider, M. R., 3847
 Schnitzler, M., 355
 Schoenberg, S. O., 4777
 Schoenmakers, E. F. P. M., 13
 Schold, S. C., 2933
 Scholes, A. G. M., 4070
 Schouten, R., 4384
 Schrader, J. W., 4015
 Schraml, P., 3669
 Schrier, P. L., 362
 Schröck, E., 4585
 Schroeder, M., 4177
 Schuetz, E. G., 3708
 Schuetz, J. D., 3708
 Schultz, D. C., 2029
 Schultz, R. M., 1116
 Schupp, J. E., 5093
 Schupsky, J. J., 1915
 Schutte, M., 1731, 3126
 Schuur, E. R., 2559
 Schwarte-Waldhoff, I., 3126
 Schwartz, Y., 2732
 Schwartz-Cornil, I., 3360
 Schwarz, E., 1460
 Schweigerer, L., 2916
 Schweinfest, C. W., 2961
 Schwendel, A., 2331
 Schwerdtle, R. F., 5009
 Scita, G., 4460
 Scolnick, D. M., 3693
 Scott, B., 3200
 Scott, G. K., 3723
 Scott, J. M. J., 3300
 Scott, M. P., 2369
 Scott, P. A. E., 963
 Scott, R. J., 3288
 Scudiero, D. A., 4285
 Seay, T., 2651
 Sebt, S. M., 1846
 Seckl, M. J., 51
 Seeber, S., 651
 Seed, M. P., 1625
 Segal, S., 5410
 Segawa, K., 1073
 Sehested, M., 4451
 Seidita, G., 1013
 Seifert, B., 5073
 Seigler, H. F., 1561
 Seiki, M., 2055, 4882, 5028
 Seitz, M., 1776
 Sekido, Y., 400, 2256
 Sekiguchi, M., 2415
 Selbo, P. K., 1481
 Selcer, K. W., 702
 Seldin, M. F., 3653
 Selhub, J., 1098
 Selkirk, J. K., 2986
 Selleslag, D., 564
 Selmayr, M., 2346
 Selmin, O., 5493
 Semenza, G. L., 4474, 5328
 Semenzato, G., 4940
 Seon, B. K., 678
 Separovic, D., 1717
 Seril, D. N., 1889
 Serody, J. S., 1547
 Serova-Sinilnikova, O. M., 828
 Serra, F. G., 5406
 Seth, P., 5441
 Setoguchi, T., 1206
 Sette, A., 4348, 4465
 Sexton, D., 3779, 4177
 Seyfried, T. N., 1580
 Sgadari, C., 2508
 Sgambato, A., 1569
 Shabaik, A., 1605
 Shackelford, K. A., 1116
 Shah, K., 4692
 Shah, N., 2268
 Shahesfaei, A., 5542
 Shalinsky, D. R., 162
 Shamah, S. M., 4141
 Shao, C., 1188
 Shao, R.-G., 4029
 Shapiro, D. N., 4042
 Sharkis, S. J., 837
 Sharma, A., 4000
 Sharma, B., 2130
 Shattuck-Brandt, R. L., 3032
 Shay, J., 3664
 Shay, J. W., 326, 2100, 2373
 Shea, T. C., 1547
 Shealy, Y. F., 3444
 Sheehan, D. M., 1903
 Shelly, C. A., 4905
 Shen, F.-m., 2749
 Sherman, L., 4889
 Sherratt, T., 4153
 Sherwin, R. N., 304
 Shi, C.-Y., 1020
 Shi, Y. E., 759, 3084
 Shi, Y.-Q., 2350
 Shibata, K., 5416
 Shibata, S., 3395
 Shigemasa, K., 2884
 Shih, C., 1116
 Shih, I.-M., 3835
 Shih, T.-W., 815
 Shiiba, K., 1851
 Shiio, Y., 3145
 Shillito, E. J., 1614
 Shimada, H., 2042
 Shimada, T., 4757
 Shimizu, K., 2350
 Shimizu, M., 1495
 Shimizu, S., 646, 1835, 2415
 Shimizu, T., 4029
 Shimoda, K., 3395
 Shimodaira, K., 5201
 Shimosaka, A., 5037
 Shinbara, K., 326
 Shinoda, S., 5292
 Shinohara, C., 2694
 Shinonaga, M., 1035
 Shinozuka, H., 795
 Shirai, T., 195
 Shiraiishi, A., 2415
 Shirasawa, S., 4714
 Shiratori, Y., 461, 4279
 Shively, J., 5460
 Shiwaku, H. O., 1851
 Shloma, Z., 3741
 Shoemaker, A. R., 1999
 Shoji, Y., 4432
 Shroot, B., 4931
 Shroyer, K. R., 5379
 Shu, C.-H., 2974
 Shu, S., 4849
 Shudo, K., 4931
 Shuin, T., 1035
 Shuker, D. E. G., 366
 Shuman, M. A., 3594
 Shvarts, A., 1353
 Siccardi, A. G., 1922
 Sidhom, S., 4378
 Sidorenko, S. P., 1758, 3941
 Sidransky, D., 1, 2888, 4183, 4997, 5356
 Siegal, G. P., 1447
 Siegfried, J. M., 433, 2116
 Siemeister, G., 5421
 Siena, S., 5534
 Sieverts, H., 3823
 Siim, B. G., 2922
 Sikes, C., 2493
 Silva, I. D. C. G., 378
 Silva, W. A., 1124
 Silver, A., 2378
 Silvestre, T., 2593
 Sim, B. K. L., 1329
 Simard, J., 3494
 Simi, B., 3717
 Simms, L., 2350
 Simons, J. W., 1537, 2559
 Simony-Lafontaine, J., 4360, 5469
 Simpfendorfer, D., 3347
 Simpson, D. J., 2703
 Singh, J., 253, 3465
 Singh, S. M., 3494
 Singh-Kaw, P., 433
 Singleton, B., 4600
 Sinha, R., 3457
 Sipponen, P., 1276
 Siprashvili, Z., 504
 Siré, E. G., 870
 Sistonen, P., 5017
 Sitlani, J., 5028
 Siviero, M., 4940
 Sjögren, H. O., 4530
 Skaar, T. C., 3486
 Skarulis, M. C., 2238, 4682
 Skilling, J. S., 1047
 Skladanowski, A., 818
 Skolnick, M. H., 4177
 Skrzypczak-Jankun, E., 559
 Slattery, J. T., 4229, 5509
 Slattery, M. L., 75
 Sledge, G., 3511
 Slee, P. H. T. J., 2109
 Sloan, D., 4838
 Sloane, J., 5386
 Slosman, D. O., 1312
 Sluiter, W., 2555
 Smets, L. A., 4811
 Smith, C. D., 3751
 Smith, C. I. E., 1523
 Smith, C. R., 156
 Smith, D. M., 1137
 Smith, D. P., 5399
 Smith, G. J., 1807
 Smith, H. S., 1590

AUTHOR INDEX TO VOLUME 57

- Smith, I. C. P., 3398
 Smith, J. R., 4707
 Smith, K., 963
 Smith, L. L., 1288
 Smith, L. M., 3046
 Smith, M. K., 2104
 Smith, M. S., 5434
 Smith, M. T., 2839
 Smith, S. A., 5399
 Smith, T. J., 1889
 Smith-McCune, K., 1294
 Smolinski, K. N., 2350, 2543
 Sneige, N., 4992
 Snipe, J. R., 1970
 So, C. K. C., 117
 So, C. W., 117
 Soans, F., 1873
 Soares, N., 4570
 Soballe, P. W., 1873, 4478
 Sobol, H., 5469
 Sobue, G., 2870
 Söderkvist, P., 2710
 Soeth, E., 3106
 Soff, G. A., 5277
 Sohn, T. A., 1731
 Sointu, P., 2281
 Solary, E., 686
 Soldatenkov, V. A., 3881
 Soldes, O. S., 5571
 Soler, A. P., 2630
 Solinas-Toldo, S., 3135
 Solomon, D., 995
 Soloway, A. H., 1129, 4333
 Soloway, M. S., 773
 Somerville, K. W., 1625
 Sommer, C., 2581
 Somorjai, R. L., 3398
 Sone, S., 94, 784
 Song, C. W., 3910
 Song, H., 5465
 Sonoda, G., 2116
 Sood, A. K., 1047
 Soose, D. J., 1116
 Sörby, M., 5598
 Sordat, B., 2593
 Sordat, I., 2593
 Sörensen, N., 2085
 Sorio, C., 2035
 Soroceanu, L., 1502
 Sosnowski, B. A., 1447
 Soukka, T., 2281
 Soutar, D., 3886
 Southern, S. A., 4210
 Southwood, S., 4348
 Souza, R. F., 1851, 2350, 2543
 Sowa, Y., 3145
 Sozzi, G., 2121, 5207
 Spandidos, D. A., 4070
 Spang-Thomsen, M., 3486
 Spanjaard, R. A., 5122
 Sparrow, L. E., 4868
 Speicher, D., 3835
 Speiser, P., 4360
 Spence, M. J., 2223
 Sperker, B., 2440
 Sperl, G., 2909
 Spiegel, A. M., 1039, 1855, 2238, 4682, 5446
 Spielholz, C., 2529
 Spivack, S., 2589
 Spriggs, D. R., 5426
 Spruck, C. H., III, 594
 Spryatos, F., 857
 Srinivasula, S. M., 615
 Srivastava, S., 2373, 2485
 St. Clair, D. K., 5265
 Stackhouse, M. A., 4325
 Stähle-Bäckdahl, M., 2336, 4677, 4882
 Stambrook, P. J., 1188
 Stampfer, M. J., 1098
 Stampfer, M. R., 3046
 Stanbridge, E. J., 2827, 4171
 Stancel, G. M., 2547
 Stanczyk, F. Z., 1020
 Stanford, J. L., 1194
 Stanley, M. A., 937
 Staretz, M. E., 259
 Stavridi, E. S., 3693
 Steck, P. A., 5221
 Steele, V., 1301, 3717
 Steele, V. E., 420, 5489
 Steenbeck, M., 4075
 Steger, G. G., 2598
 Steinberg, M. S., 5033
 Steinberg, S. R., 3436
 Steiner, B., 2598
 Stenman, G., 13
 Stenzel, T. T., 4187
 Stephenson, M. T., 659
 Sterman, D. H., 466
 Stern, P. L., 937
 Stewart, J. T., 2839
 Stifelman, M. D., 2362
 Stiles, C. D., 4141
 Stilgenbauer, S., 4608
 Stillwell, W. G., 3457
 Stirzaker, C., 2229
 Stobbe, H., 1634
 Stockmeyer, B., 696
 Stöger, R., 2619
 Stoler, D., 3798
 Stolker, J. M., 3370
 Stoll, S. W., 3055
 Stolz, W., 3149, 3554
 Stoppacciaro, A., 5452
 Störkel, S., 481, 5009
 Storthz, K. A., 1614
 Story, B. M., 3194
 Stoumen, A. L., 2452
 Stracke, M. L., 2516
 Strassburg, C. P., 2979
 Straten, P., 3660
 Stratford, I. J., 570
 Strauss, L. G., 3415
 Street, J. C., 3956
 Strickland, P. T., 5493
 Strickler, H., 3319
 Strobel, T., 1228
 Strong, J. M., 815
 Strong, L. C., 106, 1859
 Stros, M., 1487
 Struck, R. F., 815
 Studzinski, G. P., 2851
 Sturgill, R., 2020
 Styles, J. A., 1288
 Su, J., 3084
 Su, J.-S., 1516
 Su, M. S.-S., 4578
 Su, P.-H., 4177
 Subbaramaiah, K., 1081, 2890
 Sublett, J. E., 4042
 Suga, K., 1981
 Suganuma, N., 5416
 Sugimachi, K., 28, 1335
 Sugimura, H., 2350, 2543
 Sugimura, K., 4765
 Sugimura, T., 195, 1233, 3548, 5022
 Sugino, T., 3140
 Sugiyama, Y., 1934, 3506
 Suh, P.-G., 5465
 Sukumar, S., 2144, 5605
 Sulfaro, S., 2366
 Sullivan, C. M., 1137
 Sullivan, L. D., 1584
 Sumida, T., 246
 Sumizaki, H., 3792
 Sun, B.-F., 1955, 2754
 Sun, D., 3708
 Sun, H., 2124
 Sun, J., 1846
 Sun, J. S., 620
 Sun, L.-Q., 1312, 4023
 Sun, S.-Y., 4931
 Sun, Y., 18
 Super, M., 4948
 Surmacz, E., 2606
 Susini, C., 956
 Sutherland, J. A., 290
 Sutherland, M. E., 4744
 Sutoh, K., 2081
 Sutter, T. R., 4757
 Suyama, M., 4898
 Suzuki, H., 3506
 Suzuki, T., 1335
 Swalsky, P., 2485
 Swanson, L., 1228
 Swedlund, B., 4177, 5221
 Swiercz, R., 559
 Swift, S., 5485
 Swinnen, J. V., 1086
 Swisher, S. G., 4722
 Sybrecht, G. W., 2290
 Syljuäsen, R. G., 3899
 Syngal, S., 5017
 Szekeres, K., 2522
- T**
- Taatjes, D. J., 3101
 Taccogna, S., 2071
 Tada, E., 2694
 Tagliabue, E., 5207
 Taguchi, T., 2029
 Tahara, K., 4465
 Tähtelä, R., 5517
 Takagi, M., 1895
 Takahashi, A., 3910
 Takahashi, H., 513
 Takahashi, M., 1233, 2870
 Takahashi, N., 7
 Takahashi, S., 195
 Takahashi, T., 1895, 4898, 4898
 Takakura, M., 610, 1863
 Takakura, Y., 2681
 Takano, H., 5086
 Takano, T., 3792
 Takao, M., 2151
 Takashima, R., 2151
 Takatera, H., 2081
 Takatsuki, K., 4862
 Takaue, Y., 5037
 Takesako, K., 4465
 Takeshita, T., 1241
 Taketo, M. M., 1644
 Taki, T., 1882
 Takita, H., 2937
 Takita, J., 907, 3772
 Talanian, R. V., 615
 Talbot, A. J., 2703
 Tamai, I., 4118
 Tamano, S., 195
 Tamaoki, T., 461
 Tamaya, T., 5579
 Tamez, P., 199
 Tamir, S., 1823
 Tamiya, S., 4862
 Tammela, T., 314
 Tamura, K., 1895
 Tan, M., 1199
 Tan, P., 1259
 Tan, W., 3532
 Tanabe, T., 1081, 2890
 Tanaka, F., 1335, 4465
 Tanaka, S., 28
 Tanaka, T., 246, 461, 3644, 4279, 5475
 Tanaka, Y., 28
 Tang, H., 5137
 Tang, W., 472
 Tanigami, A., 32
 Tanigawa, N., 221, 1043
 Taniguchi, E., 2081
 Tanimoto, H., 2884
 Tanimoto, K., 1981
 Tanimoto, T., 4557
 Tannenbaum, S. R., 1823, 3457
 Tanner, M., 1222, 1597
 Tano, Y., 3305
 Tanscott, S. J., 3526
 Tarabichi, A., 1394
 Tarin, D., 3140
 Tarone, R. E., 4637
 Tarpley, J., 472
 Tashiro, H., 3935
 Tatarelli, C., 4523
 Tatematsu, M., 1416
 Tatenio, M., 1863
 Taverna, S., 1442
 Tavtigian, S. V., 3779, 4177, 5221
 Taylor, G., 5391
 Taylor, J. A., 5001
 Taylor, L. S., 2468
 Taylor, M. C., 3026
 Taylor, R., 2112
 Taylor, S. T., 1939
 Taylor, W. R., 4876
 Tecce, R., 1306
 Temponi, M., 1554
 Teng, C., 4356
 Teng, D. H. F., 3779
 Teng, D. H.-F., 4177, 5221
 Teng, M., 2642, 4931
 Terachi, T., 742
 Terada, M., 3548, 5022
 Terleth, C., 4384
 Terribile, D., 5406
 Terry, N. H. A., 1091, 2493
 Tesch, H., 1704
 Testa, J. R., 433, 2029, 2116, 4057
 Tewari, M., 4063
 Theillet, C., 4360, 4368
 Theleman, A., 4838
 Theodosiou, M., 206
 Therikildsen, M. H., 634
 Thiagalingam, S., 2578
 Thiel, T. J., 3653
 Thierfelder, S., 2346
 Thijssen, J. H. H., 2109
 Thölix, E., 5517
 Thomale, J., 651
 Thomas, A., 4177
 Thomas, C. F., 3424
 Thomas, D. G. T., 4196
 Thomas, G., 300, 1986
 Thomas, P., 4432

AUTHOR INDEX TO VOLUME 57

- Thompson, E. W., 5028
 Thompson, H., 5067
 Thompson, H. J., 267, 5605
 Thompson, J., 1776
 Thompson, J. S., 926
 Thomsen, L. L., 3300
 Thoresen, S., 3989
 Thorgeirsson, S. S., 2089
 Thorgeirsson, U. P., 3924
 Thorncroft, M., 3245
 Thraves, P. J., 576
 Threadgill, D. W., 3180
 Thuille, B., 300
 Tiihonen, E., 2966
 Tikoo, A., 2478
 Tillmanns, S., 1660
 Timar, J., 2522
 Timblin, C. R., 3101
 Tindall, D. J., 2651
 Tindall, K. R., 3949
 Ting, C.-Y., 1516
 Ting, P. P., 2569
 Tiraby, M., 110
 Tirkkonen, M., 1222
 Tischfield, J. A., 1188
 Titenko-Holland, N., 2839
 Titzer, S., 1704
 Tiwari, A., 815
 Tkachenko, A., 2276
 Tlsty, T. D., 3635
 Tobacman, J. K., 2823
 Tobias, V., 5399
 Todd, R. F., III, 1682
 Todd, S., 1344
 Toftgård, R., 2336, 4677, 4731
 Tognon, M., 3319
 Toh, S., 5475
 Tokino, T., 3281
 Tokman, M. G., 1785
 Toledo, S. P. A., 310
 Tolia, J., 4091
 Tomlinson, G. E., 3664
 Tomlinson, I. P. M., 5017
 Tommasi, S., 4727
 Tomonaga, M., 2799
 Tonkinson, J. L., 3351
 Tonn, J., 2085
 Toomes, H., 2440
 Topalian, S. L., 995
 Topham, J. C., 4148
 Topley, P., 3300
 Torchard, D., 828
 Tornielli, S., 2121, 5207
 Tornos, C., 5221
 Torrisi, M. R., 5498
 Tortora, G., 5107
 Tosato, G., 2508
 Tosti, M. E., 747
 Toth, M., 3159
 Toulas, C., 1364
 Toyama, K., 2100
 Tozer, G. M., 948, 1829
 Trabanelli, C., 4153
 Tracy, M., 3314
 Trail, P. A., 100, 4530
 TrailSmith, M. D., 100
 Tran, H., 1030
 Tran, P., 1030
 Trapman, J., 314
 Traquina, P., 1590
 Trautwein, C., 2048
 Traver, R. D., 2839
 Travis, E. L., 1929, 5286
 Travlos, G., 4667
 Traycoff, C. M., 3511
 Trent, J. M., 4707
 Trentin, L., 4940
 Tressel, P. O., 472
 Tricker, K. J., 3245
 Trikha, M., 2522
 Trinchieri, G., 2460
 Troncoso, P., 5221
 Tropé, C., 3818
 Trosko, J. E., 1699
 Troyer, D. A., 600
 Trump, D. L., 3759
 Tryson, K., 3436
 Tsai, H., 678
 Tsai, M. H., 4200
 Tsai, M.-J., 4511
 Tsai, S. Y., 4511
 Tsai, W.-Y., 3471
 Ttang, K.-Y., 4570
 Tschmelitsch, J., 2181
 Tso, C.-L., 495
 Tsubari, M., 2966
 Tsubouchi, H., 4862
 Tsuchiya, A., 3920
 Tsuchiya, E., 1981
 Tsugu, H., 2799
 Tsuji, A., 4118
 Tsujimoto, M., 5379
 Tsujimoto, Y., 1835
 Tsujita, T., 1495
 Tsukada, H., 3612
 Tsunematsu, Y., 1895
 Tsuruo, T., 921, 3040
 Tsuruoka, N., 4545
 Tsurutani, N., 646
 Tsutsui, T., 2216
 Tsutsumi, M., 1281, 1644
 Tsuzuki, T., 2415
 Tsvetkov, L. M., 2252
 Tsvieli, R., 3741
 Tucker, M. A., 4637
 Tukey, R. H., 2979
 Turbide, C., 2781
 Turchi, J. J., 4488, 5013
 Turk, B. F., 1962
 Turley, H., 1794
 Turley, J. M., 881, 2668
 Turm, H., 2732
 Turner, B. C., 3079
 Tyrrell, R. M., 1405
- ## U
- Uchiumi, T., 5475
 Uchiyama, T., 5452
 Udeani, G. O., 3424
 Udelsman, R., 2144
 Ueda, M., 370, 2081, 4731
 Ueda, R., 1895
 Ueda-Taniguchi, Y., 4916
 Ueno, H., 2055
 Ulich, T. R., 472
 Ulrich, C. D., II, 1475
 Umansky, S. R., 1758
 Umar, A., 2956, 3949
 Umbricht, C. B., 2144, 5605
 Undén, A. B., 2336, 4677
 Uniyal, S., 3812
 Uno, T., 4356
 Upadhyaya, P., 4757
 Urade, M., 295
 Urano, T., 3281
 Uria, J. A., 4882
 Ursin, G., 3678
 Usami, I., 5243
 Uskokovic, M., 4545
 Utsugisawa, T., 3640
 Utsunomiya, J., 1895
 Uy, H. L., 3194
- ## V
- Vacek, P., 3101
 Valente, L., 284
 Valenti, M., 870
 Valentine, M. B., 4042
 Valentinis, B., 3264
 Valerius, T., 696
 Valmori, D., 735
 Van den Berghe, H., 564
 van der Eb, A. J., 1353, 4384
 vanderSpek, J. C., 290
 Vanderveer, L., 5480
 van de Ven, J., 1238, 2109
 Van de Ven, W. J. M., 13
 van de Winkel, J. G. J., 696
 Vande Woude, G. F., 5391
 van Dijk, M. A. J., 3478
 van Eijk, M. J. T., 3537
 van Elsas, A., 362
 van Ham, R. C. A., 1353
 van Kaick, G., 4777
 van Kranen, H. J., 1238
 van Kreijl, C. F., 1238
 van Laar, T., 4384
 van Muijen, G. N. P., 3223
 Van Ness, B., 2268
 van Orsouw, N. J., 5017
 van Steeg, H., 581, 4384
 van Steenbrugge, G. J., 4075
 van't Veer, L. J., 3478
 van Weerden, W. M., 4075
 Van Winkle, T., 5155
 Varella-Garcia, M., 1, 1344
 Varki, N. M., 4948
 Varley, J. M., 3245
 Varma, V. A., 3532
 Varon, D., 5605
 Varvayanis, S., 2020
 Vaughan, E. D., 4070
 Vaughan, L. A., 4000
 Vaupel, P., 4777
 Vayssie, N., 956
 Veillette, C., 1255
 Veldscholte, J., 4075
 Venta-Perez, G., 2789
 Venturelli, D., 1180
 Venugopal, R., 440
 Venzon, D. J., 4682
 Vera, J. C., 2529
 Verhoeven, G., 1086
 Verity, M. A., 4098
 Verkroost, G., 3223
 Veronese, L. M., 3010
 Veronese, M. L., 504, 1144, 1180, 2121, 5207
 Verschraegen, C. F., 4309
 Vespasiani, G., 875
 Vestal, R. E., 2223
 Viallet, J., 2615
 Vickers, S. M., 1743, 4325
 Vidaud, M., 516
 Vihko, P., 3356
 Vihko, R., 3356
 Vijg, J., 5017
 Vikhanskaya, F., 870
 Villunger, A., 3331
 Vincent, P. C., 2229
 Vinson, V. L., 5221
 Vinton, E. G., 2209
 Virgilio, L., 5452
 Virmani, A., 2256
 Virmani, A. K., 3154
 Virudachalam, S., 2096
 Visakorpi, T., 314
 Vocke, C. D., 995
 Voeller, H. J., 4455
 Vogel, C.-A., 447, 1312
 Vogel, I., 3106
 Vogelstein, B., 2578
 Vogelstein, J. T. C., 4692
 Vogt, P. K., 123
 Vogt, T. M. M., 3554
 Vollmer, C. M., 2865
 von Ballestrem, C., 3812
 von Deimling, A., 2085
 Von Hoff, D. D., 279
 von Knebel-Doberitz, M., 4739
 von Wasielewski, R., 2501
 Vořechovský, I., 4677, 4731
 Vortmeyer, A. O., 4682, 5446
 Vorum, H., 4111
 Vukosavljevic, T., 2366
 Vuorinen, K., 5517
- ## W
- Waanders, G., 735
 Wacholder, S., 2839
 Wacker, R., 2993
 Wada, H., 5379
 Wada, M., 5475
 Wada, S., 4765
 Wadler, S., 1769
 Wagener, C., 2354
 Waghay, A., 3688
 Wagner, C. R., 2341
 Wagner, E., 3886
 Wagner, T., 2676
 Waha, A., 2085
 Wähälä, K., 2916
 Wahl, G. M., 1013, 1171
 Wainwright, B., 2085
 Wakabayashi, K., 195, 1233
 Wakasa, K., 5379
 Wakefield, L. M., 5564
 Wakimoto, H., 461
 Waldman, F. M., 2369
 Waldmann, T. A., 1955
 Waldmann, V., 2358
 Waldschmidt, T. J., 1758
 Walker, A., 1939
 Walker, B. E., 4162
 Walker, G. J., 5336
 Wallace, P. K., 4008
 Wallin, G., 4710
 Wallinger, S., 4749
 Wallis, A., 3899
 Wallrapp, C., 3135
 Walsh, K., 351
 Walsh, P. C., 4707
 Walters, M. K., 4868
 Walunas, T., 4036
 Wandall, H. H., 634
 Wands, J. R., 28
 Wang, C., 4682
 Wang, C.-X., 420, 2623, 3717
 Wang, D. Z. M., 2478
 Wang, E., 5426
 Wang, F., 5369
 Wang, H., 1750
 Wang, H.-G., 1605
 Wang, H.-M., 620
 Wang, J., 351, 2951
 Wang, J. Y. J., 3253

AUTHOR INDEX TO VOLUME 57

- Wang, J-S., 641
Wang, K., 1660
Wang, L., 615
Wang, L. G., 714
Wang, L-F., 1516
Wang, L-Y., 3471
Wang, M., 543, 759, 1438, 2951
Wang, P., 4699
Wang, Q., 5004
Wang, Q. M., 2851
Wang, R-f., 202
Wang, S., 2350, 2543, 5060
Wang, S. I., 3935, 4183
Wang, T. C., 3972
Wang, W., 3929
Wang, X., 2042, 3115, 3910
Wang, Y., 1654
Wang, Z., 3989
Wang, Z. Y., 2623
Wang, Z-Y., 1889
Wanibuchi, H., 4765
Wanner, M., 1259
Wargniez, V., 5469
Warloe, T., 404
Warnecke, P. M., 2229
Warren, R. S., 2369
Waser, B., 1377
Washburn, K. A., 4356
Wasserman, W. W., 5117
Watabe, M., 3097
Watanabe, H., 3145
Watanabe, K-I., 5243
Watanabe, M., 3612
Watanabe, T., 5037
Watson, D. K., 2961
Watson, M. A., 5493
Wattenberg, L. W., 5489
Watters, D. J., 3600
Waud, W. R., 1815, 4803
Waugh, A., 4600
Waxman, D. J., 1946, 4830
Waxman, S., 1668
Wayne, J. D., 4205
Wazer, D. E., 5584
Weaver, Z., 4585
Webber, K. O., 1955
Webber, M. M., 576
Weber, C. E., 1537
Weber, T. K., 3798
Wechsler, D. S., 4905
Wechsler-Reya, R., 3258
Wechter, W. J., 4316
Weckbecker, G., 956
Wei, Q., 1673
Weichselbaum, R. R., 1270, 4205, 4340
Weikel, W., 4777
Weil, R., 5446
Weinberg, J., 1124
Weindel, K., 5421
Weinstein, I. B., 1569
Weinstein, J. N., 4285
Weishaupt, K. R., 4000
Weissfeld, J., 2485
Weissfeld, L. A., 433
Weissman, B. E., 1157, 2986
Weitzel, J. N., 387
Welch, D. R., 2384
Welch, W. R., 387
Welsh, J., 3554
Welsh, J. A., 426
Welt, S., 2181
Werdelin, O., 3214
Werelius, B., 2474
Werner, M., 2501
Wessel, I., 4451
Wester, P. W., 1238
Westergaard, C., 3569
Westermarck, B., 5598
Westphal, C. H., 1664
Westra, W. H., 2144
Weyant, R. J., 433
Whang-Peng, J., 1516, 2974
Wharton, J. T., 87
Whary, M. T., 3972
Wheeler, K. T., 156
Wheelock, M. J., 2741
Whelan, J., 4267
Whirrett, B. R., 156
Whitacre, C. M., 1425, 2157
Whitcomb, L., 472
White, I. N. H., 1288
White, R. A., 2493
White, T. D., 2602
Whitehouse, R., 963
Whiteside, T. L., 2485
Whitley, R. J., 1502
Wicking, C., 2085
Wicklund, K. G., 1194
Widmer, F., 51
Widschwendter, A., 4158
Widschwendter, M., 3818, 4158
Wiebke, E. A., 3511
Wiedemann, L. M., 117
Wieder, R., 1750
Wiedmann, T. S., 5489
Wieman, T. J., 4551
Wieser, R., 3914
Wiest, J. S., 1, 1344
Wiestler, O. D., 2085
Wijesuriya, R., 2216, 4036
Wikstrand, C. J., 1510, 4130
Wilbur, D. S., 4015
Wilding, G., 2428
Wiley, J., 3451
Wilkens, C., 4777
Wilkens, L. R., 4787, 5077
Wilkinson, G. W. G., 4855
Willard, S. T., 4447
Willett, W. C., 1098
Williams, C. J., 2181
Williams, C. L., 1785
Williams, C. S., 1638
Williams, J. P., 4478
Williams, R. D., 4242
Williams, S. R., 4196
Willis, D., 1625
Willner, D., 100, 4530
Willoughby, D. A., 1625
Wills, K. N., 351
Willson, J. K. V., 4817
Wilson, D. F., 5155
Wilson, G., 1091
Wilson, M. C., 5320
Wilson, M. R., 1699
Wilson, R., 4667
Wilson, S. T., 1909
Wilson, T., 206, 3765
Wilson-Heiner, M., 4722
Wilson-Van Patten, C., 206
Wiltout, R., 5189
Wimmer, I., 5073
Windle, J. J., 600
Winkelman, J. W., 4551
Winkler, M., 4593
Winterpacht, A., 5009
Wirtz, H-C., 4739
Wiseman, R. W., 2710, 3121
Wishnok, J. S., 3457
Wistuba, I., 2256
Wistuba, I. I., 2373, 3154, 3664
Withers, D. A., 3092
Witiak, D. T., 620
Wlodarska, I., 564
Wlodarski, B., 5386
Wobbes, T., 3223
Wogan, G. N., 1823
Woitach, J. T., 2089
Wolf, D. M., 1244
Wolf, G., 2331, 5213
Wolf, H., 4111
Wolf, H. K., 2085
Wolf, J., 1704
Wolff, K., 362
Wolter, M., 2581
Wong, A. J., 1419
Wong, A. K. C., 4177
Wong, D. J., 2619
Woo, E. S., 4236
Woodhouse, C. S., 4015
Woodman, A., 3140
Workman, P., 3314
Worland, P., 1259
Wormhoudt, T., 4384
Wouters, B. G., 4703
Wright, J. A., 4876
Wright, J. H., 2104
Wright, N. A., 4507
Wright, W. E., 2100
Wu, C. S., 2493
Wu, H. P., 659
Wu, H-Y., 620
Wu, L., 5356
Wu, R., 3935, 4692
Wu, Y-Y., 234
Wulst, E., 5309
Wygod, M. R., 1699
Wysocka, M., 2460
- X**
- Xi, L., 2839
Xia, L., 3055
Xia, X., 2749
Xia, Y., 3629
Xiang, R., 4948
Xiao, G., 759, 3084
Xiao, W., 2715
Xie, J., 2369
Xie, J-G., 2623
Xie, S., 2295
Xie, Y., 495
Xing, L., 3084
Xing, R. H., 3585
Xu, F., 332, 3772
Xu, H-J., 1217, 3339
Xu, J., 4707
Xu, X-C., 4992
Xu, Y-H., 3451
Xue, W., 1682
- Y**
- Yacoub, A., 5457
Yager, J. D., 5493
Yahalom, J., 1750
Yahanda, A., 382
Yajima, A., 1630
Yamada, T., 3920
Yamaguchi, A., 3208
Yamaguchi, K., 4862
Yamaguchi, N., 907
Yamaguchi, R., 2410
Yamakawa, H., 1630
Yamamoto, H., 1895, 4420
Yamamoto, I., 1035
Yamamoto, K., 907, 2151, 3772
Yamamoto, M., 1416, 2799, 4673
Yamamoto, N., 295, 2187
Yamamoto, S., 4765
Yamanari, H., 1206
Yamaoka, H., 2042
Yamaoka, Y., 4916
Yamasaki, H., 370, 375, 2148, 2929, 4731
Yamashita, F., 2681
Yamashita, K., 5168
Yamashita, T., 5137
Yamauchi, A., 4916
Yamazaki, H., 4757
Yamazaki, M., 3506
Yamori, T., 921
Yan, T., 5550
Yan, Y., 2884
Yanagisawa, M., 3772
Yandell, D., 3798
Yang, C. S., 1889, 4414
Yang, D., 5238
Yang, F., 4585
Yang, G-y., 1889
Yang, J-S., 4229
Yang, L. M., 4652
Yang, L-Y., 1487
Yang, M. B., 100
Yang, R., 913
Yang, S., 1561
Yang, V. W., 199
Yang, W., 1129, 4333, 5460
Yang, W. K., 2974
Yang, Y-F., 4036
Yano, H., 3040
Yano, S., 784
Yao, J., 1199
Yao, K-S., 1050
Yao, M., 1035
Yao, T-J., 2181
Yap, W. Y., 4378
Yarom, N., 2434
Yashima, K., 2373
Yasui, A., 2151
Yatabe, Y., 4898
Yates, A., 4098
Yazaki, Y., 3548
Yen, A., 2020
Yen, P., 1468
Yenisey, C., 2130
Yeo, C. J., 1731
Yi, E. S., 472
Yih, L-H., 5051
Yin, J., 2350, 2543
Yin, J. J., 3194
Yin, S., 2839
Ying, W., 1447, 1743
Yodoi, J., 4916
Yohe, H. C., 1580
Yokoi, T., 641
Yokokura, T., 5305
Yokota, J., 907, 1895, 3772
Yokoyama, M., 2575
Yokoyama, T., 326, 3395
Yonetani, N., 7
Yoo, S., 1412
Yoo, T. M., 1955, 2754
Yoshida, K., 3140
Yoshida, M., 678, 1035
Yoshida, N., 2200
Yoshida, O., 742

AUTHOR INDEX TO VOLUME 57

Yoshida, T., 1495, 5022
Yoshida, Y., 461, 4279
Yoshiji, H., 3924
Yoshikawa, T., 2200
Yoshimatsu, K., 3208
Yoshinari, T., 2151
Yoshino, H., 3208
Yoshino, K., 5379
You, E. H., 5336
You, M., 272
Young, A., 3653
Young, C. Y. F., 2651
Young, G. P., 3697
Young, J., 2350, 2543
Youngman, L., 3989
Yu, A. L., 832
Yu, C-L., 978
Yu, D., 1199
Yu, F., 4682
Yu, G., 3084
Yu, J. C., 832
Yu, L., 1946
Yu, L. J., 4830
Yu, M., 4063, 5028
Yu, M. C., 1020
Yu, W-D., 3759
Yu, W-G., 2216
Yu, Y., 2410
Yuan, J., 3079
Yuan, Z-M., 3640
Yuasa, Y., 3920

Yudoh, K., 672
Yue, P., 4931
Yuhua, D. A., 4551
Yung, W. K. A., 1673, 5221
Yuspa, S. H., 3180
Yusuf, F. I., 4242

Z

Zabel, B., 5009
Zagars, G. K., 2493
Zagotto, G., 1710
Zahurak, M., 1731
Zaidi, N. H., 4817
Zalatan, F., 1909
Zalewski, P. D., 3697
Zalutsky, M. R., 1510
Zambello, R., 4940
Zampella, A., 3751
Zanesi, N., 4164
Zangrilli, J., 43
Zanker, K. S., 2061
Zapata, J. M., 1605
Zaphiropoulos, P. G., 2336
Zaremba, S., 4570
Zavada, J., 2827
Zborowska, E., 1425, 4817
Zedenius, J., 500, 4710
Zehnauer, B. A., 1678
Zeiger, M. A., 2144
Zeillinger, R., 4360
Zeimet, A. G., 3818, 4158

Zelada-Hedman, M., 2474
Zelnick, C. R., 5217
Zeng, H., 290
Zeng, T., 5258
Zeremski, M., 5217
Zeuthen, J., 3238, 3660
Zeytin, H., 728
Zha, Y., 1915
Zhang, D., 2410
Zhang, H-T., 1814
Zhang, L., 162, 2839, 3929, 5258
Zhang, M., 3084, 3532, 4631
Zhang, N., 337
Zhang, Q-X., 1244
Zhang, S., 646, 2651
Zhang, T., 169, 1638
Zhang, W., 3929
Zhang, X., 2369, 3751
Zhang, X-k., 3444
Zhang, Y., 1091
Zhang, Y-J., 3471
Zhang, Z-F., 1217
Zhang-Sun, G., 2615
Zhao, H., 4578
Zheng, H., 1841
Zheng, M., 3532
Zheng, P., 2410
Zheng, X., 1903
Zheng, Z., 500, 4710, 5017
Zhong, Q., 4225
Zhou, N., 3678

Zhou, P., 1569
Zhou, R-H., 4699
Zhou, T., 2749
Zhou, Y., 3339
Zhu, B. T., 2419
Zhu, D., 2485
Zhu, M., 426, 4570
Zhu, W., 2148
Zhu, Y-H., 1294
Zhu, Z., 5067
Zhuang, S-M., 2710
Zhuang, Z., 1039, 1855, 2238, 4682, 5446
Ziche, M., 1814
Ziegler, A., 407
Ziltener, H. J., 4015
Zimmerman, C. L., 5489
Zimmerman, P. V., 2256
Zimmermann, W., 1776
Zimonjic, D. B., 1166
Zingg, J-M., 594
Zirngibl, H., 3149
Zoekler, M. E., 100
Zou, H., 2749
Zou, J-P., 2216, 4036
Zou, T-T., 2350, 2543
Zou, Y., 4699
Zuna, I., 4777
Zunino, F., 1710
Zwacka, R., 5550

SUBJECT INDEX

Volume 57

A

- AAC-11**
apoptosis inhibition, 4063
- Aberrant crypt foci**
and colonic carcinoma, dimethylhydrazine-treated rats, 4507
- A431 cells**
G₁ phase accumulation by UCN-01, mechanism, 1495
- A549 cells**
cell cycle enrichment by FTI-277, 1846
- Acetaldehyde**
hemoglobin-associated
and *ALDH2* genotype, 1241
- α -N-Acetylgalactosaminidase**
serum
prognostic index, oral cancer, 295
- β -1,4-N-Acetylgalactosaminyl transferase**
gene expression, mouse brain tumors, 1580
- ACHAETE SCUTE 1 (HASH1) gene**
expression, neuroectodermal tumors, 3526
- ACHN cells**
 γ -IFN- and IL-4-regulated proteins, identification, 1137
- Acidity**
WAF1 induction, p53-dependent, 3910
- Aclacinomycin A**
topoisomerase I inhibition, 4564
- ACNU: see 1-(4-Amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chlorethyl)-3-nitrosourea**
- Actinic keratosis**
induction by ultraviolet B, skin, 2081
- Activating transcription factor 1**
induction by nickel
and thrombospondin I gene expression, 5060
- Activator protein 1**
activation
inhibition by inositol hexaphosphate, 2873
inhibition by retinyl methyl ether, breast cancer, 3444
inhibition by tea polyphenols, 4414
activity, mammary epithelial cells, 3046
eps15 interaction, molecular determinants, 240
neoplastic transformation response, 3569
- Acyl-CoA oxidase**
promoter
peroxisome proliferator detection, rat liver cells, 1575
- Adenocarcinoma: see also specific sites**
GalNAc-transferase expression, 4744
- Adenoma: see specific sites**
- Adenomatous polyposis**
familial
cyclin D1 and Cdk4 overexpression, 169
early colorectal adenoma, clonality, 355
ornithine decarboxylase and polyamines, 199
- Adenomatous polyposis coli**
APC gene
alternative splicing, 488
mutations, and intestinal cell migration, 5045
truncated, and *H. felis* infection, 3972
Apc^{Δ716} knockout mice
polyp formation, 1644
APC^{Min} mouse
intestinal adenoma, prophylaxis and treatment, 4316
intestinal neoplasia, 812
function, deletion analysis, 4624
- Adenosine**
extracellular fluid, solid tumors, 2602
- Adenosine triphosphate**
intracellular levels
apoptosis requirements, 1835
- Adenovirus**
attenuated replication competent CN706, prostate cancer, 2559
bFGF-SAP killing enhancement, 1873
gene transfer
MnSOD, hamster cheek pouch carcinoma cells, 5550
PML
prostate cancer therapy, 1868
regulatable TNF- α expression, 3339
type 12-induced hamster tumors
clonal origin, 3001
- Aflatoxin**
exposure
hepatocellular carcinoma, Taiwan, 3471
- Aflatoxin B₁**
activation by *CYP3A7*, transgenic mice, 641
- Aflatoxin B₁-aldehyde reductase**
overexpression, selenium deficiency, 4257
- Age**
-dependent busulfan-glutathione conjugation, 5509
-dependent hepatic tumor regression, rat, 1807
diagnosis
HPC1 gene, families, 4707
- Alcohol**
perillyl, dietary
colon carcinogenesis chemoprevention, 420
- Alcohol use**
and colorectal cancer, 4787
- Aldehyde dehydrogenase 2**
ALDH2 genotype
hemoglobin-associated acetaldehyde and, 1241
- Alkaline phosphatase**
isoenzymes
detection by reverse transcription-PCR, germ cell tumors, 3841
stimulation by estrogens
blockade by EM-800, human endometrial cells, 3494
- Alkylation**
tolerance
MSH5 gene mutation and, 2715
- Alkyltransferases**
human
BG-resistant, 2007
- Allelic imbalances**
chromosome 1q31-32, breast cancer, 4217
- Allelic loss: see also Loss of heterozygosity**
endocrine tumors, 2238
FHIT/FRA3B, lung cancer, 2256
nonsynthetic
hepatocellular carcinoma, high-resolution allelotype, 1986
- Allelotype**
high-resolution
hepatocellular carcinoma, 1986
- ALL1 protein**
cellular localization, 799
fusion with eps15
cellular localization, 799
- ALRT1550**
antitumor activity, oral squamous carcinoma xenografts, 162
- Alu**
1-kb germ-line *BRCA1* gene deletion, 828
- MLL* self fusion, acute myeloid leukemia, 117
- Amazon molly**
pigment cell tumors, 2993
- 9-Amino-20(S)-camptothecin**
carcinoma radioresponse potentiation, 1929
- N-[4-[2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-ethyl]-benzoyl]-L-glutamic acid: see LY231514**
- 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline**
urinary excretion, humans, 3457
- 5-Aminolevulinic acid esters**
and photodynamic therapy, 1481
- N-(3-(Aminomethyl)benzyl)acetamide: see 1400W**
- 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine**
lymphoma
inhibition by oltipraz, 2806
prostate carcinoma, rat, 195
urinary excretion, humans, 3457
- 1-(4-Amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chlorethyl)-3-nitrosourea**
transient MRP/GS-X pump and γ -GSC induction, glioma cells, 5292
- 6-Aminonicotinamide**
metabolic and radiobiological effects, quantitation, 3956
- Anaplasia**
IGF-II/IGFBP-2 mRNA ratio marker, meningioma, 2611
- ANBL6 cells**
growth properties
N- and K-ras mutation effects, 2268
- Androgen**
CD2, *CDK4*, and *p16* gene regulation, 4511
-dependent prostate carcinoma
cell growth regulation, 4511
differential gene expression, 4075
Fas regulation, LNCaP cells, 1086
GGT activity and mRNA effects, prostate carcinoma cells, 2428
-independent prostate carcinoma
differential gene expression, 4075
progression, TRAMP model, 4687
receptor
gene amplification, 314
gene polymorphisms, and prostate cancer risk, 1194
- Androgen ablation**
antiangiogenesis potentiation, prostatic cancers, 1054
quiescence, R3327-G rat prostate tumors, 2493
- Androgen deprivation therapy**
prostate cancer
failure mechanism, 314
- Anemia**
Fanconi syndrome
deregulated apoptosis, 1722
- Angiogenesis**
bFGF-induced, bladder cancer, 136
cervical carcinoma, MRI assessment, 4777
colorectal cancer, 1043
inhibition
flavonoids, 2916
linomide, potentiation by androgen ablation, prostatic cancers, 1054
2-methoxyestradiol and Taxol, mice, 81
topical diclofenac in hyaluronan, colon-26 adenocarcinoma, 1625
u-PAR blockade, prostate cancer, 3594
in vivo model, 3847
neurokinins midkine and pleiotrophin, 1814

- spontaneous apoptosis and, gastric carcinoma, 221
- squamous carcinogenesis
- cross-species comparison, 1294
- VEGF-induced
- fenestration, 765
- Angiogenic factors**
- expression, breast cancer, 963
- Angiogenic tumors**
- induction, ODC-overexpressing cells, 3016
- Angiogenin**
- antiangiogenin peptide ANI-E, development, 3733
- Angiosarcoma**
- hepatic
- connexin 37 mutations, rat, 375
- p53 gene mutations, rat, 1695
- Angiostatin**
- recombinant
- metastasis inhibition, 1329
- tumor growth inhibition, murine hemangioendothelioma, 5277
- ANI-E**
- development, 3733
- Antibodies: see also Monoclonal antibodies**
- anti-idiotypic
- antitumor immunity, 728
- avidin complexes
- and bio-TNF, tumor targeting, 1922
- bispecific
- anti-idiotypic vaccination, B-cell lymphoma, 2346
- bispecific CD3xCD19
- EBV-induced B-cell lymphoma prevention, SCID mice, 1704
- bispecific FcγR HER-2/neu
- effector mechanisms, breast carcinoma, 696
- bispecific FcγRI HER2/neu
- HER2-expressing cell lysis, 4008
- CD28
- EBV-induced B-cell lymphoma prevention, SCID mice, 1704
- huKS1/4-IL-2 fusion protein
- colon carcinoma elimination, 4948
- Anticancer drugs: see also Drug resistance; Multidrug resistance; specific drugs**
- apoptosis
- inhibition by IGF-1, HBL100 cells, 2687
- growth-inhibitory potency
- p53 characterization and, 4285
- sensitivity
- cMOAT and, hepatic cancer cells, 5475
- p21^{waf1}-mediated, sarcoma cells, 2193
- R2 gene expression and, 4876
- Antiestrogens**
- EM-800, human endometrial cells, 3494
- resistance
- estrogen receptor DNA binding, breast cancer, 3723
- estrogen receptor mRNA splice variants, breast cancer cells, 585
- steroidal and triphenylethylene, 3486
- Antifolates**
- multitargeted LY231514, 1116
- Antigens**
- ALL-1/MLL/HRX
- nuclear localization, 2035
- carcinoembryonic
- agonist CTL peptide, 4570
- cytokine induction, mouse, 4432
- gastric carcinoma, *in vivo* gene therapy, 4279
- gene family expression, colorectal adenomas, 2354
- gene family member 2 down-regulation, colorectal tumors, 1776
- nonspecific cross-reacting antigen, identification, 5460
- hepatitis B virus-encoded X
- hepatocellular carcinoma, p53 integrity, 426
- hepatitis B virus surface
- synergy with TGFα, hepatocellular carcinoma, 3606
- HLA-A2
- associated peptides, ovarian tumors, 87
- melanoma, MAGE-3-specific cytotoxic T lymphocytes, 735
- HLA-A24
- MAGE-3/HLA-A24 peptide, CTL induction, 4465
- HLA class I
- hormone-mediated suppression, HPV and, 937
- HLA-DRB1
- genotyping, renal cell carcinoma, 742
- HLA-DR-restricted potential melanoma-associated antigens, isolation, 3238
- Ku autoantigen
- heat inactivation, hyperthermic radiosensitization, 2847
- Lewis^x
- anti-Le^x MAb BR64, disulfide and thioether doxorubicin conjugates, 100
- anti-Le^x MAb BR96-doxorubicin immunoconjugate, antitumor activity, 4530
- LFA-1-dependent T-cell migration to tumor sites, IL-12-induced, 2216
- MD/CA9
- biomarker, renal cell carcinoma, 2827
- melanoma-associated
- mRNA markers, melanoma, 1371
- potential HLA-DR-restricted, isolation, 3238
- melanoma MART-1/Melan-A
- expression, melanoma, 3223
- genetic immunization, dendritic cells, 2865
- low frequency CTLp activation by
- CD34⁺-derived dendritic cells, 5534
- peptide-stimulated PBLs and TILs, T-cell receptor repertoire, 5320
- prostate-specific
- assaying, peptide substrates, 4924
- biosynthesis and secretion, LNCaP cells, 3830
- down-regulation by finasteride, 714
- positive regulatory element, 495
- pro form, expression and activation, 3111
- prostate-specific membrane
- expression, prostate cancer, *in situ* hybridization, 2321
- extracellular domains, monoclonal antibodies, 3629
- tumor-associated
- potential HLA-DR-restricted, melanoma FM3 cells, 3238
- VLA-4
- T-cell migration, IL-12-induced, 2216
- VLA-6
- cell migration and extravasation, liver, 3812
- X, hepatitis B virus-encoded
- hepatocellular carcinoma, p53 integrity, 426
- Antineoplastic agents**
- cytotoxic synergy with flavopiridol, 3375
- Antioxidant enzymes**
- and skin carcinogenesis, 1469
- Antioxidant response element**
- human
- NQO1 expression, stimulation by caffeic acid phenethyl ester, 440
- Antisense**
- cyclin D1
- growth inhibition, colon cancer cells, 1569
- oligonucleotides
- ETS1, cell migration inhibition, 2013
- transforming growth factor β2
- tumor growth inhibition, malignant mesothelioma, 3200
- APE/Ref-1**
- DNA repair activity
- phosphorylation and, 5457
- APO-1/Fas**
- drug-induced apoptosis mediation
- neuroblastoma cells, 3823
- T-acute lymphatic leukemia, 3331
- expression, esophageal adenocarcinoma, 5571
- Apolipoprotein D**
- induction by 1,25-dihydroxyvitamin D₃, breast cancer cells, 4091
- Apoptosis: see also Cell death**
- adenosine triphosphate requirements, 1835
- betulinic acid-induced, neuroectodermal tumors, 4956
- bladder carcinoma cells, 2789
- calcium influx, 537
- ceramide-induced
- and Ki-ras, colon cancer cells, 4714
- chemotherapeutic
- and mitochondrial function, 62
- control
- germ-line p53 mutations and, 1895
- deregulated, Fanconi anemia syndrome, 1722
- drug-induced
- FasL-independent mediation, T-acute lymphatic leukemia, 3331
- high molecular weight DNA fragmentation activity, 3407
- inhibition by IGF-1, HBL100 cells, 2687
- mediation by CD95, neuroblastoma cells, 3823
- endometrial
- neonatal diethylstilbestrol exposure and, hamster uteri, 1903
- etoposide-induced
- gadd153 and, leukemic cells, 686
- Fas-mediated
- prostatic carcinoma cells, 1758
- resistance, prostatic carcinoma cells, 3941
- GL331-induced
- CDC 25 and CDC 2, 2974
- glucocorticoid-induced
- inhibition by baculovirus P35, 43
- hypoxia and, HPV-expressing cervical epithelial cells, 4200
- IGF-1 receptor protective effects, 3264
- induction
- butyrate and trichostatin A, 3697
- 8-chloro-cAMP and paclitaxel or cisplatin, 5107
- cholera toxin, lung cancer cells, 2615
- CP-358,774, 4838
- E2F-1, breast and ovarian carcinoma, 4722
- ET-18-OCH₃, 1320
- farnesyl transferase inhibitors, 708
- ovarian cancer cells, 4488
- p27^{Kip1} overexpression, 5441
- quinoxalines, small cell lung cancer, 2203
- sarcosylsin-containing tripeptide, 4795
- spermine analogs, melanoma cells, 5521
- thrombospondin 1, endothelial cells, 1735
- tunicamycin, 543
- tyrphostin AG17, lymphoma cells, 2434, 5610
- tyrphostins, HPV 16-immortalized keratinocytes, 3741
- vitamin E succinate, breast cancer cells, 881
- Wilm's tumor 1-KTS isoforms, hepatoma cells, 1353

- inhibition
AAC-11, 4063
activated *N-ras*, SCID mice melanoma, 362
bcl-2 protein, mechanism, 3097
Bcl-x_L overexpression and, 3115
CD4- and Bcl-2, lymphoma, 1939
galectin-3, 5272
phorbol esters and phosphatidylserine, 5300
pim-1, murine myeloid cells, 5348
retinoblastoma, myogenesis, 351
thioredoxin, 5162
- iron-induced
inhibition by vitamin E, 2410
mutations, gastrointestinal cancer, 4420
neu differentiation factor-induced, breast tumor, 3804
paclitaxel-induced
bcl-x_L overexpression and, HL-60 cells, 1109
p53-dependent
CPP32β and Fas, 2550
phenobarbital-induced, mouse hepatocytes, 2896
photodynamic therapy
ceramide generation, L5178Y mouse lymphoma cells, 1717
PKC inhibition and ionizing radiation and, 4340
prenyltransferase inhibitors and, 1846
protein ubiquitination, Ewing's sarcoma cells, 3881
radiation-induced
ceramide production and, 1270
resistance, ceramide signaling and, 3600
regulation
chemopreventive agents, colon cancer, 1301
ING1, 1255
resistance
NADH dehydrogenase deficiency, 5243
retinoic acid-induced
oxidative stress, 4916
spontaneous
and angiogenesis, gastric carcinoma, 221
subependyma, adult rats, 2694
Taxol-induced
abrogation, ovarian carcinoma spheroids, 2388
TNF-α-induced
resistance, prostatic carcinoma cells, 3941
topotecan-induced, human cells, 2157
UVA-induced
inhibition by bcl-2 overexpression, rat 6 fibroblasts, 1405
- 1-β-D-Arabinofuranosylcytosine**
cytochrome c mitochondrial loss
inhibition, Bcl-x_L overexpression and, 3115
toxicity
physiological changes, 2446
- Architectural factors**
HMGI(Y)
rearrangements, lipomas, 2276
- Arginine-rich protein**
ARP gene
polymorphism, 2888
- [D-Arg¹, D-Trp^{5,7,9}, Leu¹¹] substance P**
growth inhibition, small cell lung cancer cells, 51
- Aromatase**
intratumoral
inhibition by vorozole, breast cancer tissue, 2109
- Artificial neural networks**
pretreatment chemotherapeutic response prediction, glioma, 4196
- Aryl hydrocarbon receptor**
CYP1B1 expression regulation, embryo fibroblasts, 4498
deficiency, liver retinoids, 2835
- Asbestos**
-induced proto-oncogenes
PKC and, mesothelial cells, 3101
- Astrocytes**
Id gene expression, 215
- Astrocytoma**
malignant
low density lipoprotein receptor-related protein expression, 2799
- Ataxia telangiectasia**
ATM gene
IκB-α phosphorylation, 24
p53 interactions, cell proliferation and G₁-S checkpoint modulation, 1664
and cellular responses to DNA damage, 2313
- Atomic force microscopy**
Ku DNA binding, 1412
- Attenuated replication competent adenovirus**
CN706, prostate cancer, 2559
- Autoantigen**
Ku
heat inactivation, hyperthermic radiosensitization, 2847
- Autografts**
skin, epidermodysplasia verruciformis, 4214
- Autotaxin**
PD-1α/autotaxin gene, neuroblastoma, 2516
- Avian winged helix proteins**
aberrant cell growth, 123
- Avidin**
antibody-avidin complexes and bio-TNF, tumor targeting, 1922
- 5-Aza-2'-deoxycytidine**
loss of imprinting, tumor cells, 48
- 3'-Azido-3'-deoxythymidine**
sensitization by DNA polymerase β, mammalian cells, 110
- Azoxymethase**
nitric oxide synthase expression and, rat colon tumors, 1233
- B**
- B-428**
combined with tamoxifen
tumor invasion and metastasis prevention, breast cancer, 3585
- B7.1**
modified melanoma cells
CTL generation, 1561
- Baculovirus P35**
glucocorticoid-induced apoptosis inhibition, 43
- Basal cell carcinoma**
chromosome aberrations, primary, 404
early and late
p53 mutations and chromosome instability, 747
familial
PTCH mRNA expression, 2336
PTCH mRNA expression, 2336
PTCH mutations, skin, 2581
smoh expression, preferential, 4731
translocation t(9;16)(q22→3), 404
- Basal cell tetrasomy**
low-grade intraepithelial lesions, 4210
- BAT-26**
replication error phenotype indicator, colon cancer, 300
- BCH-4556**
antitumor activity, renal cell carcinoma xenograft tumor models, 4803
- BCEH**
amplification, squamous cell carcinoma of lung, 2290
- BCL1**
atypical chronic lymphocytic leukemia, 1145
- Bcl-2**
apoptosis inhibition, mechanism, 3097
drug resistance increase, lymphoma, 1939
mitochondrial effects, chemotherapeutic apoptosis, 62
overexpression
nucleotide excision repair capacity and, HL60 cells, 1650
tyrphostin AG17-apoptosis and cdk2 inhibition, lymphoma cells, 2434, 5610
UVA-induced apoptosis inhibition, rat 6 fibroblasts, 1405
phosphorylation
microtubule-active drugs, 130
microtubule-targeting drugs, 229
- BCL6**
H4 histone fusion by t(3;6), non-Hodgkin's lymphoma, 7
- Bcl-x_L**
mitochondrial effects, chemotherapeutic apoptosis, 62
overexpression
apoptosis inhibition, 3115
and paclitaxel-induced apoptosis, HL-60 cells, 1109
- BENSPM: see N¹, N¹¹-Diethylnorspermine**
- Benzene poisoning**
NQO1 ⁶⁰⁹C→T mutation and Fe₆-OH, 2839
- Benzol[*g*]chrysene**
DNA adducts
formation, MCF-7 cells, 415
- O⁶-Benzylguanine**
exposure
Δ*MGMT* gene therapy protection, 5093
-resistant human alkyltransferases, 2007
- Betulinic acid**
apoptosis, neuroectodermal tumors, 4956
- B16F1 cells**
extravasation
VLA-6 and, liver, 3812
- Bile**
methotrexate transport, rats, 3506
- Biliary cancer**
combination gene therapy/radiotherapy, 4325
UGT1A expression, 2979
- Biliary glycoprotein**
isoform tumor inhibition properties, 2781
- BINI**
cellular, characterization, 3258
- Biolmaging**
metastatic tumor cell trafficking, 3612
- Biomarkers**
apoptotic index, colon cancer, 1301
- 1,3-Bis(2-chloroethyl)-1-nitrosourea**
combined with O⁶-benzylguanine
Δ*MGMT* gene therapy protection, 5093
effects on mixed colon cancer xenografts, 4817
- Bisphosphonates**
cell adhesion to bone inhibition, prostate and breast carcinoma, 3890
- 3BIT**
lymphoma therapy, SCID mice, 4824
- Black tea**
NNK-induced carcinoma inhibition, A/J mice, 1889
- Bladder**
electromotive mitomycin C delivery, 875
- Bladder carcinogenesis**
two-stage
cyclin D1, rat, 4765
- Bladder carcinoma**
angiogenesis
bFGF-induced, mechanisms, 136
cytodifferentiation pathways

- differentiation and apoptosis, 2789
epidermal growth factor survival function, 3360
growth suppression by $\beta 4$ integrin, UM-UC-2 cells, 38
papillary
 genetic alterations, comparative genomic hybridization, 2860
squamous cell
 proteome profiling, 4111
superficial
 vascular endothelial growth factor, 5281
tumor-associated hyaluronic acid, 773
tumor-derived hyaluronidase
 urinary levels, 778
- Bladder tumors**
p53 and pRb alterations, 1217
- BL6 cells**
 $\alpha 1,2$ -fucosyltransferase cDNA transfection
metastatic properties, 332
- Bleomycin**
delayed chromosomal instability induction, 4048
- Bleomycin hydrolase**
genomic structure and genetic mapping, 4191
- Blood**
 β -glucuronidase activity
 elevation by irinotecan, rats, 5305
peripheral: *see* **Peripheral blood**
PTI-1 expression, prostate carcinoma, 18
venous
 disseminated tumor cells, detection by RT-PCR, 3106
- Blood-brain barrier**
disruption
 combined with intracarotid BSH or BPA and boron neutron capture therapy, brain tumors, 1129
- Blood flow**
tumor
 enhancement by carbogen and nicotina-mide, 5261
 modification by nitric oxide synthase inhibition, 948
- B lymphocytes: see also Lymphocytes**
adhesion to bone marrow fibroblasts, multiple myeloma, 930
leukemia/lymphoma
 combination immunotoxin therapy, SCID mice, 4824
 EBV-induced, prevention in SCID mice, 1704
 immunotherapy, SCID Mice, 678
 trioma-based vaccination, 2346
neoplastic
 costimulatory molecules, 4940
- BM28**
homologue clone 10d/BM28, melanoma
 growth regulator, 5122
- Body size**
and endometrial cancer risk, 5077
- Bone**
cell adhesion
 inhibition by bisphosphonates, prostate and breast carcinoma, 3890
resorption
 PTHrP-induced, TNF effects, 3194
- Bone marrow**
disseminated tumor cells
 detection by RT-PCR, gastrointestinal cancer, 3106
fibroblasts
 B-cell adhesion, multiple myeloma, 930
- Bone morphogenetic protein-2**
growth regulation, prostate cancer cells, 5022
- Bone morphogenetic protein-6**
immunolocalization and mRNA expression, prostatic tissue, 4427
- Boron neutron capture therapy**
brain tumors, 1129
intratumoral EGF, 4333
- Boronophenylalanine**
intracarotid
 combined with boron neutron capture therapy, brain tumors, 1129
- Brain glioma**
lipid droplets, NMR and microscopy study, 407
- Brain tumors**
boron neutron capture therapy, 1129
intratumoral boronated EGF, 4333
FHIT gene locus loss of heterozygosity, 2638
ganglioside biosynthesis gene expression, mouse, 1580
malignant
 oncolysis by $\gamma 1,34.5$ HSV mutants, 1502
 p53 knockout mice, 646
 SV40 early region and large T antigen, 3319
- BRCA1 gene**
deletions, germ-line
 1-kb, 828
methylation, sporadic breast cancer, 3347
mutations
 COOH-terminal, mammary epithelial cells, 3351
 inherited, Stockholm region, 2474
 oral contraceptive breast cancer risk and, 3678
 mutations, germ-line
 carriers, tumor progression, 1222
- BRCA2 gene**
mutations
 oral contraceptive breast cancer risk and, 3678
 mutations, germ-line
 carriers, tumor progression, 1222
nuclear location and cell-cycle regulation, 5485
rodent homologues, characterization, 3121
- Breast: see also Mammary gland**
CD36 expression
 down-regulation by tamoxifen, 678
cell proliferation
 inhibition by vitamin D analogues, 4545
 steroid receptor expression and, 4987
cyclin-dependent kinase inhibitors
 induction by lovastatin, 604
epithelium
 heparin/heparan sulfate interacting protein expression and functions, 5148
 MMP-9 cell surface association, TPA-induced, 3159
MUC-1 mucin
 radioimmunotherapy effects, breast carcinoma, 1103
preneoplastic lesions
 FHIT/FRA3B abnormalities, 3664
thrombospondin-1 and -2 mRNA expression, 396
tissue
 RAR- β expression, 4158
- Breast cancer specific gene**
BCSG1
 identification by direct differential cDNA sequencing, 759
- Breast carcinogenesis**
retinoic acid receptor β mRNA levels, 4992
- Breast carcinoma: see also Mammary carcinoma; specific cells**
adjacent tissue, normal
 RAR- β expression, 4158
aggressive
 PINP and PICP serum levels, 5517
angiogenic factor expression, 956
antiestrogen-resistant
 estrogen receptor mRNA splice variants, 585
AP-1 activity, 3046
 inhibition by retinyl methyl ether, 3444
apoptosis
 drug-induced, inhibition by IGF-1, HBL100 cells, 2687
 induction by E2F-1, 4722
 induction by vitamin E succinate, 881
aromatase activity
 inhibition by vorozole, 2109
- BRCA1 gene**
COOH-terminal mutant, mammary epithelial cells, 3351
germ-line mutation carriers, tumor progression, 1222
inherited mutations, Stockholm, 2474
1-kb germ-line deletion, 828
methylation, sporadic cancer, 3347
mutations, oral contraceptive breast cancer risk and, 3678
- BRCA2 gene**
germ-line mutation carriers, tumor progression, 1222
mutations, oral contraceptive breast cancer risk and, 3678
protein, nuclear location and cell-cycle regulation, 5485
rodent homologues, characterization, 3121
cathepsin K expression, 5386
cell adhesion to bone
 inhibition by bisphosphonates, 3890
cell proliferation biomarkers
 σ_2 receptors, 156
chromosome 1q31-32 allelic imbalance, 4217
c-myc
 transcriptional suppression by oncostatin M, 2223
collagenase-3 expression regulation, 4882
elafin induction by PMA, 4631
estrogen receptor
 forms, ER-EIA, 1066
 functional assay, yeast, 3478
estrone sulfatase
 inhibition by nonsteroidal (*p*-O-sulfamoyl)-N-alkanoyl tyramines, 702
familial probands
 FHIT/FRA3B abnormalities, 3664
FHIT/FRA3B abnormalities, 3664
FHIT gene
 aberrant transcripts, 1981
 gene expression, living cells, 4447
 growth inhibition
 bFGF, 1750
 1,25-dihydroxyvitamin D $_3$, 4091
 Flt3-ligand, murine model, 3511
 2-methoxyestradiol and Taxol, mice, 81
 MRG, 3084
 RAR α and, 2642
 retinoid, resistance by cJun overexpression, 4652
 vitamin E succinate, 2668
 zidovudine, 2341
heparin/heparan sulfate interacting protein
 expression and functions, 5148
HER-2/neu bispecific antibody effector
 mechanisms against, 696
human glandular hk2 expression, 2651
immunotherapy
 Flt3-ligand, murine model, 3511
initial growth
 vascular endothelial growth factor, 3924
insulin-like growth factor I receptor signaling

- modulation by tamoxifen, 2606
 interstitial tumor space
 5-fluorouracil kinetics, 2598
 invasion
 prevention by tamoxifen and B-428, 3585
 invasive
 membrane-type MMPs, 2055
 small, p27 prognostic marker, 1259
 loss of heterozygosity, genome-wide search, 5469
 luteinizing hormone/human chorionic gonadotropin receptors, 857
 MCF-7 cells, 3071
 MeHPLAase activity, 5406
 melatonin oncostasis
 glutathione requirement, 1909
 metastasis
 asynchronous, genetic heterogeneity, 1597
 enhancement by *c-erbB-2* overexpression, 1199
 prevention by tamoxifen and B-428, 3585
 suppression by *KiSS-1*, 2384
 methylation-sensitive restriction fingerprinting, 1030
 mitogen-activated protein kinases
 modulation by TGF- β , 628
 MMP-1 expression
 mediation by tyrosine phosphorylation, 5028
 MMP-2 activation
 mediation by tyrosine phosphorylation, 5028
 multidrug resistance
 P-95, identification, 5460
 node-negative
 mitosis, 5505
 probands, familial
 FHIT/FRA3B abnormalities, 3664
 PTEN/MMAC1 mutation analysis, 3657
 radioimmunotherapy
 effects on target antigen content, 1103
 radioresistance
 mediation by IGF-IR, 3079
 recurrence after lumpectomy and radiation
 mediation by IGF-IR, 3079
 retinoic acid receptor β expression, 4158
 retinoic acid signaling
 regulation by CRABP II, 1668
 retinol metabolism, 4642
 risk
 catechol-*O*-methyltransferase and, 5493
 CYP17 gene polymorphism and, 1063
 DDT serum levels and, Mexico, 3728
 oral contraceptive, *BRCA1/BRCA2* mutations and, 3678
 small invasive
 p27 prognostic marker, 1259
 sporadic
 BRCA1 methylation, 3347
 FHIT/FRA3B abnormalities, 3664
 tamoxifen-DNA adducts, endometrium, 4148
 tamoxifen-resistant
 estrogen receptor DNA binding, 3723
 telomerase activity and cell cycle regulation, 549
 transforming growth factor β type II receptor localization, 970
 TSG101 gene splicing, 3131
 TSG101 protein, identification, 4225
Breast tumors: see also Mammary tumors
 apoptosis
 neu differentiation factor-induced, 3804
 comparative genomic hybridization, subsets, 4368
 DNA amplifications, mapping, 4360
 microenvironment
 PD-ECGF/TP regulation, 570
 primary
 cell culture, 1590
 thrombospondin-1 and -2 mRNA expression, 396
Bronchial carcinoma
 doxorubicin uptake, 2440
Bronchial epithelial cells
 cell cycle responses, 3174
Bronchial lesions
 preneoplastic
 FHIT/FRA3B allele loss, 2256
Bryostatin-1
 synergy with IFN- γ
 iNOS expression, 2468
BT-20 cells
 proliferation
 inhibition by vitamin E succinate, 2668
Burkitt's lymphoma
 radiation resistance
 ceramide signaling and, 3600
 tumorigenicity
 p53 role, 2508
Busulfan
 glutathione conjugation, age-dependent, 5509
1,3-Butadiene
 lymphomas
 p53 and *ras* mutations, mouse, 2710
Butylated hydroxytoluene
 lung tumor promotion, BALB mice, 2832
2(3)-tert-Butyl-4-hydroxyanisole
 dietary
 estrogen metabolism and action and, female CD-1 mice, 2419
Butyrate
 caspase-3 and apoptosis induction, 3697
Bystander cells
 GJIC-mediated protection from ganciclovir, 1699
Bystander effect
 Cx26 gene, HeLa cells, 2929
 herpes simplex virus thymidine kinase
 mediation by gap junctions, 1523

C

CA-125
 expression
 modulation by taxanes, ovarian carcinoma cells, 3818
CAB1
 isolation, *c-ERBB-2* amplicon, 3548
c-Abl kinase
 induction by cisplatin
 and DNA mismatch repair, 3253
Cachexia
 cancer
 prevention by IL-10 gene transfer, colon adenocarcinoma, 94
Cadherin
 adhesion
 regulation by Rho, small cell lung carcinoma cells, 1785
Cadherin-6
 renal cell carcinoma, 2741
E-Cadherin
 differentiated thyroid carcinomas, 2501
 expression, prostate cancer, 3189
 tumor cell cohesion and invasion suppression, 5033
P-Cadherin
 tumor cell cohesion and invasion suppression, 5033
Caffeic acid phenethyl ester
 hAIRE-mediated *NQO1* expression stimulation, 440
Caffeine
 and ultraviolet light sensitivity, p53-null cells, 5434
 and UVB-induced skin carcinogenesis, 5645
 SKH-1 mice, 2623
(CAG)_n tracts
 repeat expansion detection analysis, testicular germ cell cancer, 209
Calcium
 influx, apoptosis, 537
Calorie restriction
 p53-independent spontaneous carcinogenesis delay, mice, 2843
Camptothecin
 biliary excretion, rats, 1934
 cellular pharmacokinetics
 and pH, 4811
 cytotoxicity
 and pH, 4811
 potentiation by 7-hydroxystaurosporine, 4029
 derivatives
 radiation cytotoxicity, mediation by mammalian DNA topoisomerase I, 1529
 DNA replication down-regulation, 1654
 metabolites
 biliary excretion, rats, 1934
 -resistant DNA topoisomerase I, 1516
CaN19
 expression, epidermal differentiation, 3055
Cancer
 cell transformation
 CaSm protein contributions, 2961
 incidence by iron
 inhibition by vitamin E, 2410
 inflammation-related
 Sixteenth Sapporo Cancer Seminar meeting report, 3620
 Smad gene mutation frequency, 2578
Cancer-associated Sm-like protein
 transformation contributions, 2961
Cancer proneness
 radiation-induced ODC and SOS and, 4384
Cancer therapeutics
 molecular approaches
 Roswell Park Cancer Institute Symposium meeting report, 5185
Carbogen
 tumor blood flow enhancement, 5261
Carbohydrates
 tumor-associated
 recognition by T cells, 3214
Carcinoembryonic antigen
 agonist CTL peptide, 4570
 cytokine induction, mouse, 4432
 gene family
 expression, colorectal adenomas, 2354
 gene family member 2
 down-regulation, colorectal tumors, 1776
 non-specific cross-reacting antigen, identification, 5460
 -producing gastric carcinoma
 in vivo gene therapy, 4279
Carcinogenesis
 bladder
 two-stage, cyclin D1, 4765
 breast
 retinoic acid receptor β mRNA levels, 4992
 colon
 inhibition by sulindac sulfone, rats, 2909
 dietary fat, mice, 4162
 hepatocellular
 transforming growth factor α and hepatitis B virus surface antigen, 3606
 liver
 acceleration by TGF- β 1, transgenic mice, 2089
 N-nitrosodiethylamine initiation, 8-hydroxyguanine formation, 1281
 P-glycoprotein-related protein overexpression, 3708

SUBJECT INDEX TO VOLUME 57

- melanotroph
genomic imprinting, 4274
- oral
inhibition by organoselenium, rat, 3644
- renal
induction by hyperlipidemia, Eker rat, 4673
- spontaneous
p53-independent, calorie restriction and, 2843
- tongue
inhibition by organoselenium, rat, 3644
- Carcinogens**
cellular protection against
c-Fos and, 2721
-initiated epithelial cells
quiescent, 3436
- Carcinoma: see also specific sites, types**
cell growth
inhibition by 8-chloro-cAMP and paclitaxel or cisplatin, 5107
inhibition by p21^{WAF1}-derived peptides, 1442
dis3⁺ overexpression, 921
minimal residual
metastatic phenotypes, 1394
MKK4 mutations, 4177
p21^{WAF1/CIP1}/Rb/c-myc signaling by PMA, 320
radioresponse
potentiation by 9-AC, 1929
thioredoxin reductase regulation by selenium, 4965
- Carcinosarcoma**
uterus
combination tumors, molecular evidence, 5379
- A-Carrageenan**
filament disassembly, mammary myoepithelium, 2823
- Caspase-2**
adaptor molecule CRADD, 615
- Caspase-3**
expression, *in vivo* patterns, 1605
induction by butyrate and trichostatin A, 3697
p53-dependent apoptosis, 2550
- Catechol-O-methyltransferase**
and breast cancer risk, 5493
- α -Catenin**
expression, prostate cancer, 3189
- β -Catenin**
mutations, colorectal cancer, 4478
regulation by APC protein, 4624
- Cathepsin K**
expression, breast carcinoma, 5386
- CCAAT-binding proteins**
CBP/cycA, subunits, 5117
- C6 cells**
aggressiveness
TrkA expression and, 532
- CD3**
CD3xCD19 bispecific antibodies
EBV-induced B-cell lymphoma prevention, SCID mice, 1704
- CD4⁺**
chronic myelogenous leukemia-specific T cells, production method, 1547
- CD8**
cytotoxic T lymphocytes
associated peptides, ovarian tumors, 87
- CD9**
MRP1/CD9
differential display cloning, colon carcinoma, 2593
- CD19**
anti-CD19 immunotoxins
combination immunotoxin therapy, lymphoma, 4824
CD3xCD19 bispecific antibodies
EBV-induced B-cell lymphoma prevention, SCID mice, 1704
- CD22**
anti-CD22 immunotoxins
combination immunotoxin therapy, lymphoma, 4824
- CD28**
antibody
EBV-induced B-cell lymphoma prevention, SCID mice, 1704
- CD34**
-derived dendritic cells
low frequency CTLp activation to Melan-A, 5534
- CD36**
expression
down-regulation by tamoxifen, breast tissues, 378
- CD38**
anti-CD38-saporin immunotoxins
combination immunotoxin therapy, lymphoma, 4824
- CD40**
drug resistance increase, lymphoma, 1939
endothelial expression, renal cell carcinoma, 891
- CD44**
CD44v6
and malignant transformation, 2281
expression, neurofibromatosis, 4889
metastasis suppression, prostatic cancer, 846
neuroblastoma cells, 1387
peritoneal tumor implantation, 1228
shedding, MV3 cells and, 2061
splicing, colonic tumors, 3140
- CD66a**
expression, colorectal adenomas, 2354
- CD95**
drug-induced apoptosis mediation
neuroblastoma cells, 3823
T-acute lymphatic leukemia, 3331
expression, esophageal adenocarcinoma, 5571
- CD97**
dedifferentiation marker, thyroid carcinomas, 1798
- cdc2**
activation, GL331-induced apoptosis, 2974
feedback loop control, DNA damage checkpoint, 5168
- CDC 25**
activation, GL331-induced apoptosis, 2974
- CDC25A**
overexpression, head and neck cancers, 2366
- CDC25B**
overexpression, head and neck cancers, 2366
- CDK: see Cyclin-dependent kinase**
- Cell adhesion**
B-cell, multiple myeloma, 930
bone
inhibition by bisphosphonates, prostate and breast carcinoma, 3890
cadherin-mediated
regulation by Rho, small cell lung carcinoma cells, 1785
GD1 α functions, murine metastatic tumors, 1882
p53 protein level regulation, keratinocytes, 3635
- Cell adhesion molecules**
expression
colorectal adenomas, 2354
irradiated lung, 2096
ICAM-1
expression, cutaneous malignant melanoma, 1554
isoforms
tumor growth inhibition properties, 2781
MCAM/MUC18
melanoma progression, 2295, 3834
- Cell cohesion**
suppression by E- or P-cadherin, 5033
- Cell confluence**
HSP27 and, 2661
- Cell culture**
organotypic raft
chromosome 11 tumor suppressor gene localization, 1157
primary breast tumors, 1590
- Cell cycle**
arrest
CP-358,774, 4838
DNA damage, scid cells, 68
G₁, radiation-induced, cell-substratum interactions and, 1151
G₁, UV-induced, human skin fibroblasts, 3390
G₂-M, Taxol-induced, abrogation, 2388
G₁-S, cyclin accumulation, 4482
p53-dependent, multiple cycles, 1171
spermine analogs, melanoma cells, 5521
BRCA2 protein regulation, 5485
cyclin D1 overexpression effects, transgenic mouse model, 5542
DNA damage checkpoint
Cdc2 feedback loop control, 5168
DNA damage response, bronchial epithelial cells and lung fibroblasts, 3174
G₁-phase
arrest, radiation-induced, cell-substratum interactions and, 1151
arrest, UV-induced, human skin fibroblasts, 3390
1,25D₃-induced p27/Kip1 regulation, Cdk6 target, 2851
UCN-01 accumulation, mechanism, 1495
G₁-S checkpoints
arrest, cyclin accumulation, 4482
atm and *p53* interactions and, 1664
G₂
p53-induced transition, 818
radiation-induced delay, cyclin B1 levels and, 753
G₂-M
control, COOH-terminal *BRCA1* mutant, 3351
Taxol-induced arrest, abrogation, 2388
- M phase**
p53-induced transition, 818
p53 accumulation regulation, 5217
prenyltransferase inhibitors and, 1846
regulation
c-FMS, 2020
germ-line p53 mutations and, 1895
mismatch repair genes, 206
MMTV-myc and MMTV-ras mice, 600
telomerase activity and, breast cancer, 549
- S-phase**
radiation-induced entry, E2F and, 3640
- S-phase checkpoint**
abrogation by 7-hydroxystaurosporine, 4029
replication protein A phosphorylation and, 3386
- Cell death: see also Apoptosis**
doxorubicin-induced
p53 role, Rat-1 fibroblasts, 176
programmed
topotecan-induced, human cells, 2157
- Cell differentiation**
astrocyte
Id gene expression, 215

- bladder carcinoma cells, 2789
cytodifferentiation
 bladder carcinoma cells, 2789
dedifferentiation
 CD97 marker, thyroid carcinomas, 1798
epidermal
 CaN19 expression, 3055
induction
 tyrphostins, HPV 16-immortalized keratinocytes, 3741
myocyte
 apoptosis inhibition by retinoblastoma, 351
 regulation by c-FMS, 2020
Cell growth: see also Cell proliferation; Tumor growth
aberrant
 induction by avian winged helix proteins, 123
ANBL6 properties
 N- and K-ras mutation effects, 2268
gadd153
 and etoposide-induced apoptosis, leukemic cells, 686
IL-6 effects, prostate carcinoma, 141
inhibition
 angiostatin, murine hemangioendothelioma, 5277
 [D-Arg¹, D-Trp^{5,7,9}, Leu¹¹] substance P, small cell lung cancer cells, 51
 bFGF, breast cancer, 1750
 biliary glycoprotein isoform properties, 2781
 cancer agent potency, p53 characterization and, 4285
 8-chloro-cAMP and paclitaxel or cisplatin, 5107
 cobalamin analogues, leukemia cells, 4015
 1,25-dihydroxyvitamin D₃, breast cancer, 4091
 HPV16 DNA-positive tumors, mouse, 3993
 IL-10, leukemic cells, 476
 β4 integrin, UM-UC-2 cells, 38
 mammary-derived growth inhibitor-related gene *MRG*, antitumor activity, 3084
 MX11, glioblastoma, 4905
 perlecan, fibrosarcoma, 2130
 PML adenovirus, prostate cancer, 1868
 p21^{WAF1}-derived peptides, 1442
 quinoxalines, small cell lung cancer, 2203
 RARα and, breast cancer, 2642
 retinoic acid, 4460
 retinoids, non-small cell lung carcinoma, 4931
 sodium phenylacetate, ovarian carcinoma, 4309
 sulindac, mechanism, 2452
 tamoxifen-mediated, cholangiocarcinoma, 1743
 TGF-β, *DPC4* and, pancreatic adenocarcinoma cells, 3929
 tyrphostins, HPV 16-immortalized keratinocytes, 3741
initial
 vascular endothelial growth factor, breast carcinoma cells, 3924
melanoma
 regulator clone 10d/BM28, 5122
regulation
 bone morphogenetic protein-2, prostate cancer, 5022
Cell migration
endothelial cells
 inhibition by ETS1 antisense oligonucleotides, 2013
intestinal
 Apc gene mutations and, 5045
 MV3 cells
 collagen lattice reorganization, 2061
T-cells
 IL-12-induced, 2216
 TGF-α and, glioma, 5598
 VLA-6 and, liver, 3812
Cell motility
A and B gene transfection and, 3092
Cell proliferation: see also Cell growth; Tumor growth
biomarkers
 σ₂ receptors, breast cancer, 156
clonal
 human T-lymphotropic virus type I-infected cells, 4862
epithelial
 CD44v6-containing isoform regulation, 2281
hepatocellular
 transforming growth factor α and hepatitis B virus surface antigen, 3606
 induction by peroxisome proliferators, 9-*cis* retinoic acid, and T₃, 795
inhibition
 flavonoids, 2916
 nonsteroidal (*p*-*O*-sulfamoyl)-*N*-alkanoyl tyramines, breast cancer, 702
 retinoid, resistance by cJun overexpression, 4652
 sodium phenylacetate and tamoxifen combination, MCF-7ras tumors, 1023
 topical diclofenac in hyaluronan, colon-26 adenocarcinoma, 1625
 vitamin D analogues, breast, 4545
 vitamin E succinate, breast cancer, 2668
modulation
 atm and *p53* interactions, 1664
 pentose phosphate pathways and, 4242
regulation
 mevalonate metabolism and, 3498
 soluble G-CSF receptor effects, AML cells, 3395
 steroid receptor expression and, breast, 4987
Cell scattering
TGF-α and, glioma, 5598
Cell surface
MMP-9 association
 TPA-induced, 3159
Cell transformation
CaSm protein contributions, 2961
ETO gene properties, 2951
HOX11/TC13-mediated, 337
inhibition
 inositol hexaphosphate, 2873
 tea polyphenols, 4414
malignant
 CD44v6 and, 2281
 translation initiation factor eIF4G, 5042
neoplastic response
 NF-κB and AP-1, 3569
 N-nitroso-*N*-methylurea, prostate epithelial cells, 576
 src-induced
 suppression by SSeCKS, 2304
Cellular protection
c-Fos and, 2721
Cellular retinoic acid binding protein
type II
 retinoic acid signaling regulation, breast cancer, 1668
Central nervous system
primitive neuroectodermal tumors
 PTCH mutations, 2581
Ceramide
apoptosis
 and Ki-ras, colon cancer cells, 4714
generation
 inhibition by phorbol esters and phosphatidylserine, 5300
 photodynamic therapy, L5178Y mouse lymphoma cells, 1717
production
 and apoptosis, 1270
signaling
 and radiation resistance, Burkitt's lymphoma, 3600
c-erbB-2: see HER2/neu
c-erbB-3: see HER3
c-erbB-4: see HER4
Cerebrum
VEGFR-2
 up-regulation, ligand-induced, 3852
Cervical carcinoma
angiogenesis, MRI assessment, 4777
chromosome 3p alterations, 4082
chromosome 3p deletions, 3154
FHIT expression, human cells, 2112
FHIT loss of expression, 4692
human papillomavirus and hypoxia, epithelial cells, 4200
human papillomavirus-specific CTLs, 2943
RARβ loss of expression, 1460
squamous cell
 angiogenesis, cross-species comparison, 1294
 mucin-like epithelial glycoprotein, 634
Cervical dysplasia
genetic alterations, 4171
Cervical intraepithelial neoplasia
grade III
 human papillomavirus-specific CTLs, 4855
Cervical lesions
screening
 telomerase assay, 1863
Cervical squamous intraepithelial lesions
tetrasomy, 4210
Cervical tumors
hormone-mediated class I HLA down-regulation
 HPV and, 937
c-FMS
retinoblastoma, cell cycle, and differentiation regulation, 2020
c-fos
asbestos-induced expression
 PKC and, mesothelial cells, 3101
 and cellular protection, 2721
Chelerythrine chloride
combined with ionizing radiation
 apoptotic effects, 4340
Chemoprevention
deguelin-mediated, 3424
 mechanism, 3429
 R-flurbiprofen, intestinal adenoma, 4316
 organoselenium, rat tongue carcinogenesis, 3644
 sulfonamide, 272
Chemopreventive agents
apoptosis modulation, colon cancer, 1301
Chemoresistance
melanoma
 activated *N*-ras, SCID mice, 362
Chemosensitivity
p53 and, 4285
Chemotherapeutic agents: see also Drugs; specific agents
apoptosis
 and mitochondrial function, 62
Chemotherapy
combined with radioimmunotherapy
 antitumor activity, 2181
 medullary thyroid carcinoma, mouse model, 5309

- high-dose, and stem cell support
thrombopoietin serum levels, 5037
- molecular
combined with radiotherapy, cholangiocarcinoma, 4325
- response
pretreatment prediction, glioma, 4196
social housing condition and, mammary carcinoma, 1124
- retinoblastoma that failed
multidrug resistance protein expression, 2327
- small cell lung cancer
mutagenic effects, 4393
- Chernobyl**
childhood thyroid papillary carcinomas
ret/PTC gene rearrangements, 1690
childhood thyroid tumors
 G_{α} mutations, 2358
- Childhood glioma**
malignant
p53 mutations and overexpression, 304
- Childhood medulloblastoma**
comparative genomic hybridization analysis, 4042
prognosis
HER2 and HER4 coexpression and, 3272
- Childhood thyroid papillary carcinomas**
ret/PTC gene rearrangements, 1690
- Childhood thyroid tumors**
 G_{α} mutations, Chernobyl, 2358
- Chinese hamster ovary cells**
hprt locus mutation analysis, 2586
reciprocal translocation
mediation by topoisomerase II, 4699
- Chloroacetaldehyde**
ifosfamide cytotoxicity role, 2676
- 8-Chloro-cAMP**
combined with paclitaxel or cisplatin
growth inhibition and apoptosis induction, cancer cells, 5107
- Chloroethylnitrosourea**
skin tumors
MGMT protective effects against, 3331
- 2-Chloroethyl-3-sarcosinamide-1-nitrosourea**
antitumor activity, glioma xenografts, 3895
- Chlorzoxazone**
fractional excretion
benzene poisoning and, 2839
- Cholangiocarcinoma**
combined chemotherapy/radiotherapy, 4325
growth inhibition
tamoxifen-mediated, 1743
- Cholecystokinin-A**
receptor, tumors, 1377
- Cholecystokinin-B/gastrin**
receptor, tumors, 1377
- Cholera toxin**
apoptosis induction, lung cancer cells, 2615
- Cholesterol**
mitochondrial transport
gene isolation, c-*ERBB-2* amplicon, 3548
- Chromosome 1**
HPC1 locus
age at diagnosis, families, 4707
- Chromosome 1q**
copy number changes, renal cell carcinoma metastasis, 480
- Chromosome 1q31-32**
allelic imbalance, breast cancer, 4217
- Chromosome 2**
and *MSH2* and *MSH6* mutations, 3949
- Chromosome 3p**
alterations, cervical carcinoma, 4082
copy number changes, renal cell carcinoma metastasis, 480
deletions
lung tumors, 1344
uterine cervical carcinoma, 3154
loss of heterozygosity, glial tumors, 1035
- Chromosome 3p14.2**
FHIT locus
fragile site *FRA3B* position, 1166
loss of heterozygosity, brain tumors, 2638
- FRA3B* region
abnormalities, breast cancer, 3664
allele loss, lung cancer, 2256
FHIT position, 1166
- Chromosome 3q**
DNA sequence amplification
lung tumors, comparative genomic hybridization analysis, 2116
tumor suppressor locus, osteosarcoma mapping, 106
- Chromosome 3q21**
GR6 gene, identification, 3914
- Chromosome 3q26**
MDS1/EVI1
ETV6 fusion, myeloproliferative disorders, 564
- Chromosome 5p**
DNA sequence amplification
lung tumors, comparative genomic hybridization analysis, 2116
- Chromosome 6q**
deletion mapping, malignant mesothelioma, 4057
- Chromosome 6q21**
regional characterization, 4153
- Chromosome 6q24**
c-myc amplification, pancreatic cancer, 3135
- Chromosome 7p**
DNA sequence amplification
lung tumors, comparative genomic hybridization analysis, 2116
- Chromosome 8q**
DNA sequence amplification
lung tumors, comparative genomic hybridization analysis, 2116
- Chromosome 9**
deletion map, neuroblastoma, 907
tumor suppressor loci, small cell lung cancer, 400
- Chromosome 9p**
deletions, pituitary adenomas, 2703
- Chromosome 9p21**
deletions
novel homozygous, lung cancer, 1
- Chromosome 10q22-23**
Cowden Locus
loss of heterozygosity, thyroid tumors, 500
- Chromosome 10q22-24**
susceptibility locus, juvenile polyposis syndrome, 5017
- Chromosome 10q25-q26**
loss of heterozygosity, endometrial cancer, 1630
- Chromosome 11**
tumor suppressor gene
organotypic raft culture localization, 1157
- Chromosome 11p13**
CD44 metastasis suppressor gene, prostatic cancer, 846
- Chromosome 11p15.1**
deletion mapping, epithelial ovarian carcinoma, 387
- Chromosome 11q13**
allelic deletions, endocrine tumors, 2238
- Chromosome 12p13**
ETV6
MDS1/EVI1 fusion, myeloproliferative disorders, 564
- Chromosome 12q22-q24.1**
human *TDG* gene mapping, 3010
- Chromosome 14**
deletions, ovarian carcinoma, 513
- Chromosome 14q**
loss of heterozygosity and deletion mapping, renal oncocytomas, 5009
- Chromosome 16q**
loss of heterozygosity, prostate adenocarcinoma, 1058
- Chromosome 16q24.1-q24.2**
loss of heterozygosity, prostate cancer, 3356
- Chromosome 17**
D17S34 locus
deletion, primitive neuroectodermal tumors, 32
- Chromosome 18q**
loss of heterozygosity, squamous cell carcinoma, 824
- Chromosome 19p**
Peutz-Jeghers syndrome locus, fine mapping, 3653
- Chromosomes**
alterations
alb-SV40-T transgenic rat liver neoplastisms, 3451
metastatic head and neck squamous cell carcinoma, 5213
anomalies, metastatic prostatic carcinoma, 524
imbalances
adenocarcinoma and squamous cell carcinoma of lung, 2331
malignant solid tumors, maps, 2765
instability
delayed, induction by DNA strand-breaking agents, 4048
early and late basal cell carcinoma, 747
and genomic instability, 5557
intrachromosomal recombination
PCBs and TCDD, 4378
loss
induction by arsenite, fibroblasts, 5051
translocation
reciprocal, mediation by topoisomerase II, 4699
translocation t(3;6)(q27 a11)
H4 histone/*BCL6* fusion, non-Hodgkin's lymphoma, 7
translocation t(3;12)(q26→3)
ETV6 and *MDS1/EVI1* fusion, myeloproliferative disorders, 564
translocation t(8;21)
leukemia, fusion partner *ETO* gene, transformation properties, 2951
translocation t(11;18)(q21 a11), MALT-type lymphomas, 3944
translocation t(9;16)(q22→3), basal cell carcinomas, 404
- Cigarette smoking: see also Smoking**
and *FHIT* gene alterations, lung cancer, 2121
- Cisplatin**
combined with 8-chloro-cAMP
growth inhibition and apoptosis induction, cancer cells, 5107
combined with vitamin D
antitumor activity, murine squamous cell carcinoma model, 3759
resistance, DNA mismatch repair-deficient cells, 1841
signaling
and DNA mismatch repair, 3253
synergy with tamoxifen, melanoma cells, 2657
- c-jun**
asbestos-induced expression
PKC and, mesothelial cells, 3101
overexpression

- retinoid resistance induction, 4652
- c-jun NH₂-terminal kinase**
induction by cisplatin
and DNA mismatch repair, 3253
- Clear cell carcinoma**
renal
DNA gains and losses, 480
MD/CA9 protein biomarker, 2827
- Clerocidin**
DNA cleavage, 1710
- Clonal cell proliferation**
human T-lymphotropic virus type I-infected cells, 4862
- Clonal genetic alterations**
oral exfoliative cells, 5258
- Clonality**
early colorectal adenoma, 355
- Clones**
AD12-induced hamster tumor origin, 3001
10d/BM28, melanoma growth regulator, 5122
- Cloning**
CRADD, 615
differential display
MRP1/CD9, colon carcinoma, 2593
MutM homologue, mammalian, 2151
MXR7 gene, hepatocellular carcinoma, 5179
p10, 2966
P2XM gene, 3281
TEP1, novel, 2124
- Clonogenicity**
increase by CD40 and Bcl-2, lymphoma, 1939
- c-myc**
amplification, pancreatic cancer, 3135
- c-myc**
amplification
colonic carcinoma cells, 1769
metastatic prostatic carcinoma, 524
MMTV-myc mice
tumor properties, 600
signaling by PMA, cancer cells, 320
transcriptional suppression by oncostatin M, breast cancer cells, 2223
- CN706**
prostate cancer, 2559
- Cobalamin**
analogues
growth inhibition, leukemia cells, 4015
- Collagenase**
Mr92,000 type IV
induction by fibronectin, ovarian cancer cells, 5416
- Collagenase-3**
expression
regulation, breast cancer, 4882
- Collagen lattices**
reorganization by MV3 cells, 2061
- Colon adenocarcinoma**
cachexia
prevention by IL-10 gene transfer, 94
inhibition by topical diclofenac in hyaluronan, 1625
metastasis to lung
suppression by anti-platelet mAb, 3040
- Colon carcinogenesis**
inhibition
sulindac sulfone, rats, 2909
- Colon carcinoma**
aberrant crypt foci and, dimethylhydrazine-treated rats, 4507
apoptosis
ceramide-induced, and Ki-ras, 4714
modulation by chemopreventive agents, 1301
BCNU effects, mixed xenografts, 4817
biomarkers
apoptotic index, 1301
- c-myc amplification**, 1769
- cyclooxygenase-2**
modulation by dietary fat, 3465
dietary fat and, 3465
elimination by IL-2 fusion protein, 4948
energy balance and, 75
enhancement by genistein, 3717
growth inhibition
antisense cyclin D1, 1569
FMDc, mouse xenografts, 4023
metastasis to liver
radioimmunotherapy and fractionated radiotherapy, nude mice, 447
MRP1/CD9 differential display cloning, 2593
prevention by dietary perillyl alcohol, 420
prophylaxis and treatment, 4316
ras-p21 function
dietary fat and, 253
tumorigenicity
inhibition by antisense cyclin D1, 1569
- Colon tumors**
CD44 splicing, 3140
nitric oxide synthase expression, rat, 1233
reduction by short-chain fructo-oligosaccharides, *Min* mice, 225
sporadic
hMLH1 gene methylation, 808
- Colony-stimulating factor 1**
receptor
retinoblastoma, cell cycle, and differentiation regulation, 2020
- Colorectal adenocarcinoma**
metastases to liver
5-[¹⁸F]fluorouracil uptake, pharmacokinetic analysis, 3415
- Colorectal adenoma**
CEA family members expression, 2354
early
clonality, 355
human apurinic endonuclease 1 expression, 1794
- Colorectal carcinoma**
angiogenesis, 1043
 β -catenin mutations, 4478
core 2 β 1,6-N-acetylglucosaminyltransferase gene expression, 5201
- DCC gene**
and glioma progression, 382
neuroblastoma, 3772
DNA methylation and genetic instability, 3370
hereditary nonpolyposis
atypical, *hMSH6* germ-line mutation, 3920
hMSH2 and *hMLH1* germline mutations, 3798
human apurinic endonuclease 1 expression, 1794
K-ras gene mutations, 2485
metastasis mode, 1043
microsatellite instability
IGFIIR gene mutations, somatic, 1851
replication error phenotype status, 300
risk
methylenetetrahydrofolate reductase polymorphism and, 1098
Western lifestyle and, 4787
- Colorectal tumors**
CGM2 down-regulation, 1776
hMLH1 gene methylation, 808
- Combretastatin A-4**
toxicity, tumor vasculature, 1829
- Comet assay**
drug response prediction, 5528
- Comparative genomic hybridization**
breast tumor subsets, 4368
childhood medulloblastoma analysis, 4042
- 5649
- lung tumors analysis, 2116
metastatic head and neck squamous cell carcinoma pattern, 5213
non-small cell lung carcinoma patterns, 2331
papillary bladder carcinoma genetic alterations, 2860
- Comparative molecular field analysis**
model of polyamine transport inhibitor structure-function, 234
- Complementary DNA: see also DNA**
AAC-11
apoptosis inhibition, 4063
 α 1,2-fucosyltransferase
transfection, BL6 cells, metastatic properties, 332
- ConA**
MMP-1 expression and MMP-2 activation
mediation by tyrosine phosphorylation, breast carcinoma cells, 5028
- Connexin 26**
Cx26 gene
bystander effect, HeLa cells, 2929
- Connexin 37**
gene mutations, rat hepatic angiosarcomas, 375
- Connexin 43**
gene transfection
and HeLa cell genetic stability, 2148
- Core 2 β 1,6-N-acetylglucosaminyltransferase**
gene expression, colorectal cancer, 5201
- Costimulatory molecules**
neoplastic B lymphocytes, 4940
- CP-358,774**
apoptosis and cell cycle arrest, 4838
- CPP32**
expression, *in vivo* patterns, 1605
neuroblastomas, 4578
- CPP32 β**
p53-dependent apoptosis, 2550
- CPT-11: see Irinotecan**
- CRADD**
cloning, 615
- CREB-binding protein**
p53 coactivator, 3693
p300/CBP-associated factor
p53 coactivator, 3693
- Curcumin**
apoptosis modulation, colon cancer, 1301
- Cutaneous epithelium**
carcinogen-initiated cells
quiescent, 3436
- Cutaneous melanoma**
induction by UV-A, *Monodelphis domestica*, 3682
malignant
 α , β 3 integrin and ICAM-1 expression, 1554
- Cyclin**
accumulation, G₁-S-arrested cancer cells, 4482
- Cyclin A**
CBP/cycA CCAAT-binding protein, subunits, 5117
expression, MOLT-4 cells, 803
- Cyclin A1**
characterization, 913
- Cyclin B**
activation
FAC pathway and, 2244
- Cyclin B1**
expression, MOLT-4 cells, 803
levels
and radiation-induced G₂ delay, HeLa cells, 753
- Cyclin D1**
antisense
growth inhibition, colon cancer cells, 1569

- expression
and TGF- β RII, intestinal adenomas, 1638
overexpression
cell cycle, EGFR and p53 effects, 5542
familial adenomatous polyposis, 169
pancreatic carcinoma, 1634
two-stage bladder carcinogenesis, 4765
pRB pathway
mantle cell lymphoma, 4608
- Cyclin-dependent kinase**
inhibitors
genes, lack of imprinting, 926
induction by lovastatin, breast cells, 604
p15, alternatively spliced p10, 2966
p16 gene, regulation by androgen, 4511
- Cyclin-dependent kinase 2**
activation
FAC pathway and, 2244
CDK2 gene
regulation by androgen, 4511
inhibition
tyrphostin AG17, lymphoma cells, 2434, 5610
inhibitors
HPV 16-immortalized keratinocyte suppression, 3741
- Cyclin-dependent kinase 4**
CDK4 gene
regulation by androgen, 4511
expression
and TGF- β RII, intestinal adenomas, 1638
overexpression, familial adenomatous polyposis, 169
- Cyclin-dependent kinase 6**
amplification, glioma
two-dimensional genome scanning, 1250
1,25D₃-induced p27/Kip1 target, 2851
- Cyclin-dependent kinase N2A/p16**
CDKN2A/p16 gene
methylation frequency, melanoma, 5336
status, melanoma cells, 4868
expression, oral dysplasias, 3886
- Cyclooxygenase-2**
expression, gastric carcinoma, 1276
inhibition by retinoids, 1081
oral squamous carcinoma cells, 2890
modulation by dietary fat, colon carcinoma, 3465
- Cyclophosphamide**
activation
induction, hepatocytes, 1946
hemorrhagic cystitis
amelioration by keratinocyte growth factor, 472
oxidation to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide, liver microsomes, 4229
- Cysteine**
mutations
Ret, characterization, 2870
RET activation, 391
- 5-S-Cysteinyl-dopa**
serum levels, metastatic melanoma, 5073
- Cystitis**
hemorrhagic
amelioration by keratinocyte growth factor, 472
- Cytidine monophospho-N-acetylneuraminic acid hydroxylase**
gene expression, mouse brain tumors, 1580
- Cytochrome c**
Ara-C-induced mitochondrial loss
inhibition, Bcl-x_L overexpression and, 3115
- Cytochrome P450**
1A1
CYP1A1 gene, cell-specific regulation, 1264
- 1B1
gene regulation, cell-specific, 1264
gene regulation, embryo fibroblasts, 4498
tumor-specific expression, 3026
- 2D
splice variants, lung tumors, 2589
- 2D6
tamoxifen 4-hydroxylation catalysis, liver, 3402
- 3A7
CYP3A7 gene, aflatoxin B₁ activation, 641
CYP17 gene
polymorphism, and breast cancer risk, 1063
inhibition
organoselenium compounds, 4757
sulforaphane, hepatocytes, 3649
NADPH P450 reductase
gene therapy enhancement, 4830
- Cytodifferentiation**
bladder carcinoma cells, 2789
- Cytokines: see also specific cytokines**
expression
photodynamic therapy and, 3904
induction by carcinoembryonic antigen, mouse, 4432
-secreting fibroblasts, vaccine adjuvants, 3230
- Cytosine deaminase**
combined with 5-fluorocytosine
gene therapy, and radiation response, 4205
gene transfer, AFP-producing hepatoma therapy, 461
- Cytostatic drugs: see also Drugs; specific drugs**
cellular protection against
c-Fos and, 2721
- Cytotoxicity**
camptothecin
and pH, 4811
potentiation by 7-hydroxystaurosporine, 4029
etoposide
wild-type p53 effects, M1 myeloid leukemia cells, 818
flavopiridol synergy with antineoplastic agents, 3375
ganciclovir
gap junctional intercellular communication-mediated protection, 1699
ifosfamide
chloroacetaldehyde role, 2676
ionizing radiation
DNA mismatch repair, 5143
polymerase β , mammalian cells, 110
radiation
camptothecin derivatives, mediation by mammalian DNA topoisomerase I, 1529
tirapazamine
and tumor hypoxia, 2922
TNF- α and/or hyperthermia
resistance, MnSOD and, 1991
topotecan
and pH, 4811
- Cytotoxic T lymphocyte-associated molecule-4**
blockade
tumor immunity enhancement, 4036
- Cytotoxic T lymphocytes: see also Lymphocytes; T lymphocytes**
activation by IL-18, Meth A sarcoma, 4557
agonist peptide for carcinoembryonic antigen, 4570
CD8+
- associated peptides, ovarian tumors, 87
generation
B7.1-modified melanoma cells, 1561
interleukin 6 gene therapy, SCID-PBL/hu mice, 1335
melanocortin 1 receptor-derived peptide-specific, 4348
- HPV-specific
cervical cancer infiltration, 2943
CIN III, 4855
induction by MAGE-3/HLA-A24 peptide, 4465
MAGE-3-specific, melanoma, 735
precursors, low frequency
activation to Melan-A by CD34⁺-derived dendritic cells, 5534
RMA thymoma response, 2564
- D**
- Daunorubicin**
apoptosis
inhibition by phorbol esters and phosphatidylserine, 5300
- DE-333: see N¹,N¹¹-Diethylnorspermine**
- Dequelin**
chemopreventive activity, 3424
ornithine decarboxylase regulation, 3429
- Dehydroascorbic acid**
transport, melanoma cells, 2529
- Dehydroepiandrosterone**
ribose and cell proliferation inhibition, 4242
- Deleted in colorectal carcinomas**
DCC gene
and glioma progression, 382
neuroblastoma, 3772
protein
loss of expression, and glioma progression, 382
- Deleted in pancreatic carcinomas**
DPC4 gene
neuroblastoma, 3772
and TGF- β receptor-mediated signal transduction, pancreatic cancer, 3929
- Deletions: see also Mutations; specific genes**
chromosome 3p, lung tumors, 1344
chromosome 3p, uterine cervical carcinoma, 3154
chromosome 6q, malignant mesothelioma, 4057
chromosome 9, neuroblastoma, 907
chromosome 9p, pituitary adenomas, 2703
chromosome 9p21
novel homozygous, lung cancer, 1
chromosome 11p15.1, epithelial ovarian carcinoma, 387
chromosome 14, ovarian carcinoma, 513
chromosome 14q, renal oncocytomas, 5009
chromosome 17
D17S34 locus, primitive neuroectodermal tumors, 32
- 4-Demethylpenclomedine**
antitumor activity, 815
- Dendritic cells**
CD34⁺-derived
low frequency CTLp activation to Melan-A, 5534
genetic immunization, melanoma antigen MART-1/Melan-A, 2865
- DENSPM: see N¹,N¹¹-Diethylnorspermine**
- 2',3'-Deoxycytidine**
sensitization by DNA polymerase β , mammalian cells, 110
- (E)-2'-Deoxy-2'-(fluoromethylene) cytidine**
antitumor and radiosensitizing effects, colon carcinoma xenografts, 4023
- Deschloroethylcyclophosphamide**
cyclophosphamide oxidation, liver micro-

- somes, 4229
- Des(1-3) insulin-like growth factor I**
¹²⁵I-labeled
 biodistribution and catabolism, nude mice, 2754
- Diabetes**
 and colorectal cancer, 4787
- Diagnosis**
 age
HPC1 gene, families, 4707
 microsatellite analysis, 4749
- Dichlorodiphenyltrichloroethane**
 serum levels
 and breast cancer risk, Mexico, 3728
- 2',3'-Dideoxycytidine**
 lymphomas
p53 and *ras* mutations, mouse, 2710
- Diet**
 and endometrial cancer risk, 5077
 restriction
p53-independent spontaneous carcinogenesis delay, mice, 2843
 tumor progression modulation, *p53*-deficient mice, 4667
- Diethylenetriaminedipentaacetic acid**
¹¹¹In-labeled polypeptides
 physiology, 659
- N¹,N¹¹-Diethylnorspermine**
 cell cycle arrest and apoptosis, melanoma cells, 5521
- Diethylstilbestrol**
 exposure
 and methylation, mouse uterus, 4356
 exposure, neonatal
 endometrial hyperplasia/apoptosis after, hamster uteri, 1903
- Differential display cloning**
MRP1/CD9, colon carcinoma, 2593
- Dihydropyrimidine dehydrogenase**
DPD gene, structural organization, 1660
- 1,25-Dihydroxyvitamin D₃**
apoD induction, breast cancer cells, 4091
 -induced *p27/Kip1*
Cdk6 target, 2851
- Dimethylhydrazine**
 aberrant crypt foci and colon carcinoma, rat model, 4507
- 5,6-Dimethylxanthone-4-acetic acid**
 elimination factors, 284
- Diosmin**
 oral cancer inhibition, 246
- β -L-Dioxolane-cytidine: see BCH-4556**
- Diphtheria toxin**
DAB₃₈₉ GRP fusion toxin
 protein synthesis inhibition, small cell lung cancer cells, 290
- dis3⁺**
 homologues and overexpression, cancer cells, 921
- DNA**
 alkylating agents
 resistance, MGMT, pancreatic tumors, 5360
 amplification
 breast tumors, mapping, 4360
 lung tumors, comparative genomic hybridization analysis, 2116
 (CAG)_n tracts
 repeat expansion detection analysis, testicular germ cell cancer, 209
 cleavage
 clercodcin, 1710
 topoisomerase II-mediated, induction by 1,2-naphthoquinones, 620
 complementary, α 1,2-fucosyltransferase transfection, BL6 cells, metastatic properties, 332
- cross-linking agents
 hypersensitive cells, characterization, 454
 hypersensitivity, and GRP78 up-regulation, 5112
 sensitivity, mafosfamide and, 454
 gains and losses, renal cell carcinoma, 480
 genomic
 differentially methylated regions, methylation-sensitive AP-PCR, 594
 high molecular weight fragmentation activity, drug-induced apoptosis, 3407
 hypermethylation, smoking-associated lung cancers, 4913
 Ku binding, atomic force microscopy, 1412
 methylation
 and genetic instability, colorectal cancer, 3370
 mapping, *Rb* gene promoter, 2229
 markers, breast carcinoma, 1030
 restriction landmark genomic scanning, liver tumors, 3294
 plasmid
 pharmacokinetics, direct injection, 2681
 replication
 camptothecin-induced inhibition, 1654
 and cyclins A and B1 expression, MOLT-4 cells, 803
 rereplication, *p53*- or *pRb*-deficient fibroblasts, 1013
 synthesis
 induction by peroxisome proliferators, 9-*cis* retinoic acid, and T₃, 795
 mimosine effects, mammalian cells, 2252
- DNA adducts**
 benzo[*g*]chrysene
 formation, MCF-7 cells, 415
 cisplatin
 repair, fludarabine triphosphate, 1487
 NNK, rat lung cells, 259
 pyridyloxobutyl, NNK-induced rat lung cells, 259
 tamoxifen
 endometrium, breast cancer, 4148
 rat, 1438
 toremifene, rat, 1438
- DNA damage**
 carcinogen
 c-Fos and cellular protection against, 2721
 cell cycle response, bronchial epithelial cells and lung fibroblasts, 3174
 cellular responses
 ataxia telangiectasia and, 2313
 checkpoint
Cdc2 feedback loop control, 5168
 double-strand breaks
 repair defective, hypersensitive mutant phenotype, 4600
 double-strand breaks, persistent
 human YAC DNA destabilization, 1970
 growth arrest and DNA damage gene
gadd153
 and etoposide-induced apoptosis, leukemic cells, 686
 metal ion-dependent hydrogen peroxide-induced, 2394
p53 accumulation and cell cycle arrest, acid cells, 68
 platinum
 tolerance, ovarian cancer, 850
 sister chromatid exchange
 extracellular factors and α particles, 2164
 strand-breaking agents
 delayed chromosomal instability induction, 4048
 tirapazamine-induced
 and tumor hypoxia, 2922
- DNA polymerase β**
 cytotoxic action, 110
- DNA repair**
 APE/Ref-1 activity
 phosphorylation and, 5457
 cisplatin adducts
 fludarabine triphosphate, 1487
 defect, hypersensitive mutant phenotype, 4600
 excision
 capacity, *BCL2*-overexpressing HL60 cells, 1650
 lymphocytes, 651
 mismatch
 cisplatin-induced signaling and, 3253
 deficiency, cisplatin resistance, 1841
 genes, cell cycle regulation, 206
 genes, gliomas, 1673
 glioma methylator resistance, 2933
 hMSH2 gene, nonsense inhibition, 3288
 ionizing radiation cytotoxicity, 5143
 mutants, transcription-coupled repair, 3784
 Werner syndrome cells, 2956
 stimulation by oltipraz, 1050
 transcription-coupled
 mismatch repair mutants, 3784
- DNA topoisomerase**
 sequential
 resistance mechanisms, 5100
- DNA topoisomerase I**
 camptothecin-resistant, 1516
 inhibition by aclacinomycin A, 4564
 inhibitors
 and pH, 4811
 radiosensitization, mammalian cells, 1529
- DNA topoisomerase II**
 DNA cleavage
 induction by 1,2-naphthoquinones, 620
 inhibitors
 -resistant cells, topoisomerase II β transfection, 4301
 reciprocal translocation mediation, Chinese hamster ovary cells, 4699
- DNA topoisomerase II α**
 down-regulation, merbarone resistance, 5004
 levels and etoposide sensitivity
 topotecan and, 1425
 nuclear localization signal, small cell lung cancer, 4451
- DNA topoisomerase II β**
 transfection, drug-resistant cells, 4301
- Docetaxel**
 CA-125 expression modulation, ovarian carcinoma cells, 3818
- Doxorubicin**
 BR64 disulfide and thioether conjugates, 100
 BR96-doxorubicin conjugate, antitumor activity, 4530
 cell death
p53 role, Rat-1 fibroblasts, 176
 liposomal
 combined with PSC 833, multidrug-resistant solid tumors, 5246
 uptake into bronchial carcinoma, 2440
- dpp**
 MAD-related gene 2 *MADR2/JV18-1*, neuroblastoma, 3772
- DR-nm23 gene**
 structure, activity, and location, 1180
- Droloxifene**
 stimulatory effects
 blockade by EM-800, human endometrial cells, 3494
- Drosophila patched gene**
 human homologue *PTCH*
 -associated preferential *smoh* expression, basal cell carcinoma, 4731

mRNA expression, basal cell carcinoma, 2336
 mutations, basal cell carcinomas and primitive neuroectodermal tumors, 2581
 mutations, desmoplastic medulloblastomas, 2085
 mutations, sporadic extracutaneous tumors, 2369
 mutations, sporadic medulloblastomas, 842
 mutations, trichoepitheliomas, 4677
Drosophila smoothened gene
 human homologue *SMOH*
 preferential expression, basal cell carcinoma, 4731
Drug delivery
 electromotive
 mitomycin C, bladder wall, 875
Drug resistance: see also Multidrug resistance; Resistance; specific drugs
 confluence-dependent
 HSP27 and, 2661
 increase by CD40 and Bcl-2, lymphoma, 1939
 melanoma
 activated N-ras, SCID mice, 362
 phenotype, evolution, 5086
Drug sensitivity: see also specific drugs
 cMOAT and, hepatic cancer cells, 5475
 p53 and, 4285
 p21^{waf1}-mediated, sarcoma cells, 2193
 R2 gene expression and, 4876
Drugs: see also specific drugs
 chemopreventive
 apoptosis modulation, colon cancer, 1301
 cytostatic
 c-Fos and cellular protection against, 2721
 exposure
 cellular adaptation, 5086
 -induced apoptosis
 high molecular weight DNA fragmentation activity, 3407
 mediation by CD95, neuroblastoma cells, 3823
 and mitochondrial function, 62
 magnetic targeting
 clinical experiences, 3063
 preclinical experiences, 3063
 microtubule-active
 Raf-1/bcl-2 phosphorylation, 130
 microtubule-targeting
 bcl-2 phosphorylation, 229
 multicell spheroid response
 comet assay and, 5528
 topoisomerase I
 radiosensitization, mammalian cells, 1529
D17S34
 chromosome 17 locus
 deletion, primitive neuroectodermal tumors, 32
Dysplasias
 cervical
 genetic alterations, 4171
 epidermodysplasia verruciformis
 skin autografts, 4214
 oral
 retinoic acid receptor- β expression, 3886

E

E7010
 mechanism of action, 3208
Early region 4
 hGABP/E4TF1
RB gene promoter activation, 3145
Ecotropic viral insertion site I
 fusion transcripts, leukemia, 3914
MDS1/EVII gene

ETV6 fusion, myeloproliferative disorders, 564
Edelfosine: see 1-O-Octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
Ehrlich ascites tumors
 macrophage activating factor therapeutic effects, BALB/c mice, 2187
elafin
 induction by phorbol 12-myristate 13-acetate, breast carcinomas, 4631
Electromotive administration
 mitomycin C, bladder wall, 875
EM-800
 human endometrial cells, 3494
Endocrine tumors
 chromosome 11q13 allelic deletions, 2238
Endometrial adenocarcinoma
 EM-800, Ishikawa cells, 3494
Endometrial carcinoma
 chromosome 10q25-q26 loss of heterozygosity, 1630
FHIT gene expression, human cells, 2112
 microsatellite instability
IGFIR gene mutations, somatic, 1851
PTEN/MMAC1 mutations, 3935, 4736
 risk
 diet, body size, physical activity, and, 5077
 SHBG exon VII splicing variant expression, 5579
 telomerase activity, 2760
Endometrium
 hyperplasia/apoptosis
 neonatal diethylstilbestrol exposure and, hamster uteri, 1903
 tamoxifen-DNA adducts, breast cancer, 4148
 telomerase activity, 610, 2760
Endothelial cells
 apoptosis
 induction by thrombospondin 1, 1735
 human vascular
 FLT-1 upregulation by VEGF, 5421
 metastatic tumor cell adhesion
 GD1 α functions, murine tumors, 1882
 migration
 inhibition by ETS1 antisense oligonucleotides, 2013
Endothelin 1
 mitogenic signaling, ovarian carcinoma cells, 1306
Endothelin B
 receptor
 gene methylation, prostate cancer, 35
Endothelium
 tumor vascular
 mAb to PSMA extracellular domain and, 3629
Endotoxin
 epothilone B activity, macrophages, 3344
Energy balance
 and colon cancer, 75
Enolase 1
 gene
 transcriptional activation by V-SRC, 5328
Enzyme immunoassay
 estrogen receptor-, breast cancer, 1066
Enzyme-linked immunosorbent assay
 melanoma-inhibiting activity, 3149
Enzymes
 phase 2 drug-metabolizing
 inducer sulforamate, cancer chemoprevention, 272
Epidermal growth factor
 boronated
 intratumoral delivery, 4333
 protein kinase A regulation, murine fibrosarcoma cells, 5410

receptor
 amplification, *PTEN/MMAC1* mutations and, 5254
 coexpression with Grb7, advanced esophageal carcinoma, 28
 cyclin D1 overexpression effects, transgenic mouse model, 5542
 HER2, and prognosis, childhood medulloblastoma, 3272
 HER4, and prognosis, childhood medulloblastoma, 3272
 inhibitor CP-358,774, apoptosis and cell cycle arrest, 4838
 inhibitors, HPV 16-immortalized keratinocyte suppression, 3741
v-ras^{Ha}-mediated keratinocyte neoplasia effects, 3180
 receptor type III
 mAb L8A4, radioiodination, 1510
 subcellular localization, 4130
 tumor-associated variant, density, 4130
 vaccine immunotherapy against, 1419
 responsive HPL1 cells, establishment, 4898
 survival function, bladder carcinoma, 3360
Epidermodysplasia verruciformis
 skin autografts, 4214
Epidermoid carcinoma
 G₁ phase accumulation by UCN-01, mechanism, 1495
4'-Epidoxorubicin
 magnetic drug targeting, advanced solid tumors, 3063
(-)-Epigallocatechin gallate
 AP-1 and cell transformation inhibition, 4414
Epithelial carcinoma
 ovarian
 chromosome 11p15.1 deletion mapping, 387
Lot1 gene identification, rat, 2029
 protein expression
 regulation by TNF- α 3'UTR, 5426
Epithelial cells
 breast
 MMP-9 surface association, TPA-induced, 3159
 bronchial
 cell cycle responses, 3174
 carcinogen-initiated
 quiescent, 3436
 cervical
 human papillomavirus and hypoxia, 4200
 lung
 novel HPL1, establishment, 4898
 mammary
 AP-1 activity, 3046
BRCA1 mutant, COOH-terminal, 3351
 mutant p53-induced immortalization, transactivation, 5584
 proliferation
 CD44v6-containing isoform regulation, 2281
 prostate
 immortal, generation and characterization, 995
 tumorigenicity, FGFR1 and FGFR2 and, 5369
 prostate tumor, primary
 growth *in vitro*, 3688
Epithelial tumors
 invasiveness
 ornithine decarboxylase overexpression and, 2104
Epithelium
 breast
 heparin/heparan sulfate interacting protein expression and functions, 5148

- mucosal squamous
mucin-like glycoprotein, 634
oral
clonal genetic changes, exfoliative cell samples, 5258
respiratory
telomerase expression, 2373
- Epothilone B**
endotoxin activity, macrophages, 3344
- eps15**
AP-2 interaction, molecular determinants, 240
HRX/ALL1-eps15 fusion protein cellular localization, 799
- Epstein-Barr virus**
B-cell lymphoma
prevention, SCID mice, 1704
- erbB2**
coexpression with Grb7, advanced esophageal carcinoma, 28
down-regulation
neu differentiation factor-induced, breast tumor, 3804
- Erythropoiesis**
retinoblastoma protein effects, 4123
- Esophageal adenocarcinoma**
Fas protein expression, 5571
p16^{INK4a} methylation, 2619
- Esophageal carcinoma**
advanced
Grb7 and erbB expression, 28
human papillomavirus and, Norway, 3989
- Estrogen**
antiestrogens
EM-800, human endometrial cells, 3494
resistance, estrogen receptor DNA binding, breast cancer, 3723
resistance, estrogen receptor mRNA splice variants, breast cancer cells, 585
steroidal and triphenylethylene, 3486
intratumoral levels
inhibition by vorozole, breast cancer tissue, 2109
metabolism and action
dietary BHA and, female CD-1 mice, 2419
receptor
breast cancer forms, ER-EIA assay, 1066
DNA binding, tamoxifen-resistant breast cancer, 3723
functional assay, yeast, 3478
mRNA splice variants, antiestrogen-resistant breast cancer cells, 585
mutant with constitutive transcriptional activity, 1244
-regulated gene expression
inhibition by ICI 182,780, 2547
living breast cancer cells, 4447
-responsive lactoferrin gene
demethylation, diethylstilbestrol exposure and, 4356
xenoestrogens
release from fat, mice, 865
- Estrone sulfate**
inhibition by nonsteroidal (*p*-*O*-sulfamoyl)-*N*-alkanoyl tyramines, breast cancer, 702
- ETO gene**
transformation properties, 2951
- Etoposide**
apoptosis
gadd153 and, leukemic cells, 686
cytotoxicity
wild-type p53 effects, M1 myeloid leukemia cells, 818
mutagenic effects, small cell lung cancer, 4393
- sensitivity
murine *MRP* gene disruption and, 5238
topoisomerase II α sensitivity
topotecan and, 1425
- ETS1 antisense oligonucleotides**
cell migration inhibition, 2013
- ETV6**
MDS1/ETV6 fusion, myeloproliferative disorders, 564
- EVI: see Ecotropic viral insertion**
- Ewing's sarcoma**
apoptosis
protein ubiquitination, 3881
- Exfoliative cells**
oral
clonal genetic changes, 5258
- Extracellular factors**
and α particles, 2164
- Extracellular fluid**
adenosine levels, solid tumors, 2602
- Extracellular signal-regulated kinase 2**
modulation by TGF- β , breast cancer cells, 628
- Extracranial tumors**
sporadic
PTCH gene mutations, 2369
- Extravasation**
VLA-6 and, liver, 3812
- F**
- Familial adenomatous polyposis**
cyclin D1 and Cdk4 overexpression, 169
early colorectal adenoma
clonality, 355
ornithine decarboxylase and polyamines, 199
- Familial carcinoma**
basal cell
PTCH mRNA expression, 2336
breast
probands, *FHIT/FRA3B* abnormalities, 3664
medullary thyroid
Ret with cysteine mutations, characterization, 2870
- Familial melanoma**
UV hypermutability, 4637
- Familial Wilms' tumor**
genetic heterogeneity, 1855
- Fanconi's anemia syndrome**
deregulated apoptosis, 1722
group C protein FAC
cdc2 kinase activation pathway, 2244
- Farnesyltransferase inhibitors**
apoptosis induction, 708
FTI-277
cell cycle enrichment, A549 cells, 1846
- FAS: see Fatty acid synthase**
- Fas**
apoptosis
p53-dependent, 2550
prostatic carcinoma cells, 1758
drug-induced apoptosis mediation
neuroblastoma cells, 3823
T-acute lymphatic leukemia, 3331
expression, esophageal adenocarcinoma, 5571
resistance, prostatic carcinoma cells, 3941
- Fat**
dietary
carcinogenesis, mice, 4162
and colon cancer, 3465
and colonic *ras*-p21 function, 253
and mammary tumor development, rodents, 3979
xenoestrogen release, mice, 865
- Fatty acids**
polyunsaturated
antitumor effects, 2200
- Fatty acid synthase**
apoptosis
induction by vitamin E succinate, breast cancer cells, 881
ligand
expression, lung carcinomas, 1007
receptor-interacting protein RIP, adaptor molecule CRADD, 615
regulation by androgens, LNCaP cells, 1086
- Fc receptors**
Fc γ R
HER-2/neu bispecific antibodies, effector mechanisms, 696
- Fenestration**
VEGF-induced neovasculation, 765
- Fibroblast growth factor**
acidic
expression, breast cancer, 956
basic
angiogenesis, bladder cancer, 136
bFGF-SAP killing enhancement by adenovirus, melanoma, 1873
expression, breast cancer, 956
growth arrest, breast cancer cells, 1750
high molecular forms, radioresistance, 1364
receptor
targeted gene delivery via, Kaposi's sarcoma, 1447
receptor 1
tumorigenic effects, prostate epithelial cells, 5369
receptor 2
tumorigenic effects, prostate epithelial cells, 5369
- Fibroblast growth factor 4**
VEGF upregulation, 5590
- Fibroblast motility-stimulating factor**
lung, purification and characterization, 3577
- Fibroblasts**
apoptosis
doxorubicin-induced, p53 role, 176
UVA-induced, inhibition by bcl-2 overexpression, 1405
bone marrow
B-cell adhesion, multiple myeloma, 930
cytogenetic alterations
induction by arsenite, 5051
cytokine-secreting, vaccine adjuvants, 3230
DNA repair defective, hypersensitive mutant phenotype, 4600
embryo
CYP1B1 expression regulation, 4498
hepatocyte growth factor
tumor-stromal interactions mediated by, analysis, 3305
lung
cell cycle responses, 3174
Msh2-deficient
mutator phenotype, mouse, 3765
oncogene-transformed
nuclear matrix proteins, mouse cells, 147
p53- or pRb-deficient
DNA rereplication, 1013
skin
UV-induced G₁ arrest, 3390
tumorigenicity
PLC- γ 1 overexpression and, rat 3Y1 cells, 5465
- Fibronectin**
Mr92,000 type IV collagenase induction, ovarian cancer cells, 5416
oncofetal mRNA, papillary carcinoma, 3792
- Fibrosarcoma**
growth suppression by perlecan, 2130
integrin-uPAR interactions, 1682
invasion

- suppression by perlecan, 2130
 Jun-associated transcription factors
 modulation by MnSOD, 5265
 oligopeptide transport, 4118
 protein kinase A regulation by EGF, murine cells, 5410
- Fibrosis**
 lung
 radiation-induced, genetic model, 5286
- Filaments**
 disassembly
 λ -carrageenan, mammary myoepithelium, 2823
- Finasteride**
 prostate-specific antigen expression down-regulation, 714
- Flavonoids**
in vitro angiogenesis inhibition, 2916
- Flavopiridol**
 cytotoxic synergy with antineoplastic agents, 3375
- flk-1/vascular endothelial growth factor receptor 2**
 up-regulation
 ligand-induced, cerebral system, 3852
- FLT-1: see Fms-like tyrosine kinase 1**
- Fludarabine triphosphate**
 cisplatin-induced DNA adduct repair, 1487
- Fluorescence *in situ* hybridization**
 c-myc amplification, metastatic prostatic carcinoma, 524
 tumor response modifier evaluation, 672
- 5-Fluorocytosine**
 combined with cytosine deaminase
 gene therapy, and radiation response, 4205
- 5-Fluorouracil**
 combined with ^{131}I -mAb A33, antitumor activity, 2181
 tumor interstitial kinetics, breast cancer, 2598
 uptake, pharmacokinetic analysis, 3415
- R-Flurbiprofen**
 intestinal adenoma chemoprevention and treatment, mouse model, 4316
- FM3 cells**
 potential HLA-DR-restricted tumor-associated antigens, isolation, 3238
- Fms-like tyrosine kinase 1**
 upregulation by VEGF, HUVECs, 5421
- Fms-like tyrosine kinase 3**
 antitumor activity, breast cancer, 3511
- Folate**
 antifolates
 multitargeted LY231514, 1116
 deficiency
hprt locus mutations and, Chinese hamster ovary cells, 2586
- Follicular thyroid adenoma**
 chromosome 10q22-23 Cowden Locus loss of heterozygosity, 500
 telomerase activity, 2144
- Follicular thyroid tumors**
 telomerase activity, 2144
- FP-846**
 photodynamic therapy, 4551
- Fragile histidine triad (FHIT) gene**
 abnormalities, breast cancer, 3664
 abnormal transcripts, breast carcinomas, 1981
 allele loss, lung cancer, 2256
 alterations, lung cancer, 2121
 chromosome 3p14.2 *FRA3B* site
 abnormalities, breast cancer, 3664
 loss of heterozygosity, brain tumors, 2638
 position, 1166
 expression, 504
- human cancer cells, 2112
 lung carcinogenesis, 5207
 expression loss, cervical carcinomas, 4692
 hybrid transcripts, pleomorphic adenoma of parotid gland, 13
 mutations, gastric cancer, 1435
 structure, 504
- Fructo-oligosaccharides**
 short-chain
 colon tumor reduction, *Min* mice, 225
- $\alpha 1,2$ -Fucosyltransferase**
 cDNA transfection, BL6 cells
 metastatic properties, 332
- Fusion proteins**
 antibody-IL-2
 colon carcinoma elimination, 4948
 HRX/ALL1-eps15
 cellular localization, 799
 melanoma epitope-MHC class I
 T-cell induction, 202
- Fusion toxins**
 DAB₃₈₉ GRP
 protein synthesis inhibition, small cell lung cancer cells, 290
- Fusion transcripts**
 EV11, leukemia, 3914
- Fv fragment**
 anti-Tac disulfide-stabilized
 biodistribution, circulating soluble IL-2 receptor α blockade and, 1955
- G**
- GA binding protein**
 hGABP/E4TF1
RB gene promoter activation, 3145
- Galectin-3**
 apoptosis inhibition, 5272
- Ganciclovir**
 cytotoxicity
 gap junctional intercellular communication-mediated protection, 1699
- Gangliosides**
 biosynthesis gene expression, mouse brain tumors, 1580
 GD1 α
 adhesion functions, murine metastatic tumors, 1882
- Gap junctions**
 bystander effect mediation, 1523
 intercellular communication
 protection from ganciclovir-mediated cytotoxicity, 1699
- Gastric carcinoma**
 carcinoembryonic antigen-producing
in vivo gene therapy, 4279
 cyclooxygenase-2 expression, 1276
FHIT gene mutations, 1435
 microsatellite instability, 4523
IGFIR gene mutations, somatic, 1851
Smad4 inactivation, 4221
 spontaneous apoptosis and angiogenesis, 221
 tumorigenicity
 TGF- β RII-expressing cells, 2856
- Gastric mucosa**
 MHC induction by MNNG, rat, 1416
- Gastrin**
 receptor, tumors, 1377
- Gastrinomas**
 chromosome 11q13 allelic deletions, 2238
 sporadic
MEN1 mutations, 4682
- Gastrin-releasing peptide**
 DAB₃₈₉ fusion toxin
 protein synthesis inhibition, small cell lung cancer cells, 290
- Gastrointestinal carcinoma**
 apoptotic and mutator mutations, 4420
- disseminated tumor cells
 detection by RT-PCR, 3106
- Gastrointestinal tumors**
E2F-4 mutations, 2350
- Gc protein**
 serum
 precursor activity, serum α -N-acetylgalactosaminidase index, 295
- Gene amplification**
 androgen receptor, 314
BCHE and *SLC2A2*, squamous cell lung carcinoma, 2290
- Genes: see also Oncogenes; specific genes**
 alterations
 cervical dysplasia, 4171
 clonal, oral exfoliative cells, 5258
 endocrine tumors, 2238
 induction by arsenite, fibroblasts, 5051
 papillary bladder carcinoma, comparative genomic hybridization, 2860
 expression
 estrogen-regulated, inhibition by ICI 182,780, 2547
 living breast cancer cells, 4447
 helix-loop-helix, basic
 expression, neuroectodermal tumors, 3526
 instability
 Eighth Annual Pezcoller Symposium meeting report, 4437
 mismatch repair
 cell cycle regulation, 206
 gliomas, 1673
 mutations
 tamoxifen, *lacI* transgenic rat livers, 1288
 ovarian cancer
 identification, rat, 2029
 P-glycoprotein-like, new
 P-glycoprotein-related protein, 3708
 senescence
 chromosome 6q21 region, characterization, 4153
 tumor suppressor
 chromosome 11, organotypic raft culture localization, 1157
 chromosome 3q locus, osteosarcoma, 106
- Gene therapy**
 AFP-producing hepatoma, 461
 combined with radiotherapy, biliary cancer, 4325
 enhancement by *P450 reductase*, 4830
 enzyme/prodrug combination
 and radiation response, 4205
in vivo, CEA-producing gastric carcinoma, 4279
 interleukin 6, SCID-PBL/hu mice, 1335
 Δ *MGMT*
 BG-BCNU administration protection, 5093
- Genetic immunization**
 melanoma antigen MART-1/Melan-A dendritic cells, 2865
- Genetic models**
 radiation-induced lung fibrosis, 5286
- Gene transfer**
 adenovirus-MnSOD, hamster cheek pouch carcinoma cells, 5550
 A and B
 and cell motility, 3092
 connexin 43
 and HeLa cell genetic stability, 2148
 direct
 plasmid DNA pharmacokinetics, 2681
 via fibroblast growth factor receptor, Kaposis's sarcoma, 1447
 interleukin 10
 cancer cachexia prevention, colon adenocarcinoma, 94

- KISS-1**
metastasis suppression, breast carcinoma, 2384
- macrophage colony-stimulating factor
into metastatic lung cancer, SCID mice, 784
- Salmonella* vector, 4537
- Genistein**
colon cancer enhancement, 3717
- Genomes**
comparative genomic hybridization
breast tumor subsets, 4368
childhood medulloblastoma analysis, 4042
lung tumors analysis, 2116
metastatic head and neck squamous cell carcinoma pattern, 5213
non-small cell lung carcinoma patterns, 2331
papillary bladder carcinoma genetic alterations, 2860
instability
chromosomal instability and, 5557
Eighth Annual Pezcoller Symposium meeting report, 4437
R2 gene expression and, 4876
- Genome scanning**
restriction landmark
DNA methylation status, mouse liver tumors, 3294
two-dimensional
gliomas, 1250
- Genotypes**
ALDH2
hemoglobin-associated acetaldehyde and, 1241
- Geranylgeranyltransferase**
inhibitor GGTI-298
apoptosis and cell cycle blockade, 1846
- Germ cell cancer**
testicular
trinucleotide expansions, 209
- Germ cell tumors**
alkaline phosphatase isoenzymes
detection by reverse transcription-PCR, 3841
- GL331**
apoptosis
CDC 25 and CDC 2, 2974
- Glial cell line-derived neurotrophic factor**
mutations, pheochromocytomas, 310
- Glioblastoma**
growth inhibition by *MXII*, 4905
PTEN/MMAC1 mutations and EGFR amplification, 5254
WAF1 induction by acidity, p53-dependent, 3910
- Glioblastoma multiforme**
somatic *PTEN* mutations, 4183
- Glioma**
aggressiveness
TrkA expression and, 532
cell scattering
TGF- α and, 5598
chemotherapy
response, pretreatment prediction, 4196
childhood, malignant
p53 mutations and overexpression, 304
chromosome 3p loss of heterozygosity and
VHL gene mutations, 1035
hypoxia regulation, rat, 3860
inhibition
SarCNU, xenografts, 3895
invasion
low density lipoprotein receptor-related protein expression, 2799
invasiveness
TrkA expression and, 532
- lipid droplets, NMR and microscopy study, 407
- malignant
oncolysis by $\gamma_{134.5}$ HSV mutants, 1502
- malignant childhood
p53 mutations and overexpression, 304
Met and hepatocyte growth factor/scatter factor expression, 5391
methylator resistance
mismatch repair, 2933
mismatch repair genes, 1673
MRP/GS-X pump and γ -GCS induction by ACNU, 5292
oligodendrocyte mRNAs, 4098
progression
DCC loss of expression and, 382
PTEN mutations, 4187
two-dimensional genome scanning, 1250
vascular endothelial growth factor expression
up-regulation, rat, 3860
- Glucocorticoids**
apoptosis
inhibition by baculovirus P35, 43
P-glycoprotein inhibition, 720
- Glucose-regulated stress protein**
GRP78
up-regulation, hypersensitivity to DNA cross-linking agents and, 5112
- β -Glucuronidase**
blood activity
elevation by irinotecan, rats, 5305
and doxorubicin uptake, bronchial carcinoma, 2440
- Glucuronide**
prodrug HMR 1826
doxorubicin release, bronchial carcinoma, 2440
- γ -Glutamylcysteine synthetase**
transient induction by ACNU, glioma cells, 5292
- γ -Glutamyl transpeptidase**
activity and mRNA, prostate carcinoma cells, 2428
- Glutathione**
busulfan conjugation, age-dependent, 5509
cotransport with toxins by multidrug resistance protein, 5232
levels
murine *MRP* gene disruption and, 5238
melatonin oncostasis requirement, breast cancer, 1909
metabolism, non-small cell lung cancers, 152
- Glutathione peroxidase**
and skin carcinogenesis, 1469
- Glutathione S-transferase**
expression, hepatocellular carcinoma, 2749
GSTA5
overexpression, selenium deficiency, 4257
induction by sulforaphane, hepatocytes, 3649
- N-Glycans**
cell-surface expression, NIH3T3 cells and transformants, 1073
- Glycine**
nitrosated
derivatives, *O*⁶-methylguanine source, 366
- Glycoprotein**
biliary
isoforms, tumor inhibition properties, 2781
gp95
P-95, identification, 5460
gp100
expression, melanoma, 3223
mucin-like, mucosal squamous epithelia, 634
- Glycosylation**
hepatocellular carcinoma, mouse model, 5655
- 4249
- N-linked**
inhibition by tunicamycin, and apoptosis, 543
- GOK gene**
rhabdomyosarcoma and rhabdoid tumor development, 4493
- Good samaritan effect**
GJIC-mediated protection from ganciclovir, 1699
- Granulocyte colony-stimulating factor**
combined with Fc γ R bispecific antibodies
effector mechanisms, breast carcinoma, 696
photodynamic therapy, rat rhabdomyosarcoma, 2555
receptor
soluble, proliferative effects, 3395
- Granulocyte-macrophage colony-stimulating factor**
-transduced renal cell carcinoma vaccines, bioactivity, 1537
- Grb7**
coexpression with erbB, advanced esophageal carcinoma, 28
- Green fluorescent protein**
expression, micrometastasis visualization, 2042
- GR6 gene**
identification, 3914
- Growth arrest and DNA damage genes**
gadd153
and etoposide-induced apoptosis, leukemic cells, 686
- Growth factors: see specific factors**
- G α protein**
mutations, thyroid neoplasia, 2358
- GTPase**
p190 domain
tumor suppression, 2478
- Gut-associated lymphoid tissue**
development by short-chain fructo-oligosaccharides, *Min* mice, 225
- H**
- Hamster cheek pouch carcinoma**
adenovirus-MnSOD gene transfer, 5550
- Hamster tumors**
AD12-induced
clonal origin, 3001
- HASH1 gene**
expression, neuroectodermal tumors, 3526
- HBL100 cells**
drug-induced apoptosis
inhibition by IGF-1, 2687
- Head and neck carcinoma**
CDC25A and CDC25B overexpression, 2366
squamous cell
metastatic, comparative genomic hybridization pattern, 5213
p53 mutations, smokers, 4070
- Heat shock protein 27**
and cell confluence, 2661
- H-4-II-E cells**
peroxisome proliferators
detection with rat acyl-CoA oxidase promoter, rat liver, 1575
- HeLa cells**
Cx26 gene bystander effect, 2929
genetic stability
connexin 43 gene transfection and, 2148
radiation-induced G₂ delay
cyclin B1 levels and, 753
radioresistance
high molecular bFGF, 1364

- Helicobacter felis**
infection
truncated *Apc* and, 3972
- Helix-loop-helix genes**
basic
expression, neuroectodermal tumors, 3526
- Hemangioendothelioma**
growth inhibition by angiostatin, murine, 5277
- Hematological malignancies**
dsRNA-activated protein kinase, 943
p15^{INK4B} and *p16^{INK4A}* patterns of inactivation, 837
- Hematopoietic neoplasms**
HIC1 methylation, 1678
- Hemoglobin-associated acetaldehyde**
and *ALDH2* genotype, 1241
- Hemorrhagic cystitis**
cyclophosphamide-induced
amelioration by keratinocyte growth factor, 472
- Heparin/heparan sulfate interacting protein**
expression and functions, breast cancer cells, 5148
- Hepatic angiosarcoma**
connexin 37 mutations, rat, 375
p53 gene mutations, rat, 1695
- Hepatitis B virus**
hepatocellular carcinoma
chronic infection, Taiwan, 3471
GST expression, 2749
surface antigen
synergy with TGF α , hepatocellular carcinoma, 3606
X protein
transactivation and *p53*-interacting functions, 5137
- Hepatitis B virus-encoded X antigen**
hepatocellular carcinoma
p53 integrity, 426
- Hepatocellular carcinogenesis**
transforming growth factor α and hepatitis B virus surface antigen, 3606
- Hepatocellular carcinoma: see also Liver**
aflatoxin exposure, Taiwan, 3471
AFP-producing
gene therapy, 461
drug sensitivity
cMOAT and, 5475
glycosylation, mouse model, 4249
GST expression, 2749
HBV infection, chronic
Taiwan, 3471
HBxAg-positive and -negative
p53 integrity, 426
high-resolution allelotyping, 1986
IGF2 promoter control, 2048
MXR7 cloning and expression, 5179
p53 mutations, Taiwan, 3471
proliferation
transforming growth factor α and hepatitis B virus surface antigen, 3606
- Hepatocyte growth factor**
expression, gliomas, 5391
and prognosis, non-small cell lung cancer, 433
responsive HPL1 cells, establishment, 4898
tumor-stromal interactions mediated by, analysis, 3305
- Hepatocytes**
apoptosis
phenobarbital-induced, mouse, 2896
cyclophosphamide and ifosfamide activation
induction, 1946
CYPs and GSTs
sulforaphane effects, 3649
radiolabeled polypeptide delivery, 659
- Hepatoma**
AFP-producing
gene therapy, 461
alb-SV40-T transgenic rat
chromosomes, 3451
apoptosis induction by Wilms' tumor 1-KTS isoforms, 1353
- Hepsin**
overexpression, ovarian cancer, 2884
- HER2/neu**
amplicon gene isolation, 3548
bispecific antibodies
effector mechanisms, breast carcinoma, 696
coexpression with Grb7, advanced esophageal carcinoma, 28
expression
bispecific antibody lysis, 4008
MMTV-*neu* mice
loss of heterozygosity, mammary tumors, 3520
neu differentiation factor
apoptosis, breast tumor, 3804
overexpression
metastasis enhancement, breast cancer cells, 1199
and prognosis, childhood medulloblastoma, 3272
- HER4**
and prognosis, childhood medulloblastoma, 3272
- Hereditary nonpolyposis colorectal cancer**
atypical
hMSH6 germ-line mutation, 3920
hMSH2 and *hMLH1* germline mutations, 3798
- Hereditary prostate cancer 1 (HPC1) gene families**
age at diagnosis, 4707
- Herpes simplex virus**
enhanced reactivation
and cancer proneness, 4384
 γ ₁34.5' mutants
oncolysis, malignant glioma, 1502
malignant mesothelioma treatment, 466
- Herpes simplex virus thymidine kinase**
bystander effect
mediation by gap junctions, 1523
- Hesperidin**
oral cancer inhibition, 246
- Heterocyclic aromatic amine**
human urinary metabolites, 3457
- Heterozygosity, loss of**
breast carcinoma, genome-wide search, 5469
chromosome 3p, glial tumors, 1035
chromosome 3p14.2, brain tumors, 2638
chromosome 10q22-23 Cowden Locus, thyroid tumors, 500
chromosome 10q25-q26, endometrial cancer, 1630
chromosome 14q, renal oncocyctomas, 5009
chromosome 16q, prostate adenocarcinoma, 1058
chromosome 16q24.1-q24.2, prostate cancer, 3356
chromosome 18q, squamous cell carcinoma, 824
FHIT gene locus, brain tumors, 2638
mammary tumors, transgenic mice, 3520
MEN1 gene localization, 1855
and mitotic recombination, 1188
- HIG gene**
inactivation, Wilms' tumorigenesis, 4469
- HIC1**
methylation, leukemia, 1678
- High mobility group proteins**
HMGIC gene
- hybrid transcripts, pleomorphic adenoma of parotid gland, 13
- Hirschsprung's disease**
phenotype
Ret with cysteine mutations, characterization, 2870
- Histoblood group A**
A gene transfection
and cell motility, 3092
- Histoblood group B**
B gene transfection
and cell motility, 3092
- Histone**
H4
BCL6 fusion by t(3;6), non-Hodgkin's lymphoma, 7
- Histone deacetylase**
inhibitors butyrate and trichostatin A
caspase-3 and apoptosis induction, 3697
- HL-60 cells**
apoptosis-resistant
NADH dehydrogenase deficiency, 5243
BCL2-overexpressing
nucleotide excision repair capacity, 1650
1,25D₃-induced *p27/Kip1*
Cdk6 target, 2851
paclitaxel-induced apoptosis
bcl-x_L overexpression and, 1109
- hmc (homologue to the mitotic-control gene)**
isolation and overexpression, cancer cells, 921
- HMG(I)Y**
rearrangements, lipomas, 2276
- HMR 1826**
doxorubicin release, bronchial carcinoma, 2440
- Homeobox genes**
HOX11/TCL3
transformation, 337
- Hormones**
class I HLA down-regulation
HPV and, cervical tumor cells, 937
pretreatment
spermatogenesis protection, 1091
- Housing**
social
and chemotherapy response, Shionogi mouse mammary carcinoma, 1124
- HOX11/TCL3 gene**
transformation, 337
- HPL1 cells**
establishment, 4898
- hprt gene**
locus
mutation analysis, Chinese hamster ovary cells, 2586
- HRX/ALL1 protein**
cellular localization, 799
fusion with *eps15*
cellular localization, 799
- Hs294T cells**
I- κ B α degradation, 3032
- HT1080 cells**
oligopeptide transport, 4118
- Human apurinic endonuclease 1**
expression, colorectal adenoma-carcinoma, 1794
- Human chorionic gonadotropin**
receptors, breast cancer, 857
 β subunit
gene expression, nontrophoblastic cells, 516
- Human elav-like neuronal protein 1**
Hel-N1 gene
mutations, lung cancer, 5356
- Human leukocyte antigen**
A2

- associated peptides, ovarian tumors, 87
melanoma, MAGE-3-specific cytotoxic T lymphocytes, 735
- A24**
MAGE-3/HLA-A24 peptide, CTL induction, 4465
- class I**
hormone-mediated suppression, HPV and, 937
- DR**
-restricted potential melanoma-associated antigens, isolation, 3238
- DRB1**
genotyping, renal cell carcinoma, 742
- Human papillomavirus**
and esophageal cancer, Norway, 3989
and hormone-mediated class I HLA suppression, cervical tumor cells, 937
and hypoxia, cervical epithelial cells, 4200
promoters, oral cancer cells, 1615
-specific CTLs
cervical cancer infiltration, 2943
CIN III, 4855
- type 16**
DNA-positive tumors, growth inhibition, 3993
E7 protein, bladder carcinoma, 2789
-immortalized keratinocytes, suppression by typhostins, 3741
- Human T-cell leukemia virus**
and myelodysplastic syndrome, 4718
- type I**
-infected lymphocytes, RA-induced apoptosis, oxidative stress, 4916
- Human T-lymphotropic virus**
type I
infection, clonal proliferation, 4862
- Human vascular endothelial cells**
FLT-1 upregulation by VEGF, 5421
- Hyaluronan**
receptor
CD44, neuroblastoma cells, 1387
- Hyaluronic acid**
tumor-associated, bladder cancer, 773
- Hyaluronidase**
tumor-derived
urinary levels, bladder cancer, 778
- Hydrogen peroxide**
delayed chromosomal instability induction, 4048
DNA damage
metal ion-dependent, 2394
production
initiation by α particles, 3963
- 4-Hydroxycyclophosphamide**
cyclophosphamide oxidation, liver microsomes, 4229
- 8-Hydroxyguanine**
N-nitrosodiethylamine initiation, rat liver carcinogenesis, 1281
- 8-Hydroxyguanine glycosylase/apurinic, apyrimidinic lyase**
mammalian homologue, cloning and characterization, 2151
- 6-Hydroxymethylacylfulvene**
antitumor activity, 281
- N*-[2-[(4-Hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide: see E7010**
- 7-Hydroxystaurosporine**
 G_1 -phase accumulation, mechanism, 1495
 S -phase checkpoint abrogation, 4029
- 4-Hydroxytamoxifen**
combined with sodium phenylacetate
antiproliferative effects, MCF-7 *ras* tumors, 1023
- N*-(2-Hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide: see SR-4554**
- Hypercalcemia**
PTHrP-induced
TNF effects, 3194
- Hyperlipidemia**
renal carcinogenesis induction, Eker rat, 4673
- Hyperplasia**
endometrial
neonatal diethylstilbestrol exposure and, hamster uteri, 1903
epidermal and oral
CaN19 expression, 3055
- Hypersensitivity**
DNA cross-linking agents
and GRP78 up-regulation, 5112
- Hyperthermia**
and polyunsaturated fatty acids
antitumor effects, 2200
radiosensitization
Ku autoantigen heat inactivation, 2847
resistance
MnSOD and, 1991
- Hypoxia**
human papillomavirus and, cervical epithelial cells, 4200
induction by tamoxifen, MCF-7 xenografts, 5155
regulation, rat glioma, 3860
tumor
SR-4554 probe, preclinical evaluation, 3314
tirapazamine-induced DNA damage and, 2922
- Hypoxia-inducible factor 1**
induction by V-SRC, 5328
- I**
- ICI 182,780**
estrogen-regulated gene expression inhibition, 2547
resistance, MCH7/LCC9, 3486
- Id genes**
expression, astrocytes, 215
- Idiotypic**
anti-idiotypic antibodies
antitumor immunity, 728
- Ifosfamide**
activation
induction, hepatocytes, 1946
cytotoxicity
chloroacetaldehyde role, 2676
- Imaging: see also specific modalities**
bioimaging
metastatic tumor cell trafficking, 3612
- Immortality**
genomic instability and
Eighth Annual Pezcoller Symposium meeting report, 4437
- Immortalization**
mutant p53-induced
transactivation, mammary epithelial cells, 5584
- Immune response**
antitumor
human, monitoring in SCID mice, 2937
- Immunity**
tumor
CD40/CD154 interactions and, 2569
induction by anti-idiotypic antibody, 728
- Immunocjugates**
BR96-doxorubicin, antitumor activity, 4530
- Immunotherapy**
B-cell tumors, SCID mice, 678
Flt3-ligand, breast cancer, 3511
- vaccine
against EGFRvIII, 1419
- Immunotoxins**
combination anti-CD19, -CD22, and -CD38-saporin
lymphoma therapy, SCID mice, 4824
- Imprinting, loss of**
5-aza-2'-deoxycytidine, tumor cells, 48
IGF2 gene, renal cell carcinoma, 2575
- Indium-111-diethylenetriaminepentaacetic acid-octreotide**
physiology, 659
- Infants**
leukemia, acute
ALL1-positive, breakpoint mapping, 2879
- Infection**
Helicobacter felis
truncated *Apc* and, 3972
hepatitis B virus, chronic
hepatocellular carcinoma, Taiwan, 3471
human T-lymphotropic virus type I
clonal proliferation, 4862
- Inflammation-related cancer**
pathogenesis
Sixteenth Sapporo Cancer Seminar meeting report, 3620
- ING1 gene**
apoptosis regulation, 1255
- Inhibitory molecules**
I κ B- α
phosphorylation by *ATM*, 24
- Inositol hexaphosphate**
antitumor promotion, 2873
- In situ hybridization**
prostate-specific membrane antigen expression, prostate cancer, 2321
- Insulin-like growth factor binding protein 2**
IGF-II/IGFBP-2 mRNA ratio
anaplasia marker, meningioma, 2611
- Insulin-like growth factor I**
drug-induced apoptosis inhibition, HBL100 cells, 2687
¹²⁵I-labeled Des(1-3)
biodistribution and catabolism, nude mice, 2754
mitogenesis
nuclear phospholipase C β_1 and, 2137
- receptor**
down-regulation, apoptosis induction, 543
modulation by tamoxifen, breast cancer, 2606
overexpression, radioresistance mediation, breast cancer, 3079
protective effects, apoptosis, 3264
reduction by dietary restriction, p53-deficient mice, 4667
- Insulin-like growth factor II**
expression
excessive, IGFII receptor-mutant tumors, 2543
IGF2 gene
deletion, and liver tumorigenesis, 4615
loss of imprinting, renal cell carcinoma, 2575
IGF2 gene promoter
control, hepatocellular carcinoma, 2048
IGF-II/IGFBP-2 mRNA ratio
anaplasia marker, meningioma, 2611
- receptor**
mutations, deficient TGF- β 1 activation and, 2543
mutations, somatic, microsatellite unstable cancers, 1851
- Insulinomas**
sporadic
MEN1 mutations, 4682
- Integrins**
 α_2

- shedding, MV3 cells and, 2061
- $\alpha 2 b \beta 3$
melanoma cell invasion, 2522
- $\alpha 5 \beta 3$
expression, cutaneous malignant melanoma, 1554
- $\alpha 6 \beta 1$
cell migration and extravasation, liver, 3812
- $\beta 1$
shedding, MV3 cells and, 2061
uPAR interactions, fibrosarcoma, 1682
- $\beta 3$
uPAR interactions, fibrosarcoma, 1682
- $\beta 4$
growth suppression, UM-UC-2 cells, 38
- Intercellular adhesion molecule-1**
expression, cutaneous malignant melanoma, 1554
- Interferon γ**
-regulated proteins, identification, 1137
synergy with bryostatin-1
iNOS expression, 2468
- Interleukin 1**
photodynamic therapy, rat rhabdomyosarcoma, 2555
- Interleukin 2**
huKS1/4-IL-2 fusion protein
colon carcinoma elimination, 4948
receptor α
circulating soluble, blockade, 1955
soluble, circulating, blockade, 1955
- Interleukin 3**
gene radiotherapy, 3899
- Interleukin 4**
-regulated proteins, identification, 1137
- Interleukin 6**
-dependent ANBL6 cells
growth properties, N- and K-*ras* mutation effects, 2268
expression
photodynamic therapy and, 3904
gene therapy, SCID-PBL/hu mice, 1335
growth effects, prostate carcinoma cells, 141
- Interleukin 10**
expression
photodynamic therapy and, 3904
gene transfer
cancer cachexia prevention, colon adenocarcinoma, 94
growth inhibition, leukemia cells, 476
- Interleukin 12**
desensitization and antitumor efficacy, 2460
recombinant
antitumor efficacy, desensitization and, 2460
T-cell migration to tumor sites, 2216
- Interleukin 18**
antitumor killer cell activation, Meth A sarcoma, 4557
- Interleukin 1 β converting enzyme**
family proteases, neuroblastomas, 4578
- Interstitial tumor space**
5-fluorouracil kinetics, breast cancer, 2598
- Intestinal adenomas**
cyclin D1 and Cdk4 overexpression, familial adenomatous polyposis, 169
prophylaxis and treatment, *APC^{Min}* mouse model, 4316
transforming growth factor β type II receptor expression
cyclin D1 and Cdk4 and, 1638
- Intestinal neoplasia**
APC^{Min} mouse, 812
multiple
cyclin D1 and Cdk4 overexpression, 169
- Intestinal tumors**
mutational mechanisms, Min mice, 1999
- Intestine**
cell migration
ApC gene mutations and, 5045
preneoplastic changes
dietary polyamines and, rat, 573
- Intraepithelial lesions**
low-grade
tetrasomy, 4210
- Invasion: see also specific sites of origin, tumors**
hepatocyte growth factor and, 3305
suppression by E- or P-cadherin, 5033
visualization by green fluorescent protein expression, 2042
- Ionizing radiation: see Radiation**
- Irinotecan**
biliary excretion, rats, 1934
blood β -glucuronidase activity elevation, rats, 5305
- Iron**
cancer incidence
inhibition by vitamin E, 2410
- Ishikawa cells**
EM-800, 3494
- J**
- Jun-associated transcription factors**
modulation by MnSOD, fibrosarcoma, 5265
- Jun kinase**
activation by MEN2B RET, neuroblastoma cells, 5399
- Jun N-terminal kinase**
modulation by TGF- β , breast cancer cells, 628
- Juvenile polyposis syndrome**
susceptibility locus, 5017
- JV18-1 gene**
neuroblastoma, 3772
- K**
- Kallikrein**
human hK2
expression, breast cancer cells, 2651
hKLK2 gene, peripheral blood detection by RT-PCR, 4167
pro-PSA activation, 3111
- Kaposi's sarcoma**
targeted gene delivery via fibroblast growth factor receptor, 1447
- Karyotyping**
spectral, multicolor
mouse plasmacytomas, 4585
- Keratinocyte growth factor**
cyclophosphamide-induced hemorrhagic cystitis amelioration, 472
- Keratinocyte neoplasia**
v-*ras*^{Hu}-mediated
epidermal growth factor receptor role, 3180
- Keratinocytes**
HPV 16-immortalized
suppression by tyrphostins, 3741
p53 protein levels
regulation by cell adhesion, 3635
- Keratinosis**
induction by ultraviolet B, skin, 2081
- Kidney: see also Renal cell carcinoma**
cell proliferation by peroxisome proliferators, 9-*cis* retinoic acid, and T₃, 795
radiolabeled polypeptide delivery, 659
tamoxifen- and toremifene-induced DNA adducts, rat, 1438
- Ki-ras**
ceramide-induced apoptosis and, colon cancer cells, 4714
- KiSS-1**
metastasis suppression, breast carcinoma, 5658
- 2384
- K-ras**
mutations
ANBL6 growth property effects, 2268
colorectal cancer, 2485
pancreatic adenocarcinoma precursors, 2140
- Ku**
DNA binding, atomic force microscopy, 1412
heat inactivation
hyperthermic radiosensitization, 2847
- L**
- L86-8275: see Flavopiridol**
- L8A4**
radioiodination, 1510
- Lactoferrin**
estrogen-responsive gene
demethylation, diethylstilbestrol exposure and, 4356
- Lambda/*lacI* transgenic rats**
gene mutations
tamoxifen, liver, 1288
- β -Lapachone**
topoisomerase II-mediated DNA cleavage, 620
- L1210 cells**
polyamine transport inhibitors
structure-function relationships, predictive model, 234
- Lesions: see also Neoplasia; Tumors**
cervical
telomerase assay, 1863
cervical squamous intraepithelial tetrasomy, 4210
intraepithelial
low-grade, basal cell tetrasomy, 4210
melanocytic
gp100, MART-1, and tyrosinase expression, 3223
preneoplastic, breast
FHIT/FRA3B abnormalities, 3664
preneoplastic, bronchial
FHIT/FRA3B allele loss, 2256
- Letters to the Editor**
re: DeFrank, *et al.*, 56: 5365-5368, 5434
re: Hemminki, *et al.*, 56: 4374-4377, 4148
re: Lübke, *et al.*, 56: 4964-4701; and 56: 4686-4693, 3063
re: Martini *et al.*, 56: 4820-4825, 3319
re: Meyn, 55: 5991-6001, 2313
re: Palumbo, *et al.*, 57: 2434-2439, 5610
re: Rao, *et al.*, 56: 3395-3398, 2806
- Leukemia: see also specific cells**
apoptosis
inhibition by bcl-2 protein, mechanism, 3097
B-cell
immunotherapy, SCID Mice, 678
cell growth
inhibition by cobalamin analogues, 4015
inhibition by IL-10, 476
cyclin A1, characterization, 913
dsRNA-activated protein kinase, 943
etoposide-induced apoptosis
gadd153 and, leukemic cells, 686
fusion transcripts with EVI1, 3914
HIC1 methylation, 1678
lymphocytes
DNA excision repair profiles, 651
mixed lineage
MLL gene, Alu-mediated self fusion, acute myeloid leukemia, 117
t(8;21)
fusion partner *ETO* gene, transformation properties, 2951

- T-cell
 human T-cell leukemia virus, and myelodysplastic syndrome, 4718
 human T-cell leukemia virus type I-infected lymphocytes, RA-induced apoptosis, oxidative stress, 4916
 TCL1 gene overexpression, 5452
- Leukemia, acute lymphoblastic**
ALL-1/MLL/HRX gene
 antigen, nuclear localization, 2035
 -positive acute leukemias, breakpoint mapping, 2879
 protein, cellular localization, 799
- T-cell
 drug-induced apoptosis, FasL-independent mediation, 3331
p15 methylation and deletion, 832
p16 deletion, 832
- Leukemia, acute myeloblastic**
 cell proliferation
 soluble G-CSF receptor effects, 3395
- Leukemia, acute myeloid**
M4/M5 subtypes, Alu-mediated *MLL* self fusion, 117
 paclitaxel-induced apoptosis, bcl-x_L overexpression and, 1109
- Leukemia, chronic lymphocytic**
 atypical *BCL1*+, 1145
- Leukemia, chronic myelogenous**
 CD4+ specific T cells, production method, 1547
- Leukemia, myeloid**
 etoposide cytotoxicity
 wild-type p53 effects, M1 cells, 818
 human
 2-5A synthetase expression, 2732
- Leukemia, promyelocytic**
 nucleotide excision repair capacity, *BCL2*-overexpressing HL60 cells, 1650
PML gene
 adenovirus, prostate cancer therapy, 1868
- Lewis^x antigen**
 anti-Le^x MAb BR64
 disulfide and thioether doxorubicin conjugates, 100
 anti-Le^x MAb BR96
 doxorubicin immunoconjugate, antitumor activity, 4530
- Li-Fraumeni families**
TP53 mutations, germ-line, 3245
- Linoleic acid**
 conjugated
 mammary gland effects, 5067
- Linomide**
 antiangiogenic effects
 potentiation by androgen ablation, prostatic cancers, 1054
- Lipids**
 glioma droplets, NMR and microscopy study, 407
- Lipomas**
HMGI(Y) rearrangements, 2276
- Liposome**
 -associated ET-18-OCD₃, therapeutic effects, 1915
- Liver**
 cell migration and extravasation
 VLA-6 and, 3812
 gene mutations
 tamoxifen, *lacI* transgenic rat, 1288
 metastasis
 microvascular regulation, 4105
 metastasis, colon cancer
 radioimmunotherapy and fractionated radiotherapy, nude mice, 447
 metastasis, colorectal adenocarcinoma
 5-[¹⁸F]fluorouracil uptake, pharmacokinetic analysis, 3415
- microsomes
 cyclophosphamide oxidation to HCY and DCCY, 4229
- peroxisome proliferators
 detection with rat acyl-CoA oxidase promoter, rat, 1575
- retinoic acid metabolism, aryl hydrocarbon receptor knockout mice, 2835
- retinoids, aryl hydrocarbon receptor knockout mice, 2835
- tamoxifen- and toremifene-induced DNA adducts, rat, 1438
- Liver carcinogenesis: see also Hepatocellular carcinoma**
 acceleration by TGF-β1, transgenic mice, 2089
N-nitrosodiethylamine initiation
 8-hydroxyguanine formation, rat, 1281
 P-glycoprotein-related protein overexpression, 3708
- Liver neoplasms**
 alb-SV40-T transgenic rat
 chromosomal alterations, 3451
- Liver tumorigenesis**
Igf2 deletion and, 4615
- Liver tumors**
 alb-SV40-T transgenic rat
 chromosomes, 3451
 DNA methylation status
 restriction landmark genomic scanning, mouse, 3294
 regression
 age-dependent, rat, 1807
 UGT1A expression, 2979
- LNCaP cells**
 FAS regulation by androgens, 1086
 prostate-specific antigen biosynthesis and secretion, 3830
 prostate-specific antigen expression
 down-regulation by finasteride, 714
- Loss of heterozygosity**
 breast carcinoma, genome-wide search, 5469
 chromosome 3p, glial tumors, 1035
 chromosome 3p14.2, brain tumors, 2638
 chromosome 10q22-23 Cowden Locus, thyroid tumors, 500
 chromosome 10q25-q26, endometrial cancer, 1630
 chromosome 14q, renal oncocyctomas, 5009
 chromosome 16q, prostate adenocarcinoma, 1058
 chromosome 16q24.1-q24.2, prostate cancer, 3356
 chromosome 18q, squamous cell carcinoma, 824
FHIT gene locus, brain tumors, 2638
 mammary tumors, transgenic mice, 3520
MEN1 gene localization, 1855
 and mitotic recombination, 1188
- Loss of imprinting**
 5-aza-2'-deoxycytidine, tumor cells, 48
IGF2 gene, renal cell carcinoma, 2575
- Lost on transformation *Lot1* gene**
 identification, rat, 2029
- Lovastatin**
 cyclin-dependent kinase inhibitor induction, breast cells, 604
- Low density lipoprotein receptor-related protein/α2-macroglobulin receptor**
 expression, malignant astrocytomas, 2799
- Lumpectomy**
 local breast cancer recurrence after
 mediation by IGF-IR, 3079
- Lung**
 epithelial cells
 novel HPL1, establishment, 4898
 fibroblast motility-stimulating factor, purification and characterization, 3577
- fibroblasts
 cell cycle responses, 3174
- fibrosis
 radiation-induced, genetic model, 5286
- irradiated
 cell adhesion molecules expression, 2096
- metastases
 loss of heterozygosity, transgenic mice, 3520
 suppression by anti-platelet mAb, 3040
 NNK-induced DNA adducts, rat, 259
 RAGE expression, 3669
- Lung adenocarcinoma**
 chromosomal imbalances, 2331
- Lung carcinoma**
 apoptosis
 induction by cholera toxin, 2615
 Fas ligand expression, 1007
FHIT/FRA3B allele loss, 2256
FHIT gene alterations, smokers and non-smokers, 2121
Hel-N1 mutation analysis, 5356
- metastatic
 M-CSF gene transduction into, SCID mice, 784
 modifier loci, genetic mapping, 4164
 non-small cell
 comparative genomic hybridization analysis, 2116
 comparative genomic hybridization patterns, 2331
 DNA hypermethylation, and smoking history, 4913
 glutathione metabolism, 152
 growth inhibition by retinoids, 4931
 prognosis, hepatocyte growth factor and, 433
 prognosis, p27 role, 3381
 RAGE expression, 3669
- risk
 myeloperoxidase genetic polymorphism and, 5001
- small cell
 apoptosis induction by quinoxalines, 2203
 cadherin-mediated adhesion, regulation by Rho, 1785
 chromosome 9 tumor suppressor loci, identification, 400
 etoposide chemotherapy, mutagenic effects, 4393
 growth inhibition by [D-Arg¹, D-Trp^{5,7,9}, Leu¹¹] substance P, 51
 protein synthesis inhibition by DAB₃₈₉ GRP fusion toxin, 290
 topoisomerase IIα nuclear localization signal, 4451
- smoking-associated
 DNA hypermethylation, 4913
- squamous cell
BCHE and *SLC2A2* gene amplification, 2290
 chromosomal imbalances, 2331
 chromosome 9p21 deletion, novel homozygous, 1
 telomerase expression, respiratory epithelium, 2373
- Lung tumorigenesis**
 transforming growth factor β and, transgenic mice, 5564
- Lung tumors**
 chromosome 3p deletions, 1344
 CYP2D splice variants, 2589
Fhit expression, 5207
 NNK-induced
 inhibition by black tea, A/J mice, 1889
 promotion

butylated hydroxytoluene, BALB mice, 2832

Luteinizing hormone/human chorionic gonadotropin
receptors, breast cancer, 857

LY231514
multitargeted antifolate, 1116

Lymph nodes
-negative breast cancer
mitosis, 5505

Lymphoblastoid cells
nuclear protein patterns, 55

Lymphocyte function-associated antigen 1
-dependent T-cell migration to tumor sites
IL-12-induced, 2216

Lymphocytes; see also B lymphocytes; Cytotoxic T lymphocytes; T lymphocytes
DNA excision repair profiles, 651
human T-cell leukemia virus type I-infected
RA-induced apoptosis, oxidative stress, 4916
peripheral blood
antitumor response, monitoring, 2937
DNA excision repair profiles, 651
interleukin 6 gene therapy, SCID-PBL/hu mice, 1335
MART-1 peptide-stimulated, T-cell receptor repertoire, 5320
tumor-infiltrating
MART-1 peptide-stimulated, T-cell receptor repertoire, 5320
 ζ -chain expression, renal cell carcinoma, 3517

Lymphoid tissue
gut-associated
development by short-chain fructo-oligosaccharides, *Min* mice, 225
mucosa-associated
-type lymphomas, cytogenetic analysis, 3944

Lymphoma
B-cell
combination immunotoxin therapy, SCID mice, 4824
EBV-induced, prevention in SCID mice, 1704
immunotherapy, SCID Mice, 678
trioma-based vaccination, 2346
Burkitt's
radiation resistance, ceramide signaling and, 3600
tumorigenicity, p53 role, 2508
drug resistance
increase by CD40 and Bcl-2, 1939
inhibition by olipraz, 2806
mantle cell
retinoblastoma protein pathway, 4608
non-Hodgkin's
H4 histone/*BCL6* fusion by t(3;6), 7
non-Hodgkin's MALT-type
cytogenetic analysis, 3944
p53 and *ras* mutations, mouse, 2710
photodynamic therapy
ceramide generation, L5178Y mouse cells, 1717
ResX
nitrotyrosine formation and, SJL mice, 1823
risk
TCRG-TCRB trans-rearrangements and, SCID mice, 4408
tyrphostin AG17 apoptosis and cdk2 inhibition, 2434, 5610

Lysosomes
radiolabeled polypeptide delivery, 659

M

$\alpha 2$ -Macroglobulin receptor
expression, malignant astrocytomas, 2799

Macrophage activating factor
antitumor activity, Ehrlich ascites tumor, 2187

Macrophage colony-stimulating factor
gene transduction into metastatic lung cancer, SCID mice, 784

Macrophages
epithelone B endotoxin activity, 3344

MAD-related gene 2 *MADR2/JV18-1*
neuroblastoma, 3772

Mafosfamide
and DNA cross-linking agent sensitivity, 454

MAGE-3
MAGE-3/HLA-A24 peptide
CTL induction, 4465
-specific cytotoxic T lymphocytes, melanoma, 735

Magnetic drug targeting
clinical experiences, 3063
preclinical experiences, 3063

Magnetic resonance imaging
cervical carcinoma assessment, 4777

Magnetic resonance spectroscopy
¹H
prostate tissue, 3398
pancreatic cancer studies, 1452

Major histocompatibility complex
class I
melanoma epitope fusion proteins, T-cell induction, 202
class II
induction by MNNG, rat stomach mucosa, 1416

Malignancy
apoptosis
induction by tunicamycin, 543
astrocytoma
low density lipoprotein receptor-related protein expression, 2799
BIN1 localization, 3258
cell transformation
translation initiation factor eIF4G, 5042
cutaneous melanoma
 α , β 3 integrin and ICAM-1 expression, 1554
endometrial
telomerase activity, 2760
epidermal and oral hyperplasias
CaN19 expression, 3055
glioma
childhood, p53 mutations and overexpression, 304
oncolysis by γ 134.5' HSV mutants, 1502
hematological
dsRNA-activated protein kinase, 943
p15^{INK4B} and p16^{INK4A} patterns of inactivation, 837
melanoma
MMAC1/*PTEN* disruption, 3660
mesothelioma
chromosome 6q deletion mapping, 4057
herpes simplex virus treatment, 466
tumor growth inhibition by antisense TGF- β 2, 3200
phenotypes
cell-surface N-glycans expression and, 1073
prostate
transformation by N-nitroso-N-methylurea, 576
prostate tissue
¹H MRS classification, 3398
solid tumors

chromosomal imbalance maps, 2765
thyroid tumor
TBR11 receptor expression, 2071
transformation
CD44v6 and, 2281

MALME-3M cells
cell cycle arrest and apoptosis
induction by spermine analogs, 5521

Mammalian cells
DNA polymerase β cytotoxicity, 110
DNA synthesis
mimosine effects, 2252
pro-PSA expression, 3111
radiosensitization by topoisomerase I drugs, 1529

Mammary carcinoma; see also Breast carcinoma
benzo[a]chrysene-DNA adduct formation, MCF-7 cells, 415
chemotherapy response
social housing condition and, Shionogi mouse, 1124
inhibition by sulindac sulfone, 267
p150, novel overexpressed protein, 988
risk
conjugated linoleic acid and, 5067

Mammary-derived growth inhibitor-related gene *MRG*
antitumor activity, 3084

Mammary epithelial cells
AP-1 activity, 3046
BRCA1 gene
COOH-terminal mutant, 3351
immortalization
mutant p53-induced, transactivation, 5584

Mammary gland
conjugated linoleic acid effects, 5067
mevalonate synthesis
regulation by dietary n-3 and n-6 PUFAs, rat, 3685
myoepithelium
loss and filament disassembly after λ -carageenan exposure, 2823
telomerase activity, rat, 5605

Mammary tumorigenesis
transforming growth factor β and, transgenic mice, 5564

Mammary tumors
development
fat and, rodents, 3979
growth inhibition
zidovudine, rat, 2341
loss of heterozygosity, transgenic mice, 3520
metastases to lung
loss of heterozygosity, transgenic mice, 3520
MMTV-myc and MMTV-ras mice
cell cycle regulation, 600

Manganese superoxide dismutase
adenovirus-mediated gene transfer, hamster cheek pouch carcinoma cells, 5550
Jun-associated transcription factor modulation, fibrosarcoma, 5265
TNF- α and/or hyperthermia resistance and, 1991

MART-1/Melan-A
expression, melanoma, 3223
genetic immunization, dendritic cells, 2865
low frequency CTLp activation by CD34⁺-derived dendritic cells, 5534
peptide-stimulated PBLs and TILs
T-cell receptor repertoire, 5320

Matrix
collagen
local reorganization by MV3 cells, 2061

Matrix metalloproteinase
membrane type I

- expression and tissue localization, invasive breast carcinoma, 2055
mediation by tyrosine phosphorylation, breast carcinoma cells, 5028
membrane type 2
expression and tissue localization, invasive breast carcinoma, 2055
mediation by tyrosine phosphorylation, breast carcinoma cells, 5028
membrane type 3
expression and tissue localization, invasive breast carcinoma, 2055
- Matrix metalloproteinase-9**
cell surface association
TPA-induced, 3159
- Matrix metalloproteinase-13**
expression
regulation, breast cancer, 4882
- MCa-4 carcinoma**
radioresponse
potentiation by 9-AC, 1929
- MCAM/MUC18**
melanoma progression, 2295
- M1 cells**
etoposide cytotoxicity
wild-type p53 effects, 818
- MCF-7 cells**
antiestrogen-resistant
estrogen receptor mRNA splice variants, 585
benzo[a]chrysene-DNA adduct formation, 415
growth inhibition
bFGF, 1750
hypoxia induction by tamoxifen, xenografts, 5155
perspective, 3071
- MCF-7ras cells**
proliferation
inhibition by sodium phenylacetate and tamoxifen combination, 1023
- MCF-10A cells**
MMP-9 surface association
TPA-induced, 3159
- MCH7/LCC9**
antiestrogen resistance, 3486
- MDA-MB-231 cells**
MMP-1 expression and MMP-2 activation
mediation by tyrosine phosphorylation, 5028
- MDA-MB-435 cells**
metastasis
suppression by *KiSS-1*, 2384
- MD/CA9 protein**
biomarker, renal cell carcinoma, 2827
- mdm2**
expression
translational enhancement, 3562
and p53 interaction, 5013
- Medullary thyroid carcinoma**
combined radioimmuno-chemotherapy, nude mouse model, 5309
familial
Ret with cysteine mutations, characterization, 2870
- Medulloblastoma**
childhood
comparative genomic hybridization analysis, 4042
prognosis, HER2 and HER4 coexpression and, 3272
desmoplastic
PTCH mutations, 2085
sporadic
PTCH mutations, 842
- Meeting Reports**
National Cancer Institute
renal cell carcinoma, recent progress and future directions, 5189
Pezcoller Symposium, Eighth
genomic instability and immortality, 4437
Roswell Park Cancer Institute Symposium
molecular approaches to cancer therapeutics, 5185
Sapporo Cancer Seminar, Sixteenth
inflammation-promoted pathogenesis, 3620
- Meiosis**
postmeiotic segregation homologue
human *hPMS2* gene, cell cycle regulation, 206
- Melanocortin 1 receptor-derived peptides**
cytotoxic T lymphocytes against, generation, 4348
- Melanocytes**
vitamin C uptake, 2529
- Melanocytic lesions**
gp100, MART-1, and tyrosinase expression, 3223
- Melanoma**
antigen MART-1/Melan-A
expression, melanoma, 3223
genetic immunization, dendritic cells, 2865
low frequency CTLp activation by CD34⁺-derived dendritic cells, 5534
bFGF-SAP killing
enhancement by adenovirus, 1873
B7.1-modified
CTL generation, 1561
CDKN2A/p16 methylation frequency, 5336
CDKN2A/p16 status, 4868
cell cycle arrest and apoptosis
induction by spermine analogs, MALME-3M cells, 5521
chemoresistance
activated *N-ras*, SCID Mice, 362
cisplatin and tamoxifen synergy, 2657
cutaneous
induction by UV-A, *Monodelphis domestica*, 3682
malignant, $\alpha_5\beta_3$ integrin and ICAM-1 expression, 1554
dehydroascorbic acid transport, 2529
epitope-MHC class I fusion proteins
T-cell induction, 202
extravasation
VLA-6 and, liver, 3812
familial
UV hypermutability, 4637
 α 1,2-fucosyltransferase cDNA transfection
metastatic properties, 332
gp100, MART-1, and tyrosinase expression, 3223
growth regulator clone 10d/BM28, 5122
I- κ B α degradation, Hs294T cells, 3032
invasion
 α IIb β 3 integrin, 2522
MAGE-3-specific cytotoxic T lymphocytes, 735
malignant
cutaneous, $\alpha_5\beta_3$ integrin and ICAM-1 expression, 1554
MMAC1/PTEN disruption, 3660
metastatic
serum 5-S-cysteinyl-dopa levels, 5073
mRNA markers
melanoma-associated antigens, 1371
MV3 cells
collagen lattice reorganization, 2061
progression
MCAM/MUC18 and, 2295
Mel-CAM/ligand adhesion, 3834
vitamin C uptake, 2529
- Melanoma-associated antigens**
mRNA markers, melanoma, 1371
potential HLA-DR-restricted, isolation, 3238
- Melanoma-inhibiting activity**
ELISA, 3149
- Melanotroph**
carcinogenesis
genomic imprinting, 4274
- Melatonin**
oncogenesis
glutathione requirement, breast cancer, 1909
- Mel-cell adhesion molecule**
melanoma progression, 3834
- Meningioma**
activated PDGF receptors, 4141
anaplasia
IGF-II/IGFBP-2 mRNA ratio marker, 2611
- Merbarone**
resistance
topoisomerase II α down-regulation, 5004
- Mesothelial cells**
asbestos-induced proto-oncogenes
PKC and, 3101
- Mesothelioma**
malignant
chromosome 6q deletion mapping, 4057
herpes simplex virus treatment, 466
tumor growth inhibition by antisense TGF- β 2, 3200
- Messenger RNA: see also RNA**
detection by reverse transcription-PCR, thyroid carcinomas, 3792
markers
melanoma-associated antigens, melanoma, 1371
- Met**
expression, gliomas, 5391
- Metall**
-dependent hydrogen peroxide-induced DNA damage, 2394
- Metallothionein**
nucleocytoplasmic functionality, 4236
- Metastasis**
adhesion
GD1 α functions, murine tumors, 1882
breast carcinoma
asynchronous, genetic heterogeneity, 1597
enhancement by *c-erbB-2* overexpression, 1199
prevention by tamoxifen and B-428, 3585
suppression by *KiSS-1*, 2384
colon carcinoma
MRP1/CD9 differential display cloning, 2593
colon carcinoma to liver
radioimmunotherapy and fractionated radiotherapy, nude mice, 447
colorectal adenocarcinoma to liver
5-[¹⁸F]fluorouracil uptake, pharmacokinetic analysis, 3415
colorectal carcinoma
mode, 1043
head and neck squamous cell carcinoma
comparative genomic hybridization pattern, 5213
hepatic
microvascular regulation, 4105
inhibition by recombinant Angiostatin protein, 1329
lung
loss of heterozygosity, transgenic mice, 3520
suppression by anti-platelet mAb, 3040
lung carcinoma
M-CSF gene transduction into, SCID mice, 784

- melanoma
 MCAM/MUC18 and, 2295
 serum 5-S-cysteinyl-dopa levels, 5073
- micrometastasis
 visualization by green fluorescent protein expression, 2042
- minimal residual cancer
 phenotypes, 1394
- neuroblastoma
 enhancement by MEN2B RET, 5399
- pancreatic tumors
 P-selectin expression, 1206
- prostate carcinoma
 chromosome 16q24.1-q24.2 loss of heterozygosity, 3356
 c-myc amplification, 524
 SCID mice model, 1584
 suppression by CD44, 846
 transgenic mouse model, 900
- regulation
 hepatic microvasculature, 4105
- renal cell carcinoma
 DNA gains and losses, 481
 tumor cell trafficking, differential, 3612
- Methotrexate**
 transport, rats, 3506
- 2-Methoxyestradiol**
 angiogenesis and breast cancer inhibition, mice, 81
- Methylation**
 diethylstilbestrol exposure and, mouse uterus, 4356
 -sensitive arbitrarily primed PCR, 594
 -sensitive restriction fingerprinting, breast carcinoma, 1030
- Methylators**
 resistance
 glioma, mismatch repair, 2933
- 5-Methylcytosine**
 bases
 sunlight-induced pyrimidine dimers, 4727
- [*N*-Methyl-¹¹C]N-[2-(Dimethylamino)ethyl]-*l*-acridine-4-carboxamide
 metabolism, rats and humans, 2172
- Methylenetetrahydrofolate reductase**
 polymorphism
 and colorectal cancer risk, 1098
- O⁶-Methylguanine**
 nitrosated glycine derivatives source, 366
- O⁶-Methylguanine-DNA methyltransferase**
 G156A, gene transfer
 BG-BCNU therapy protection, 5093
- MGMT** gene
 silencing, promoter region methylation hot spots, 3672
 tumorigenesis, knockout mice, 2415
 protective effects, chloroethylnitrosourea-induced cancer, 3331
 resistance, pancreatic tumors, 5360
- Methyl-p-hydroxyphenyllactate-esterase**
 activity, breast cancer, 5406
- N-Methyl-N'-nitro-N-nitrosoguanidine**
 MHC induction, rat stomach mucosa, 1416
- 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone**
 DNA adducts, rat lung cells, 259
 lung tumorigenesis
 inhibition by black tea, A/J mice, 1889
- Methylnitrosourea**
 tumorigenesis, *MGMT* gene knockout mice, 2415
- Mevalonate**
 metabolism
 Ras and, 3498
 synthesis
 regulation by dietary n-3 and n-6 PUFAs, rat mammary glands, 3685
- Mexico**
 breast cancer risk
 DDT serum levels and, 3728
- MF13**
 apoptosis, 4795
- Microenvironment**
 PD-ECGF/TP regulation, breast tumor cells, 570
- Microfilaments**
 depletion by sphinxolides, 3751
- Micrometastasis**
 visualization by green fluorescent protein expression, 2042
- Microsatellites**
 instability
 analysis, diagnostic, 4749
 analysis, multicenter study, 4739
 DNA methylation and, colorectal cancer, 3370
 gastric cancer, 4523
IGF1R gene mutations, somatic, 1851
- Microscopy**
 atomic force
 Ku DNA binding, 1412
 glioma lipid droplets study, 407
- Microtubules**
 -active drugs
 Raf-1/bcl-2 phosphorylation, 130
 inhibitors 2-methoxyestradiol and Taxol
 angiogenesis and breast cancer inhibition, mice, 81
 -targeting drugs
 bcl-2 phosphorylation, 229
- Midkine**
 tumorigenesis role, 1814
- Mimosine**
 DNA synthesis effects, mammalian cells, 2252
- Minimal residual tumor disease**
 metastatic phenotypes, 1394
- Min mice**
 germ-free and *beige* mutant, 812
- Mitochondria**
 cholesterol transport
 gene isolation, c-*ERBB-2* amplicon, 3548
 cytochrome *c* loss,
 inhibition, Bcl-x_L overexpression and, 3115
 dysfunction
 chemotherapeutic apoptosis, 62
 permeability
 ara-C toxicity, 2446
- Mitogen-activated protein kinase**
 activation by thapsigargin, 3168
- MKK4**
 mutations, cancer cells, 4177
 modulation by TGF- β , breast cancer cells, 628
- Mitogenesis**
 nuclear phospholipase C β_1 and, 2137
 signaling by ET-1, ovarian carcinoma cells, 1306
- Mitomycin C**
 electromotive delivery, bladder wall, 875
- Mitosis**
 node-negative breast cancer, 5505
- Mitosis**
 disturbance by arsenite, fibroblasts, 5051
 inhibition by E7010, mechanism of action, 3208
 recombination
 loss of heterozygosity and, 1188
- Mitotic-control gene**
 homologues *hmc* and *HMC*, isolation, 921
- Mitotoxin**
 bFGF-SAP killing
 enhancement by adenovirus, melanoma, 1873
- MMAC1/PTEN** gene
 deletions
 thyroid tumors, 4710
 disruption, malignant melanoma, 3660
 inactivation, prostate cancer, 4997
 mutations
 breast carcinomas, 3657
 and EGFR amplification, glioblastoma, 5254
 endometrial carcinomas, 3935, 4736
 gliomas, 4187
 somatic, glioblastoma multiforme, 4183
 thyroid tumors, 4710
 tumors, 5221
 susceptibility locus, juvenile polyposis syndrome, 5017
- MN**
 expression, renal cell carcinoma, 2362
- MNNG: see N-Methyl-N'-nitro-N-nitrosoguanidine**
- Molecular approaches**
 cancer therapeutics
 Roswell Park Cancer Institute Symposium meeting report, 5185
- MOLT-4 cells**
 DNA replication and cyclins A and B1 expression, 803
- Monoclonal antibodies**
 A33, ¹³¹I-labeled
 combined with fluorouracil, antitumor activity, 2181
 anti-Le^y BR64
 disulfide and thioether doxorubicin conjugates, 100
 anti-platelet
 lung metastasis suppression, 3040
 anti-VEGF
 humanization, solid tumor therapy, 4593
 BR96-doxorubicin conjugate, antitumor activity, 4530
 prostate-specific membrane antigen extracellular domain, 3629
 radioiodination, 1510
- Monocyte chemoattractant protein 1**
 T-cell inhibition, 4849
- Monodelphis domestica**
 UV-A-induced cutaneous melanoma precursors, 3682
- Mononuclear cells**
 peripheral blood
 ALL-1/MLL/HRX antigen localization, nuclear, 2035
- Mothers against dpp**
 MAD-related gene 2 *MADR2/JV18-I*, neuroblastoma, 3772
- Motility-related protein**
 differential display cloning, colon carcinoma, 2593
- Mouse mammary tumor virus**
 MMTV-MTAg and MMTV-*neu* mice
 loss of heterozygosity, mammary tumors, 3520
 MMTV-myc and MMTV-ras mice
 tumor properties, 600
- MTAg cells**
 MMTV-MTAg mice
 loss of heterozygosity, mammary tumors, 3520
 sugar chains, 1073
- MT1 cells**
 sugar chains, 1073
- MTPy cells**
 sugar chains, 1073
- Mucin**
 MCAM/MUC18
 melanoma progression, 2295
 MUC-1

- radioimmunotherapy effects, breast carcinoma, 1103
- Mucin-like glycoprotein**
mucosal squamous epithelia, 634
- Mucosa**
pyloric
MHC induction by MNNG, rat stomach, 1416
- Mucosa-associated lymphoid tissue**
-type lymphomas, cytogenetic analysis, 3944
- Mucosal squamous epithelia**
mucin-like glycoprotein, 634
- Multidrug resistance: see also Drug resistance**
circumvention by sphinxolides, 3751
combination liposomal doxorubicin and PSC 833 therapy, solid tumors, 5246
P-95, identification, breast cancer cells, 5460
- Multidrug resistance protein**
expression
retinoblastoma that failed chemotherapy, 2327
glutathione and toxin cotransport, 5232
MRP1 gene
homologue expression, cancer cells, 3537
MRP gene, murine
disruption, 5238
MRP/GS-X pump
transient induction by ACNU, glioma cells, 5292
- Multiple endocrine neoplasia**
type 1
-associated tumors, chromosome 11q13
allelic deletions, 2238
MEN1 gene localization, 1039
MEN1 gene localization, loss of heterozygosity analysis, 1855
MEN1 gene mutations, pituitary tumors, 5446
MEN1 gene mutations, sporadic gastrinomas and insulinomas, 4682
type 2A
Ret with cysteine mutations, characterization, 2870
type 2B
RET, Jnk1 activation and metastasis enhancement, 5399
- Multiple intestinal neoplasia**
cyclin D1 and Cdk4 overexpression, 169
- Multiple myeloma**
B-cell adhesion to bone marrow fibroblasts, 930
- Multispecific organic anion transporter**
canalicular
and drug sensitivity, hepatic cancer cells, 5475
expression, cancer cells, 3537
methotrexate transport, rats, 3506
- Mutations: see also specific genes**
apoptotic, gastrointestinal cancer, 4420
etoposide chemotherapy, small cell lung cancer, 4393
mechanisms, Min mice, 1999
mutator, gastrointestinal cancer, 4420
- MutL homologue**
human hMLH1 gene
cell cycle regulation, 206
germline mutations, hereditary nonpolyposis colorectal cancers, 3798
methylation, colorectal tumors, 808
transcription-coupled repair, 3784
- MutM homologue**
mammalian, cloning and characterization, 2151
- MutS homologue**
human hMSH2 gene
cell cycle regulation, 206
- germline mutations, hereditary nonpolyposis colorectal cancers, 3798
nonsense inhibition, 3288
transcription-coupled repair, 3784
human hMSH6/GTBP gene
germ-line mutation, atypical hereditary nonpolyposis colorectal cancer, 3920
MSH2 gene
deficiency, mutator phenotype, mouse fibroblasts, 3765
mutations, chromosome 2 and, 3949
MSH5 gene
mutation, alkylation tolerance, 2715
MSH6 gene
mutations, chromosome 2 and, 3949
- MV3 cells**
collagen lattice reorganization, 2061
- MXII gene**
growth suppression, glioblastoma cells, 4905
- MXR7 gene**
cloning and expression, hepatocellular carcinoma, 5179
- Myelodysplastic syndrome**
human T-cell leukemia virus and, 4718
- Myeloid cells**
apoptosis
inhibition by pim-1, murine, 5348
- Myeloma**
ANBL6 cells
growth properties, N- and K-ras mutation effects, 2268
multiple
B-cell adhesion to bone marrow fibroblasts, 930
- Myeloperoxidase**
genetic polymorphism
and lung cancer risk, 5001
- Myeloproliferative disorders**
ETV6 and MDS1/EVII fusion, 564
- Myoepithelial cells**
mammary
loss and filament disassembly after α -caragenean exposure, 2823
- Myogenesis**
apoptosis
inhibition by retinoblastoma, 351
- N
- NADH dehydrogenase**
deficiency, apoptosis resistance, 5243
- NADPH P450 reductase**
gene therapy enhancement, 4830
- NAD(P)H:quinone oxidoreductase**
NQO1 gene
⁶⁰⁹C→T mutation, benzene poisoning and, 2839
hARE-mediated expression, stimulation by caffeic acid phenethyl ester, 440
- 1,2-Naphthoquinones**
topoisomerase II-mediated DNA cleavage, 620
- National Cancer Institute (NCI)**
Anticancer Drug Screen
cell lines, p53 characterization, 4285
renal cell carcinoma
recent progress and future directions, meeting report, 5189
- Natural killer cells**
activation by IL-18, Meth A sarcoma, 4557
beige locus
mutations, germ-free Min mice, 812
- NCI: see National Cancer Institute**
- Neocarzinostatin**
delayed chromosomal instability induction, 4048
- Neonates**
diethylstilbestrol exposure
endometrial hyperplasia/apoptosis after, hamster uteri, 1903
- Neoplasia: see also Lesions; Tumors; specific sites**
cervical intraepithelial, grade III
human papillomavirus-specific CTLs, 4855
hematopoietic
HIC1 methylation, 1678
liver
chromosomal alterations, alb-SV40-T transgenic rat, 3451
nontrophoblastic
hCG β gene expression, 516
pp60^{c-src} mutational activation, preneoplastic Syrian hamster embryo cells, 1962
progression
apoptosis, calcium influx, 537
transformation response
NF- κ B and AP-1, 3569
- Neovascularization: see also Angiogenesis**
VEGF-induced
fenestration, 765
- neu: see HER2/neu**
- neu differentiation factor**
-induced apoptosis, breast tumor, 3804
- Neuroblastoma**
CD44 hyaluronan receptor, 1387
chromosome 9 deletions and p16 alterations, 907
CPP32, 4578
DCC, DPC4, and MADR2/JV18-1 genes, 3772
drug-induced apoptosis
mediation by CD95, 3823
interleukin 1 β converting enzyme family proteases, 4578
Jnk
activation by MEN2B RET, 5399
metastasis
enhancement by MEN2B RET, 5399
PD-1 α /autotaxin gene, 2516
- NEUROD gene**
expression, neuroectodermal tumors, 3526
- Neuroectodermal tumors: see also Primitive neuroectodermal tumors**
apoptosis
betulinic acid-induced, 4956
NEUROD and HASH1, 3526
- Neuroepithelioma**
peripheral
p21 induction, p53-dependent without p53 induction, 2986
- Neurofibromatosis**
CD44 expression, 4889
- Neurofilament heavy chain-like messenger RNA and protein**
prostate, 3532
- Neurokines**
midkine and pleiotrophin
tumorigenesis role, 1814
- Neutral sphingomyelinase**
activation
inhibition by phorbol esters and phosphatidylserine, 5300
- Neutron capture therapy**
boron, brain tumors, 1129
intratumoral boronated EGF, 4333
- Nickel**
ATF-1 induction, and thrombospondin 1 gene expression, 5060
- Nicotinamide**
tumor blood flow enhancement, 5261
- NIH3T3 cells**
growth inhibition by retinoic acid, 4460
ODC-overexpressing
angiogenic tumor induction, 3016

sugar chains, 1073
transformants
sugar chains, 1073

Nitric oxide
p53 conformation and function modulation, 3365
production
ResX tumor, nitrotyrosine formation and, 1823

Nitric oxide synthase
expression, rat colon tumors, 1233
inducible
expression, induction by bryostatin and IFN- γ , 2468
inhibitor 1400W, tumor growth inhibition, 3300
inhibition
tumor blood flow modification, 948

4-Nitroquinoline 1-oxide
oral carcinogenesis
inhibition by diosmin and hesperidin, 246

Nitrosated glycine
derivatives, *O*⁶-methylguanine source, 366

N-Nitrosodiethylamine
carcinogenesis initiation
8-hydroxyguanine formation, rat liver, 1281

N-Nitroso-N-methylurea
malignant transformation, prostate epithelial cells, 576

Nitrotyrosine
formation
and ResX tumor, SJL mice, 1823

NKX3.1 gene
coding region, prostate cancers, 4455

NNK: see 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone

Non-specific cross-reacting antigen
identification, 5460

Nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines
estrone sulfatase inhibition, breast cancer, 702

Nontrophoblastic cells
hCG β gene expression, 516

Norway
esophageal cancer
human papillomavirus and, 3989

N-ras
activated
melanoma chemoresistance, SCID Mice, 362
mutations
ANBL6 growth property effects, 2268

NSC 649890: see Flavopiridol

Nuclear factor- κ B
I- κ B α
degradation, Hs294T melanoma cells, 3032
neoplastic transformation response, 3569

Nuclear factor-Y
CBP/cycA subunit, 5117

Nuclear magnetic resonance
glioma lipid droplets study, 407
spectroscopy
pretreatment chemotherapeutic response prediction, glioma, 4196

Nuclear matrix proteins
oncogene-transformed fibroblasts, mouse cells, 147

Nuclear proteins
lymphoblastoid cells, 55

Nucleocytoplasm
metallothionein functionality, 4236

Nucleotide excision repair
capacity, BCL2-overexpressing HL60 cells, 1650

cisplatin adducts
fludarabine triphosphate, 1487

Nucleotide pyrophosphatase
PD-1 α /autotaxin gene, neuroblastoma, 2516

O

Obesity
and colorectal cancer, 4787

1-O-Octadecyl-2-O-sn-glycero-3-phosphocholine
liposome-associated, therapeutic effects, 1915

1-O-Octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
selective apoptosis induction, 1320

Okadaic acid
apoptosis
IGF-I receptor protective effects, 3264

Oligodendrocytes
mRNAs, glial tumors, 4098

Oligonucleotides
antisense
ETS1, cell migration inhibition, 2013

Oligopeptides
transport in tumor cells, 4118

Oltipraz
DNA repair stimulation, 1050
lymphoma inhibition, 2806

Oncocytoma
renal
chromosome 14q loss of heterozygosity and deletion mapping, 5009

Oncogenes: see also specific genes
asbestos-induced proto-oncogenes
PKC and, mesothelial cells, 3101
-transformed fibroblasts
nuclear matrix proteins, mouse cells, 147

Oncolysis
 γ ,34.5' HSV mutants, malignant glioma, 1502

Oncostatin M
transcriptional suppression of c-myc, breast cancer cells, 2223

Oral carcinogenesis
inhibition by organoselenium, rat, 3644

Oral carcinoma
human papillomavirus promoters, 1615
inhibition by diosmin and hesperidin, 246
prognosis
serum α -N-acetylgalactosaminidase index, 295
squamous cell
ALRT1550 antitumor activity, nude mice xenografts, 162
cyclooxygenase-2 inhibition by retinoids, 2890
mucin-like epithelial glycoprotein, 634

Oral contraceptives
breast cancer risk
BRCA1/BRCA2 mutations and, 3678

Oral dysplasias
retinoic acid receptor- β expression, 3886

Oral exfoliative cells
clonal genetic changes, 5258

Organoselenium
chemopreventive activity, rat tongue carcinogenesis, 3644
compounds
human P450 inhibition, 4757

Organotypic raft culture
chromosome 11 tumor suppressor gene localization, 1157

Ornithine decarboxylase
familial adenomatous polyposis, 199
overexpression
angiogenic tumor induction, 3016
and epithelial tumor invasiveness, 2104

and skin carcinogenesis, mouse, 2630
radiation-induced
and cancer proneness, 4384
regulation by deguelin, 3429

Osteosarcoma
chromosome 3q tumor suppressor locus, mapping, 106

Ovarian carcinoma
apoptosis induction, 4488
E2F-1, 4722
CA-125 expression
modulation by taxanes, 3818
chromosome 14 deletions, 513
collagenase, Mr92,000 type IV
induction by fibronectin, 5416

epithelial
chromosome 11p15.1 deletion mapping, 387
Lot1 gene identification, rat, 2029
FHIT gene expression, human cells, 2112
genomic instability, 1047
growth inhibition by sodium phenylacetate, 4309
hepsin overexpression, 2884
mitogenic signaling by ET-1, 1306
paclitaxel sensitivity
p53 status and, 870
peritoneal tumor implantation
CD44 role, 1228
platinum-DNA damage tolerance, 850
Taxol resistance, spheroids, 2388

Ovarian teratoma
susceptibility, murine, 591

Ovarian tumors
HLA-A2-associated peptides, 87

Oxazaphosphorine
activation
induction, 1946

Oxidative stress
ara-C toxicity, 2446
retinoic acid-induced apoptosis, 4916

Oxygen tension
PD-ECGF/TP regulation, breast tumor cells, 570

Oxythiamine
ribose and cell proliferation inhibition, 4242

P

P-95
identification, 5460

p10
cloning and characterization, 2966

p15
alternatively spliced p10, cloning and characterization, 2966
deletion, T-cell acute lymphoblastic leukemia, 832
methylation, T-cell acute lymphoblastic leukemia, 832

p15^{INK4B}
inactivation patterns, hematological malignancies, 837

p16
alterations, neuroblastoma, 907
CDKN2A/p16
expression, oral dysplasias, 3886
methylation frequency, melanoma, 5336
status, melanoma cells, 4868
deletion, T-cell acute lymphoblastic leukemia, 832
mutations, pancreatic adenocarcinoma precursors, 2140
Rb/p16 pathway
mantle cell lymphoma, 4608
pancreatic carcinoma, 3126
regulation by androgen, 4511

p16^{INK4A}
inactivation patterns, hematological malignancies, 837

- nancies, 837
methylation, esophageal adenocarcinomas, 2619
- p21**
colonic function
dietary fat and, 253
induction
p53-dependent without p53 induction, 2986
WT1, 1429
- p21^{WAF1/CIP1}**
-derived peptides
cell growth inhibition, 1442
induction
p53-dependent, acidity, glioblastoma cells, 3910
TGF- β , *DPC4* and, pancreatic adenocarcinoma cells, 3929
-mediated drug sensitivity, sarcoma cells, 2193
and radiation sensitization, 4703
signaling by PMA, cancer cells, 320
transcriptional regulation by *cis* elements, 3'-untranslated region, 5129
UV-induced, human skin fibroblasts, 3390
- p27**
prognostic marker, small invasive breast carcinoma, 1259
prognostic role, non-small cell lung cancer, 3381
- p27^{Kip1}**
1,25D₃-induced
Cdk6 target, 2851
overexpression
apoptosis induction, 5441
- p53**
accumulation
cell adhesion and, keratinocytes, 3635
cell-cycle dependence, 5217
DNA damage, scid cells, 68
alterations
bladder tumors, 1217
cyclin D1 overexpression effects, transgenic mouse model, 5542
atm interactions
cell proliferation and G₁-S checkpoint modulation, 1664
and chemosensitivity, 4285
coactivators CREB-binding protein and p300/CBP-associated factor, 3693
deficiency
brain tumors, knockout mice, 466
DNA replication, fibroblasts, 1013
tumor progression modulation by dietary restriction, mice, 4667
ultraviolet light sensitivity, null cells, 5434
-dependent apoptosis
CPP32 β and Fas, 2550
-dependent cell cycle arrest, multiple cycles, 1171
-dependent p21 induction without p53 induction, 2986
doxorubicin-induced cell death, Rat-1 fibroblasts, 176
HBxAg-positive and -negative hepatocellular carcinoma, 426
hepatitis B virus X protein-interacting functions, 5137
-independent spontaneous carcinogenesis induction by calorie restriction, mice, 2843
Mdm-2 interaction, 5013
mutations
childhood malignant gliomas, 304
early and late basal cell carcinoma, 747
frameshift, ovarian cancer, 1047
- germ-line, cell cycle and apoptosis control and, 1895
hepatocellular carcinoma, Taiwan, 3471
immortalization, transactivation, 5584
liver angiosarcomas, rat, 1695
lymphomas, mouse, 2710
squamous cell carcinoma of the head and neck smokers, 4070
UVA-induced skin tumors, mice, 1238
overexpression, childhood malignant gliomas, 304
and paclitaxel sensitivity, ovarian cancer cells, 870
-regulated *P2X_M* gene, cloning, 3281
regulation
cellular adhesion, keratinocytes, 3635
tumorigenicity, Burkitt's lymphoma, 2508
vascular endothelial growth factor transcription repression, 4474
wild-type
conformation modulation by nitric oxide, 3365
function modulation by nitric oxide, 3365
G₂ to M transition, 818
mdm2 expression, translational enhancement, 3562
- p60^{c-src}**
pseudosubstrate peptide inhibitors, 1877
- p150**
novel protein, mammary carcinoma, 988
- p185^{erbB-2}**
metastasis enhancement, breast cancer cells, 1199
- p190**
GTPase and Rho GAP domains
tumor suppression, 2478
- p300/CBP-associated factor**
p53 coactivator, 3693
- PACE4**
expression
and tumor progression, 5226
- Paclitaxel: see also Taxol**
apoptosis
bcl-x_L overexpression and, HL-60 cells, 1109
CA-125 expression modulation, ovarian carcinoma cells, 3818
combined with 8-chloro-cAMP
growth inhibition and apoptosis induction, cancer cells, 5107
sensitivity
p53 status and, ovarian cancer cells, 870
- Pancreas**
cell proliferation by peroxisome proliferators, 9-*cis* retinoic acid, and T₃, 795
radiolabeled polypeptide delivery, 659
- Pancreatic adenocarcinoma**
precursors
K-*ras* and *p16* mutations, 2140
TGF- β receptor-mediated signal transduction
DPC4 gene and, 3929
vasoactive intestinal peptide receptors, 1475
- Pancreatic carcinoma**
c-*myb* amplification, 3135
cyclin D1 overexpression, 1634
DPC4 gene
neuroblastoma, 3772
and TGF- β receptor-mediated signal transduction, pancreatic adenocarcinoma, 3929
magnetic resonance spectroscopy studies, 1452
Rb/p16 pathway, 3126
telomerase activity, 326
tumorigenicity
reversal by *ss12*, 956
tumor-suppressive pathways, 1731
- Pancreatic tumors**
endocrine
chromosome 11q13 allelic deletions, 2238
metastatic
P-selectin expression, 1206
resistance
MGMT, 5360
- Papillary carcinoma**
bladder
genetic alterations, comparative genomic hybridization, 2860
oncofetal fibronectin mRNA, 3792
thyroid
ret/PTC gene rearrangements, children, 1690
- Parathyroid hormone-related peptide**
induction by *ras* oncogene, 4517
- Parathyroid hormone-related protein**
hypercalcemia and bone resorption
TNF effects, 3194
- Parotid gland**
pleomorphic adenoma
HMGIC and *FHIT* hybrid transcript expression, 13
- Particles, α**
extracellular factors and, 2164
reactive oxygen species and, 3963
- Patched (PTCH) gene**
-associated preferential *smoh* expression, basal cell carcinoma, 4731
mRNA expression, basal cell carcinoma, 2336
mutations
basal cell carcinomas and primitive neuroectodermal tumors, 2581
desmoplastic medulloblastomas, 2085
sporadic extracutaneous tumors, 2369
sporadic medulloblastomas, 842
trichoeplitheliomas, 4677
- Penclomedine**
antitumor-active metabolite 4-demethylpenclomedine, 815
- Pentose phosphate**
pathways
and tumor proliferation, 4242
- Perillyl alcohol**
dietary
colon carcinogenesis chemoprevention, 420
- Peripheral blood**
hKLK2, detection by RT-PCR, 4167
lymphocytes
antitumor response, monitoring, 2937
DNA excision repair profiles, 651
interleukin 6 gene therapy, SCID-PBL/hu mice, 1335
MART-1 peptide-stimulated, T-cell receptor repertoire, 5320
mononuclear cells
ALL-1/MLL/HRX antigen localization, nuclear, 2035
stem cells, high-dose chemotherapy support thrombopoietin serum levels, 5037
SV40 early region and large T antigen cells, 3319
- Peripheral neuroepithelioma**
p21 induction
p53-dependent without p53 induction, 2986
- Peritoneal tumors**
implantation
CD44 role, 1228
- Perlecan**
growth suppression, fibrosarcoma, 2130
- Peroxisome proliferators**
cell proliferation, rat pancreas and kidneys, 795

- detection with rat acyl-CoA oxidase promoter, rat liver cells, 1575
- Perspectives in Cancer Research**
MCF-7 breast cancer cells, 3071
- Peutz-Jeghers syndrome**
chromosome 19p locus, fine mapping, 3653
- P-glycoprotein**
inhibition by glucocorticoids, 720
- P-glycoprotein-like genes**
new
P-glycoprotein-related protein, 3708
- P-glycoprotein-related protein**
new P-glycoprotein-like gene, 3708
- pH**
PD-ECGF/TP regulation, breast tumor cells, 570
topoisomerase I inhibitors and, 4811
- Phenethyl isothiocyanate**
and pyridyloxobutyl DNA adducts, NNK-induced rat lung cells, 259
- Phenobarbital**
-induced apoptosis, mouse hepatocytes, 2896
- Phenotypes**
drug-resistant, evolution, 5086
Hirschsprung's disease
Ret with cysteine mutations, characterization, 2870
tumorigenic
pp60^{c-src} mutational activation and, preneoplastic Syrian hamster embryo cells, 1962
- Phenylacetate**
growth inhibitory effects, ovarian carcinoma cells, 4309
- 1,4-Phenylenedis(methylene)selenocyanate**
chemopreventive activity, rat tongue carcinogenesis, 3644
- Phenylethyl-3-methylcaffeate**
apoptosis modulation, colon cancer, 1301
- 6-Phenylhexyl isothiocyanate**
apoptosis modulation, colon cancer, 1301
- Phenochromocytomas**
sporadic
glial cell line-derived neurotrophic factor mutations, 310
- Phorbol ester**
cyclooxygenase-2 induction
inhibition by retinoids, 1081
neutral sphingomyelinase activation inhibition, 5300
- Phorbol 12-myristate 13-acetate**
elafin induction, breast carcinomas, 4631
p21^{WAF1/CIP1}/Rb/c-myc signaling, cancer cells, 320
- Phosphatidylinositol-3' kinase**
targeting by inositol hexaphosphate, 2873
- Phosphatidylserine**
neutral sphingomyelinase activation inhibition, 5300
- Phosphodiesterase I/nucleotide pyrophosphatase**
PD-1a/autotaxin gene, neuroblastoma, 2516
- Phospholipase C β_1**
nuclear
and mitogenesis, 2137
- Phospholipase C $\gamma 1$**
overexpression
tumorigenicity and, 3Y1 fibroblast cells, 5465
- Photodynamic therapy**
5-aminolevulinic acid esters and, 1481
ceramide generation, L5178Y mouse lymphoma cells, 1717
and cytokine expression, 3904
IL-1 and G-CSF role, rat rhabdomyosarcoma, 2555
protoporphyrinogen oxidase inhibitor, 4551
- Photofrin**
photodynamic therapy
IL-1 and G-CSF role, rat rhabdomyosarcoma, 2555
- Photosensitizers**
pyropheophorbide derivatives, quantitative structure-activity relationship, 4000
- Physical activity**
and endometrial cancer risk, 5077
- PICP**
serum levels, aggressive breast cancer, 5517
- Pigment cell tumors**
Amazon molly, 2993
- Pim-1**
apoptosis inhibition, murine myeloid cells, 5348
- PINP**
serum levels, aggressive breast cancer, 5517
- Pituitary adenomas**
chromosome 9p deletions, 2703
- Pituitary tumors**
MEN1 gene mutations, 5446
- Placenta growth factor**
expression, breast cancer, 956
- Plasmacytoma**
spectral karyotyping, mouse, 4585
- Plasmid DNA**
pharmacokinetics, direct injection, 2681
- Platelet-derived endothelial cell growth factor**
expression, breast cancer, 956
regulation
tumor microenvironmental, breast tumor cells, 570
- Platelet-derived growth factor**
receptors
activated, meningioma, 4141
- Platelet surface molecule**
anti-platelet mAb
lung metastasis suppression, 3040
- Platinum**
DNA damage
tolerance, ovarian cancer, 850
- Pleiotrophin**
expression, breast cancer, 963
tumorigenesis role, 1814
- PMA: see Phorbol 12-myristate 13-acetate**
- Poecilia formosa**
pigment cell tumors, 2993
- Polyamines**
dietary
and preneoplastic changes, rat intestine, 573
familial adenomatous polyposis, 199
transport inhibitors
structure-function relationships, L1210 cells, 234
- Polychlorinated biphenyls**
intrachromosomal recombination, 4378
- Polymerase chain reaction**
methylation-sensitive arbitrarily primed, 594
reverse transcription
alkaline phosphatase isoenzyme detection, germ cell tumors, 3841
disseminated tumor cell detection, 3106
mRNA detection, thyroid carcinomas, 3792
peripheral blood *hKLK2* detection, 4167
reverse transcription, multiplex
mismatch repair genes, gliomas, 1673
- Polypeptides**
radiolabeled, physiology, 659
- Polyps**
formation, *Apc*^{Δ716} knockout mice, 1644
- Polyunsaturated fatty acids**
antitumor effects, 2200
n-3 and n-6, dietary
- mevalonate synthesis regulation, rat mammary glands, 3685
- Positron emission tomography**
5-[¹⁸F]fluorouracil uptake, pharmacokinetic analysis, 3415
metastatic tumor cell trafficking, 3612
- Postmeiotic segregation homologue**
human *hPMS2* gene
cell cycle regulation, 206
- pp60^{c-src}**
mutational activation, preneoplastic Syrian hamster embryo cells, 1962
- Prenyltransferase**
inhibitors
apoptosis and cell cycle and, 1846
- Primitive neuroectodermal tumors**
D17S34 locus deletion, 32
PTCH mutations, 2581
- Procabazine**
testicular damage
hormonal protection against, 1091
- L-Prolyl-L-m-([bis(chloroethyl)amino]-phenylalanyl-L-norvaline ethyl ester**
apoptosis, 4795
- Prostaglandins**
-independent tumor regression by sulindac, 4267
- Prostate**
epithelial cells
immortal, generation and characterization, 995
malignant transformation by *N*-nitroso-*N*-methylurea, 576
tumorigenicity, FGFR1 and FGFR2 and, 5369
NF-H-like mRNA and protein, 3532
5 α -reductase activity
modulation by missense substitution, 1020
- tissue
BMP-6, immunolocalization and mRNA expression, 4427
¹H MRS classification, 3398
- Prostate adenocarcinoma**
chromosome 16q loss of heterozygosity, 1058
TRAMP model cells, characterization, 3325
- Prostate carcinoma**
androgen-dependent
cell growth regulation, 4511
differential gene expression, 4075
androgen deprivation therapy
failure mechanism, 314
androgen-independent
differential gene expression, 4075
progression, TRAMP model, 4687
antiangiogenesis
potentiation by androgen ablation, 1054
attenuated replication competent adenovirus CN706, 2559
cell adhesion to bone
inhibition by bisphosphonates, 3890
cell growth
IL-6 effects, 141
chromosome 16q24.1-q24.2 loss of heterozygosity, 3356
circulating peripheral blood cells
detection by RT-PCR for *hKLK2*, 4167
endothelin B receptor gene methylation, 35
Fas-mediated apoptosis, 1758
FAS regulation by androgens, LNCaP cells, 1086
Fas resistance, dominance, 3941
gene expression, differential, 4075
 γ -glutamyl transpeptidase activity and mRNA, 2428
growth inhibition
PML adenovirus, 1868
u-PAR blockade, 3594

growth regulation by bone morphogenetic protein-2, 5022

HPC1 gene
age at diagnosis, families, 4707

metastasis
c-myc amplification, 524
SCID mice model, 1584
suppression by CD44, 846
transgenic mouse model, 900

neovascularization
inhibition by u-PAR blockade, 3594

NF-H-like mRNA and protein, 3532

NKX3.1 gene coding region, 4455

PhIP-induced, rat, 195

prognosis
E-cadherin and α -catenin expression and, 3189

prostate-specific membrane antigen expression, *in situ* hybridization, 2321

PTEN/MMAC1 inactivation, 4997

PTI-1 expression, blood samples, 18

risk
androgen receptor gene polymorphisms and, 1194

size
reduction by urokinase inhibitors, xenografts, 559

TRAMP model cells, characterization, 3325

Prostate-specific antigen
assaying
peptide substrates, 4924
biosynthesis and secretion, LNCaP cells, 3830

expression
down-regulation by finasteride, 714
positive regulatory element, 495

pro form
expression and activation, 3111

Prostate-specific membrane antigen
expression
prostate cancer, *in situ* hybridization, 2321

extracellular domains
monoclonal antibodies, 3629

Prostate tumor inducing gene-1
expression, tumor cells and prostate carcinoma blood samples, 18

Prostate tumors
androgen ablation
quiescence, R3327-G rat, 2493

epithelial cells
primary, growth *in vitro*, 3688

Prostatic intraepithelial neoplasia
c-myc amplification, 524

Protein kinase
DNA-dependent
Mdm-2 protein phosphorylation, and p53 interaction, 5013

dsRNA-activated, leukemic cells, 943

Protein kinase A
activity
regulation by EGF, murine fibrosarcoma cells, 5410

Protein kinase C
and asbestos-induced proto-oncogenes, mesothelial cells, 3101

inhibition
combined with ionizing radiation, apoptotic effects, 4340

substrate SSeCKS
src-induced transformation suppression, 2304

Protein kinase C η
up-regulation, s-EL4 cells, 2209

Proteins: see also specific proteins
avian winged helix
aberrant cell growth, 123

expression

regulation by TNF- α 3'UTR, epithelial carcinoma cells, 5426

fusion
antibody-IL-2, colon carcinoma elimination, 4948

HRX/ALL1-eps15, cellular localization, 799

melanoma epitope-MHC class I, T-cell induction, 202

IFN- γ - and IL-4-regulated, renal carcinoma, 1137

nuclear
lymphoblastoid cells, 55

nuclear matrix
oncogene-transformed fibroblasts, mouse cells, 147

synthesis
inhibition by DAB₃₈₉ GRP fusion toxin, small cell lung cancer cells, 290

ubiquitination
apoptosis, Ewing's sarcoma cells, 3881

Protein tyrosine kinase
p60^{c-src}
pseudosubstrate peptide inhibitors, 1877

Protein tyrosine phosphatase
novel TEPI, cloning and characterization, 2124

Proteomes
bladder squamous cell carcinoma, profiling, 4111

Proto-oncogenes: see also Genes; Oncogenes
asbestos-induced
PKC and, mesothelial cells, 3101

Protoporphyrinogen oxidase
inhibitors
photodynamic therapy, 4551

Proximal renal tubule
cadherin-6, 2741

PSC 833
combined with liposomal doxorubicin, multidrug-resistant solid tumors, 5246

PTCH gene
-associated preferential *smoh* expression, basal cell carcinoma, 4731

mRNA expression, basal cell carcinoma, 2336

mutations
basal cell carcinomas and primitive neuroectodermal tumors, 2581

desmoplastic medulloblastomas, 2085

sporadic extracranial tumors, 2369

sporadic medulloblastomas, 842

trichoeptitheliomas, 4677

PTEN/MMAC1 gene
deletions
thyroid tumors, 4710

disruption, malignant melanoma, 3660

inactivation, prostate cancer, 4997

mutations
breast carcinomas, 3657

and EGFR amplification, glioblastoma, 5254

endometrial carcinomas, 3935, 4736

gliomas, 4187

somatic, glioblastoma multiforme, 4183

thyroid tumors, 4710

tumors, 5221

susceptibility locus, juvenile polyposis syndrome, 5017

Pulmonary adenoma
resistance
PAR genes, SMXA recombinant inbred mouse strains, 2904

P2X receptor
P2XM gene, cloning, 3281

Pyloric mucosa
MHC induction by MNNG, rat stomach, 5667

1416

Pyridyloxobutyl
DNA adducts, NNK-induced rat lung cells, 259

Pyrimidine dimers
sunlight-induced, 4727

Pyropheophorbide derivatives
photosensitizers, quantitative structure-activity relationship, 4000

Q

Quiescence
androgen ablation, R3327-G rat prostate tumors, 2493

Quinoxalines
apoptosis induction, small cell lung cancer, 2203

R

RAD54
human homologue *hRAD54*, characterization, 2378

Radiation
apoptosis
ceramide production and, 1270

carcinoma radioresponse
potentiation by 9-AC, 1929

G₁ arrest
cell-substratum interactions and, 1151

G₁-S checkpoints
atm and p53 interactions and, 1664

G₂ delay
cyclin B1 levels and, HeLa cells, 753

γ
p53-dependent cell cycle arrest, multiple cycles, 1171

ionizing
cell adhesion molecules expression and, lung, 2096

combined with PKC inhibition, apoptotic effects, 4340

cytotoxicity, DNA mismatch repair, 5143

delayed chromosomal instability induction, 4048

S-phase entry, E2F and, 3640

subependyma apoptosis, adult rats, 2694

lung fibrosis, genetic model, 5286

ornithine decarboxylase
and cancer proneness, 4384

replication protein A phosphorylation and S-phase checkpoint, 3386

thyroid papillary carcinomas
ret/PTC gene rearrangements, children, 1690

ultraviolet
G₁ arrest, human skin fibroblasts, 3390

hypermutability, familial melanoma, 4637

telomerase activity, skin, 370

ultraviolet A
apoptosis, inhibition by bcl-2 overexpression, 1405

cutaneous melanoma, *Monodelphis domestica*, 3682

skin tumors, p53 mutations, 1238

ultraviolet B
keratosis induction, 2081

skin carcinogenesis, 2081

skin carcinogenesis, tea, decaffeinated tea, and caffeine and, 2623

transcription effects, RNA fingerprinting, 3554

Radioimmunotherapy
combined with chemotherapy
antitumor activity, 2181

medullary thyroid carcinoma, mouse model, 5309

- combined with radiotherapy
 - timing effects, solid tumors, 1312
 - liver metastases, nude mice, 447
 - target antigen content effects, breast carcinoma, 1103
- Radiiodination**
 - monoclonal antibody, 1510
- Radioresistance**
 - ceramide signaling and, Burkitt's lymphoma, 3600
 - high molecular bFGF, HeLa cells, 1364
 - mediation by IGF-IR, breast cancer, 3079
- Radiosensitization**
 - FMdC, colon carcinoma xenografts, 4023
 - hyperthermic
 - Ku autoantigen heat inactivation, 2847
 - p21^{Waf1/Cip1} and, 4703
 - topoisomerase I drugs, mammalian cells, 1529
- Radiotherapy**
 - combined with enzyme/prodrug gene therapy, 4205
 - combined with molecular chemotherapy, cholangiocarcinoma, 4325
 - combined with radioimmunotherapy
 - timing effects, solid tumors, 1312
 - fractionated
 - liver metastases, nude mice, 447
 - hypersensitive mutant phenotype
 - DNA repair defect, 4600
 - interleukin 3 gene, 3899
 - local breast cancer recurrence after
 - mediation by IGF-IR, 3079
 - tumor response modifiers
 - FISH evaluation, 672
- Raf-1/bcl-2**
 - activation by thapsigargin, 3168
 - phosphorylation by microtubule-active drugs, 130
- RAGE: see Receptor for advanced glycosylated end products**
- Raloxifene**
 - stimulatory effects
 - blockade by EM-800, human endometrial cells, 3494
- ras**
 - anti-Ras tumor suppression by GTPase and Rho GAP p190 domains, 2478
 - and mevalonate metabolism, 3498
 - MMTV-ras mice, tumor properties, 600
 - mutations
 - lymphomas, mouse, 2710
 - parathyroid hormone-related peptide induction, 4517
- ras-p21**
 - colonic function
 - dietary fat and, 253
- Reactive oxygen species**
 - and α particles, 3963
- Receptor for advanced glycosylated end products**
 - expression, non-small cell lung carcinoma, 3669
- Receptors: see also specific receptors**
 - σ_2
 - tumor cell proliferation biomarkers, breast cancer, 156
 - survival factor
 - toxin-induced increase, 2404
- 5 α -Reductase**
 - activity
 - modulation by missense substitution, prostate, 1020
- Renal carcinogenesis**
 - induction by hyperlipidemia, Eker rat, 4673
- Renal cell carcinoma**
 - cadherin-6, 2741
- DNA gains and losses, 481
- endothelial CD40 expression, 891
- HLA-DRB1 genotyping, 742
- IFN- γ - and IL-4-regulated proteins, identification, 1137
- IGF2 loss of imprinting, 2575
- inhibition
 - BCH-4556, xenograft models, 4803
- iron-induced
 - inhibition by vitamin E, 2410
- MD/CA9 protein biomarker, 2827
- MN gene expression, 2362
- progress and future directions, meeting report, 5189
- vaccines
 - GM-CSF-transduced, bioactivity, 1537
- ζ -chain expression, tumor-infiltrating lymphocytes, 3517
- Renal oncocyoma**
 - chromosome 14q loss of heterozygosity and deletion mapping, 5009
- Renal tubules**
 - proximal
 - cadherin-6, 2741
- Replication errors**
 - phenotype
 - status, colon cancer, 300
- Replication protein A**
 - phosphorylation
 - and S-phase checkpoint, 3386
- Resistance: see also Drug resistance; Multi-drug resistance**
 - antiestrogens
 - estrogen receptor DNA binding, breast cancer, 3723
 - estrogen receptor mRNA splice variants, breast cancer cells, 585
 - apoptosis
 - NADH dehydrogenase deficiency, 5243
 - O⁶-benzylguanine, human alkyltransferases, 2007
 - camptothecin, DNA topoisomerase I, 1516
 - chemoresistance
 - melanoma, activated N-ras, 362
 - cisplatin
 - DNA mismatch repair-deficient cells, 1841
 - confluence-dependent
 - HSP27 and, 2661
 - cross-resistance
 - tamoxifen, MCH7/LCC9, 3486
 - Fas, prostatic carcinoma cells, 3941
 - glioma methylator
 - DNA mismatch repair, 2933
 - hyperthermia
 - MnSOD and, 1991
 - ICI 182,780, MCH7/LCC9, 3486
 - merbarone
 - topoisomerase II α down-regulation, 5004
 - methylator
 - mismatch repair, glioma, 2933
 - MGMT, pancreatic tumors, 5360
 - PAR genes, pulmonary adenoma, 2904
 - radioresistance
 - ceramide signaling and, Burkitt's lymphoma, 3600
 - high molecular bFGF, HeLa cells, 1364
 - mediation by IGF-IR, breast cancer, 3079
 - retinoid
 - induction by cJun overexpression, 4652
 - tamoxifen
 - estrogen receptor DNA binding, breast cancer, 3723
 - Taxol, ovarian carcinoma spheroids, 2388
 - topoisomerase, mechanisms, 5100
 - tumor necrosis factor α
 - MnSOD and, 1991
- prostatic carcinoma cells, 3941
- Respiratory epithelium**
 - telomerase expression, 2373
- Restriction endonucleases**
 - delayed chromosomal instability induction, 4048
- Restriction fingerprinting**
 - methylation-sensitive, breast carcinoma, 1030
- Restriction landmark genomic scanning**
 - DNA methylation status, mouse liver tumors, 3294
- ResX tumor**
 - nitrotyrosine formation and, SJL mice, 1823
- Ret**
 - activation by cysteine 620 mutations, 391
 - cysteine mutations, characterization, 2870
 - Jnk1 activation and metastasis enhancement, neuroblastoma cells, 5399
- ret/PTC gene**
 - rearrangements, thyroid papillary carcinomas in children, 1690
- Retinoblastoma binding factor 1**
 - RB gene promoter site
 - activation by hGABP/E4TF1, 3145
- Retinoblastoma protein**
 - alterations, bladder tumors, 1217
 - apoptosis inhibition, myogenesis, 351
 - chemotherapy failure
 - multidrug resistance protein expression, 2327
 - cyclin D1/p16-pRb pathway
 - mantle cell lymphoma, 4608
 - pancreatic carcinoma, 3126
 - deficient fibroblasts
 - DNA rereplication, 1013
 - erythropoiesis effects, 4123
- Rb gene**
 - disruption, melanotroph carcinogenesis, 4274
- Rb gene promoter**
 - activation by hGABP/E4TF1, 3145
 - DNA methylation mapping, 2229
- regulation by c-FMS, 2020
- signaling by PMA, cancer cells, 320
- Retinoic acid**
 - apoptosis
 - oxidative stress, 4916
 - cell growth inhibition, 4460
 - metabolism, 4460
 - liver, aryl hydrocarbon receptor knockout mice, 2835
 - signaling
 - regulation by CRABP II, breast cancer, 1668
- 9-cis Retinoic acid**
 - cell proliferation, rat pancreas and kidneys, 795
- Retinoic acid receptor**
 - and retinoic acid metabolism and cell growth inhibition, 4460
 - selective retinoid ALRT1550
 - antitumor activity, oral squamous carcinoma xenografts, 162
- Retinoic acid receptor α**
 - growth inhibition, breast cancer cells, 2642
- Retinoic acid receptor β**
 - expression
 - breast cancer, 4158
 - cervical carcinoma cells, 1460
 - oral dysplasias, 3886
 - mRNA levels, breast carcinogenesis, 4992
- Retinoids**
 - ALRT1550
 - antitumor activity, oral squamous carcinoma xenografts, 162
 - antiproliferative effects

- resistance by cJun overexpression, 4652
 cyclooxygenase-2 inhibition, 1081
 cyclooxygenase-2 inhibition, oral squamous carcinoma cells, 2890
 growth inhibition, non-small cell lung carcinoma cells, 4931
 liver, aryl hydrocarbon receptor knockout mice, 2835
- Retinol**
 metabolism, breast cancer cells, 4642
- Retinyl methyl ether**
 AP-1 inhibition, breast cancer, 3444
- Rhabdoid tumors**
 development
 GOK gene involvement, 4493
- Rhabdomyosarcoma**
 development
 GOK gene involvement, 4493
 photodynamic therapy
 IL-1 and G-CSF role, rat, 2555
- Rho**
 cadherin-mediated adhesion regulation, small cell lung carcinoma cells, 1785
- Rho GAP**
 p190 domain
 tumor suppression, 2478
- Ribonucleotide reductase**
R2 gene
 expression, and genome instability, 4876
- RIF-1 cells**
 6-aminonicotinamide metabolic and radiobiological effects, quantitation, 3956
- RIP**
 adaptor molecule CRADD, 615
- RMA thymoma**
 CTL response, 2564
- RNA: see also Messenger RNA**
 double-stranded
 -activated protein kinase, leukemic cells, 943
 fingerprinting
 UVB-induced transcription effects, 3554
- Rotenoids**
 deguelin
 chemopreventive activity, 3424
 ornithine decarboxylase regulation, 3429
- S**
- Salmonella**
 tumor-targeted, anticancer vector, 4537
- Saporin**
 anti-CD38-saporin immunotoxins
 lymphoma therapy, SCID mice, 4824
 bFGF-SAP killing
 enhancement by adenovirus, melanoma, 1873
- Sarcosylsin**
 -containing tripeptide
 apoptosis, 4795
- Sarcoma**
 drug sensitivity
 p21^{waf1}-mediated, 2193
 Ewing's sarcoma
 apoptosis, protein ubiquitination, 3881
 Kaposi's sarcoma
 targeted gene delivery via fibroblast growth factor receptor, 1447
 Meth A
 killer cell activation by IL-18, mice, 4557
 soft tissue
 lung FMSF, purification and characterization, 3577
- Scatter factor**
 expression, gliomas, 5391
- Schizosaccharomyces pombe**
dis3⁺ gene
 homologues and overexpression, cancer cells, 921
- Schwann cell tumors**
NF2 mutations
 CD44 expression, 4889
- P-Selectin**
 expression, metastatic pancreatic tumor cells, 1206
- Selenium**
 deficiency
 AFB₁-aldehyde reductase and GSTA5 overexpression, 4257
 thioredoxin reductase regulation, cancer cells, 4965
- Senescence genes**
 chromosome 6q21 region, characterization, 4153
- Sensitivity**
 chemosensitivity
 p53 and, 4285
 DNA cross-linking agents
 mafosfamide and, 454
 drug
 cMOAT and, hepatic cancer cells, 5475
 p21^{waf1}-mediated, sarcoma cells, 2193
 R2 gene expression and, 4876
 etoposide
 DNA topoisomerase II α levels and, topotecan and, 1425
 hypersensitivity
 DNA cross-linking agents, and GRP78 up-regulation, 5112
 paclitaxel
 p53 status and, ovarian cancer cells, 870
 ultraviolet light
 p53-null cells, caffeine and, 5434
- Severe combined immunodeficiency**
 B-cell mouse model
 immunotherapy, 678
 DNA damage
 p53 accumulation and cell cycle arrest, 68
 human antitumor response
 monitoring, mice, 2937
 interleukin 6 gene therapy, SCID-PBL/hu mice, 1335
 lymphoma
 combination immunotoxin therapy, mice, 4824
 lymphoma, EBV-induced B-cell prevention, mice, 1704
 melanoma chemoresistance
 activated N-ras, mice, 362
 metastatic lung carcinoma
 M-CSF gene transduction into, mice, 784
 metastatic prostate carcinoma model, mice, 1584
 prostate cancer
 size reduction by urokinase inhibitors, xenografts, 559
TCRF-TCRB trans-rearrangements, mice, 4408
- Sex hormone-binding globulin**
 exon VII splicing variant
 expression, uterine endometrial cancers, 5579
- σ_2 receptors**
 tumor cell proliferation biomarkers, breast cancer, 156
- Simian virus 40**
 albumin T antigen
 chromosomal changes, rat liver neoplasms, 3451
 early region T antigen, brain tumors, 3319
 large T antigen
 brain tumors, 3319
- Sister chromatid exchange**
 extracellular factors and α particles, 2164
- Skin**
 autografts, epidermodysplasia verruciformis, 4214
 fibroblasts
 UV-induced G₁ arrest, 3390
 UV-associated telomerase activity, 370
- Skin carcinoma**
 antioxidant enzymes and, 1469
 basal cell
 PTCH mutations, 2581
 smoh expression, preferential, 4731
 ornithine decarboxylase overexpression and, mouse, 2630
 UVB-induced
 SCID mice, 2081
 tea, decaffeinated tea, and caffeine and, 2623
 XPA knockout mice, 581
- Skin tumors**
 chloroethylnitrosourea-induced
 MGMT protective effects against, 3331
 UVA-induced
 p53 mutations, mice, 1238
- SLC2A2**
 amplification, squamous cell carcinoma of lung, 2290
- Smad gene**
 mutation frequency, cancers, 2578
- Smad4 gene**
 inactivation, gastric carcinomas, 4221
- SMAD5 gene**
 localization and evaluation, 3779
- Small cell lung cancer**
 apoptosis
 induction by quinoxalines, 2203
 cadherin-mediated adhesion
 regulation by Rho, 1785
 chromosome 9 tumor suppressor loci, identification, 400
 etoposide chemotherapy
 mutagenic effects, 4393
 growth inhibition
 [D-Arg¹, D-Trp^{5,7,9}, Leu¹¹] substance P, 51
 quinoxalines, 2203
 protein synthesis
 inhibition by DAB₃₈₉ GRP fusion toxin, 290
 topoisomerase II α nuclear localization signal, 4451
- SMOH gene**
 preferential expression, basal cell carcinoma, 4731
- Smoking**
 and colorectal cancer, 4787
 head and neck squamous cell carcinoma
 p53 mutations, 4070
 lung cancers
 DNA hypermethylation, 4913
 FHIT gene alterations and, 2121
- Smoothed (SMOH) gene**
 preferential expression, basal cell carcinoma, 4731
- Social housing**
 and chemotherapy response, Shionogi mouse mammary carcinoma, 1124
- Sodium arsenite**
 cytogenetic alterations, fibroblasts, 5051
- Sodium borocaptate**
 intracarotid
 combined with boron neutron capture therapy, brain tumors, 1129
- Sodium phenylacetate**
 combined with tamoxifen
 antiproliferative effects, MCF-7ras tumors, 1023
 growth inhibitory effects, ovarian carcinoma cells, 4309
- Soft tissue sarcoma**
 lung FMSF, purification and characterization, 3577

- tion, 3577
- Solid tumors**
- advanced
 - magnetic drug targeting, 4'-epidoxorubicin, 3063
 - combined radioimmunotherapy and radiotherapy
 - timing effects, 1312
 - extracellular fluid adenosine, 2602
 - humanized anti-VEGF MAb therapy, 4593
 - malignant
 - chromosomal imbalance maps, 2765
 - multidrug resistant
 - combination liposomal doxorubicin and PSC 833 therapy, 5246
- Somatostatin**
- receptor sst2
 - tumorigenicity reversal, pancreatic cancer cells, 956
- SOS**
- and cancer proneness, 4384
- Spectral karyotyping**
- multicolor
 - mouse plasmacytomas, 4585
- Spectroscopy**
- magnetic resonance
 - pancreatic cancer studies, 1452
 - prostate tissue, 3398
 - nuclear magnetic resonance
 - pretreatment chemotherapeutic response prediction, glioma, 4196
- Spermatogenesis**
- hormonal protection, 1091
- Sperm fluids**
- SV40 early region and large T antigen, 3319
- Spermine**
- analogs
 - cell cycle arrest and apoptosis, melanoma cells, 5521
- Sphingomyelinase**
- activation
 - combined with ionizing radiation, apoptotic effects, 4340
- Sphinxolides**
- microfilament depletion, 3751
- Spontaneous carcinogenesis**
- p53-independent
 - induction by calorie restriction, mice, 2843
- Sporadic carcinoma**
- basal cell
 - PTCH* mRNA expression, 2336
 - PTCH* mutations, 2581
 - breast
 - BRCA1* methylation, 3347
 - FHIT/FRA3B* abnormalities, 3664
- Sporadic gastrinomas**
- MEN1* mutations, 4682
- Sporadic insulinomas**
- MEN1* mutations, 4682
- Sporadic medulloblastoma**
- PTCH* mutations, 842
- Sporadic pheochromocytomas**
- glial cell line-derived neurotrophic factor mutations, 310
- Sporadic tumors**
- colon
 - hMLH1* gene methylation, 808
 - extracutaneous
 - PTCH* gene mutations, 2369
 - primitive neuroectodermal
 - PTCH* mutations, 2581
- Squamous cell carcinoma: see also specific sites**
- chromosome 18q loss of heterozygosity, 824
 - inhibition
 - cisplatin and vitamin D, murine model, 3759
 - expression, human myeloid leukemia cells, 2732
- Squamous epithelium**
- mucosal
 - mucin-like glycoprotein, 634
- SR-4554**
- preclinical evaluation, 3314
- Src tyrosine kinase**
- activation by thapsigargin, 3168
- SSeCKS**
- src*-induced transformation suppression, 2304
- Stem cells**
- high-dose chemotherapy support
 - thrombopoietin serum levels, 5037
- Steroids**
- antiestrogens, 3486
 - class I HLA down-regulation
 - HPV and, cervical tumor cells, 937
 - receptors
 - expression, and cell proliferation, breast, 4987
- Stockholm**
- inherited *BRCA1* mutations, 2474
- Stomach cancer: see Gastric carcinoma**
- Stomach mucosa**
- MHC induction by MNNG, rat, 1416
- Stress**
- oxidative
 - ara-C toxicity, 2446
 - retinoic acid-induced apoptosis, 4916
- Stress-activated protein kinase/Jun N-terminal kinase**
- modulation by TGF- β , breast cancer cells, 628
- Stroma**
- tumor-stromal interactions
 - HGF-mediated, analysis, 3305
- Subependyma**
- apoptosis, adult rats, 2694
- Substance P**
- analogue [D-Arg¹, D-Trp^{5,7,9}, Leu¹¹]SP
 - growth inhibition, small cell lung cancer cells, 51
- N-Succinimidyl 5-iodo-3-pyridinecarboxylate**
- mAb L8A4 labeling, radioiodination, 1510
- SUIT-2 cells**
- P-selectin expression, 1206
- Sulfone**
- sulindac metabolite
 - mammary carcinogenesis inhibition, 267
- Sulfonamide**
- cancer chemoprevention, 272
- Sulfuraphane**
- effects on CYPs and GSTs, hepatocytes, 3649
- Sulindac**
- apoptosis modulation, colon cancer, 1301
 - growth inhibition, mechanism, 2452
 - tumor regression, prostaglandin-independent, 4267
- Sulindac sulfone**
- colon carcinogenesis inhibition, rats, 2909
 - mammary carcinogenesis inhibition, 267
- Sunlight**
- induced pyrimidine dimers, 4727
- Superficial bladder cancer**
- vascular endothelial growth factor, 5281
- Superoxide anions**
- production
 - initiation by α particles, 3963
- Superoxide dismutase**
- manganese-containing
 - TNF- α and/or hyperthermia resistance and, 1991
 - and skin carcinogenesis, 1469
- Survival factor receptors**
- toxin-induced increase, 2404
- Synthetase**
- 2-5A
- T**
- Tac**
- anti-Tac disulfide-stabilized Fv fragment, radiolabeled
 - biodistribution, circulating soluble IL-2 receptor α blockade and, 1955
- Tamoxifen**
- CD36 expression down-regulation, breast tissue, 378
 - chronic
 - DNA adducts, rat, 1438
 - combined with B-428
 - tumor invasion and metastasis prevention, breast cancer, 3585
 - combined with sodium phenylacetate
 - antiproliferative effects, MCF-7 *ras* tumors, 1023
 - cross-resistance, MCH7/LCC9, 3486
 - DNA adducts
 - endometrium, breast cancer, 4148
 - gene mutations, *lacI* transgenic rat livers, 1288
 - growth inhibition, cholangiocarcinoma, 1743
 - 4-hydroxylation
 - catalysis by CYP2D6, liver, 3402
 - hypoxia induction, MCF-7 xenografts, 5155
 - IGF-IR signaling modulation, breast cancer, 2606
 - resistant breast cancer
 - estrogen receptor DNA binding, 3723
 - synergy with cisplatin, melanoma cells, 2657
 - tumor invasion and metastasis prevention, breast cancer, 3585
- OH-Tamoxifen**
- stimulatory effects
 - blockade by EM-800, human endometrial cells, 3494
- Taxanes**
- CA-125 expression modulation, ovarian carcinoma cells, 3818
- Taxol: see also Paclitaxel**
- angiogenesis and breast cancer inhibition, mice, 81
 - resistance, ovarian carcinoma spheroids, 2388
- TCL3 gene**
- transformation, 337
- T47-D cells**
- human glandular hk2 expression, 2651
- Tea**
- decaffeinated
 - and UVB-induced skin carcinogenesis, SKH-1 mice, 2623
 - polyphenols
 - AP-1 and cell transformation inhibition, 4414
 - and UVB-induced skin carcinogenesis, SKH-1 mice, 2623
- Telomerase**
- activity
 - and cell cycle regulation, breast cancer, 549
 - endometrial carcinoma, 2760
 - endometrium, 610, 2760
 - follicular thyroid tumors, 2144
 - in situ* telomeric repeat amplification protocol assay, 2100
 - mammary gland, rat, 5605
 - pancreatic cancer, 326
 - UV-associated, skin, 370
- assay**
- cervical lesion screening, 1863
- expression, respiratory epithelium, 2373**
- TEP1**
- novel protein tyrosine phosphatase, cloning

- and characterization, 2124
- Teratoma**
ovarian
susceptibility, murine, 590
- Testicular germ cell cancer**
trinucleotide expansions, 209
- Testicular tumors**
trinucleotide expansions, 209
- Testis**
cyclin A1, characterization, 913
procarbazine damage
hormonal protection against, 1091
- 2,3,7,8-Tetrachlorodibenzo-p-dioxin**
intrachromosomal recombination, 4378
- Tetracycline**
-regulatable TNF- α expression, adenovirus, 3339
- 12-O-Tetradecanoyl-phorbol-13-acetate**
-induced MMP-9 cell surface association, 3159
- Tetrahydrothiophenium ion**
busulfan conjugation, age-dependent, 5509
- Tetrasomy**
low-grade intraepithelial lesions, 4210
- Thapsigargin**
Src, Raf-1, and MAP kinase activation, 3168
- Theaflavins**
AP-1 and cell transformation inhibition, 4414
- Thioredoxin**
apoptosis inhibition, 5162
- Thioredoxin reductase**
regulation by selenium, cancer cells, 4965
- Thrombopoietin**
serum levels, high-dose chemotherapy and stem cell support, 5037
- Thrombospondin 1**
apoptosis induction, endothelial cells, 1735
gene expression
regulation by ATF-1, 5060
mRNA expression, breast tissues, 396
- Thrombospondin 2**
mRNA expression, breast tissues, 396
- Thymidine phosphorylase**
regulation
tumor microenvironmental, breast tumor cells, 570
- Thymine-DNA glycosylase**
TDG gene, mapping, 3010
- Thymoma**
RMA
CTL response, 2564
sensitive EL4 mouse cells
protein kinase C η up-regulation, 2209
- Thyroid adenoma**
follicular
chromosome 10q22-23 Cowden Locus
loss of heterozygosity, 500
telomerase activity, 2144
- Thyroid carcinoma**
CD97 dedifferentiation marker, 1798
chromosome 10q22-23 Cowden Locus loss of heterozygosity, 500
differentiated
E-cadherin, 2501
familial medullary
Ret with cysteine mutations, characterization, 2870
follicular
telomerase activity, 2144
medullary
combined radioimmuno-chemotherapy, nude mouse model, 5309
familial, Ret with cysteine mutations, 2870
mRNAs
detection by reverse transcription-PCR, 3792
- papillary
ret/PTC gene rearrangements, children, 1690
- Thyroid neoplasia**
G α mutations, 2358
- Thyroid tumors**
childhood
G α mutations, Chernobyl, 2358
follicular
telomerase activity, 2144
malignant
TBR1 receptor expression, 2071
PTEN deletions and mutations, 4710
- Tirapazamine**
DNA damage
and tumor hypoxia, 2922
- T lymphocytes; see also Cytotoxic T lymphocytes; Lymphocytes**
acute lymphoblastic leukemia
p15 methylation and deletion, 832
p16 deletion, 832
antitumor responses
enhancement by CTLA-4 blockade, 4036
autologous
EBV-induced B-cell lymphoma prevention, SCID mice, 1704
CD4+ CML-specific, production method, 1547
induction by melanoma epitope-MHC class I fusion proteins, 202
inhibition by monocyte chemoattractant protein 1, 4849
leukemia
human T-cell leukemia virus, and myelodysplastic syndrome, 4718
TCL1 gene, adult T-cell leukemia, 5452
leukemia, acute lymphatic
drug-induced apoptosis, FasL-independent mediation, 3331
migration to tumor sites
IL-12-induced, 2216
nuclear protein patterns, 55
receptor
MART-1 peptide-stimulated PBLs and TILs, 5320
TCRG-TCRB trans-rearrangements, SCID mice, 4408
 ζ -chain expression, tumor-infiltrating lymphocytes, renal cell carcinoma, 3517
tumor-associated carbohydrate recognition, 3214
- Tongue carcinogenesis**
inhibition by organoselenium, rat, 3644
- Topotecan**
apoptosis, human cells, 2157
cellular pharmacokinetics and cytotoxicity and pH, 4811
topoisomerase II α levels and etoposide sensitivity and, 1425
- Toremifene**
chronic
DNA adducts, rat, 1438
- OH-Toremifene**
stimulatory effects
blockade by EM-800, human endometrial cells, 3494
- Toxicity**
ara-C
physiological changes, 2446
combretastatin A-4, tumor vasculature, 1829
cytotoxicity
camptothecin, and pH, 4811
camptothecin, potentiation by 7-hydroxytaurosiporine, 4029
etoposide, wild-type p53 effects, 818
flavopiridol synergy with antineoplastic agents, 3375
- ganciclovir, gap junctional intercellular communication-mediated protection, 1699
ifosfamide, chloroacetaldehyde role, 2676
ionizing radiation, DNA mismatch repair, 5143
polymerase β , mammalian cells, 110
radiation, camptothecin derivatives, mediation by mammalian DNA topoisomerase I, 1529
tirapazamine, and tumor hypoxia, 2922
TNF- α and/or hyperthermia, MnSOD and, 1991
topotecan, and pH, 4811
tumor vasculature
combretastatin A-4, 1829
- Toxins**
cotransport with glutathione by multidrug resistance protein, 5232
survival factor receptor increase, 2404
- TP53 gene**
germ-line mutations, Li-Fraumeni families, 3245
- TRAMP cells**
characterization, 3325
- Transactivation**
hepatitis B virus X protein functions, 5137
mutant p53-induced immortalization, mammary epithelial cells, 5584
- Transcription**
estrogen receptor mutant with constitutive activity, 1244
UVB-induced effects
RNA fingerprinting, 3554
- Transcription-coupled repair**
mismatch repair mutants, 3784
- Transcription factors**
AP-1
activity, mammary epithelial cells, 3046
inhibition by inositol hexaphosphate, 2873
inhibition by retinyl methyl ether, breast cancer, 3444
neoplastic transformation response, 3569
AP-2
eps15 interaction, molecular determinants, 240
ATF-1
induction by nickel, and thrombospondin I gene expression, 5060
E2F
radiation-induced S-phase entry, 3640
E2F-1
apoptosis induction, breast and ovarian carcinoma, 4722
p21^{waf1}-mediated phosphorylation inhibition, sarcoma cells, 2193
E2F-4
gene mutations, gastrointestinal tumors, 2350
ETS
hGABP/E4TF1, RB gene promoter activation, 3145
ETS1
antisense oligonucleotides, cell migration inhibition, 2013
HRX/ALL1 protein
cellular localization, 799
Jun-associated
modulation by MnSOD, fibrosarcoma, 5265
Sp3
and topoisomerase II α down-regulation, merbarone resistance, 5004
- Transforming growth factor α**
cell scattering and migration, glioma, 5598
synergy with HBsAg antigen, hepatocellular carcinoma, 3606

Transforming growth factor β

- mitogen-activated protein kinase modulation, breast cancer cells, 628
- p21^{waf1}* induction and growth inhibition *DPC4* and, pancreatic adenocarcinoma cells, 3929
- regulated TEP1, cloning and characterization, 2124
- type II receptor
 - expression, intestinal adenomas, 1638
 - expression, thyroid tumors, 2071
 - expression, tumorigenicity, gastric cancer cells, 2856
 - localization, breast carcinoma cells, 970
 - tumorigenesis and, mammary gland and lung, 5564

Transforming growth factor β 1

- activation
 - deficient, IGFII receptor-mutant tumors, 2543
 - expression, breast cancer, 956
 - hepatocarcinogenesis acceleration, transgenic mice, 2089
 - responsive HPL1 cells, establishment, 4898

Transforming growth factor β 2

- antisense
 - tumor growth inhibition, malignant mesothelioma, 3200

Translation initiation factor eIF4G

- malignant cell transformation, 5041

Trichoepitheliomas

- PTCH* mutations, 4677

Trichostatin A

- caspase-3 and apoptosis induction, 3697

3,3',5-Triiodo-L-thyronine

- cell proliferation, rat pancreas and kidneys, 795

Trinucleotide expansions

- (CAG)_n tracts, testicular germ cell cancer, 209

Trioma cells

- vaccination, B-cell lymphoma, 2346

Triphenylethylene

- antiestrogens, 3486

TrkA

- expression
 - and glioma aggressiveness, 532

TSG101

- gene splicing, breast cancer, 3131
- protein
 - breast cancer cells, identification, 4225

Tumor-associated antigens

- potential HLA-DR-restricted, melanoma FM3 cells, 3238

Tumor-associated carbohydrates

- recognition by T cells, 3214

Tumor blood flow

- enhancement by carbogen and nicotinamide, 5261
- modification by nitric oxide synthase inhibition, 948

Tumor cells: see also specific cells

- cohesion
 - suppression by E- or P-cadherin, 5033
- disseminated
 - detection by RT-PCR, 3106
- loss of imprinting by 5-aza-2'-deoxycytidine, 48
- metastatic
 - trafficking, differential, 3612
- peptide transport, 4118
- radiolabeled polypeptide delivery, 659

Tumor growth: see also Cell growth; Cell proliferation; specific tumors

- inhibition
 - angiostatin, murine hemangioendothelioma, 5277

- antisense TGF- β 2, malignant mesothelioma, 3200
- sulindac, prostaglandin-independent, 4267
- 1400W, 3300
- zidovudine, breast cancer and mammary tumors, 2341

invasive

- hepatocyte growth factor and, 3305

Tumorigenesis: see also Carcinogenesis

- HMGI(Y) rearrangements and, 2276
- inhibition
 - PML* adenovirus, prostate cancer, 1868
- liver
 - Igf2* deletion and, 4615
- lung
 - transforming growth factor β and, transgenic mice, 5564
- mammary gland
 - transforming growth factor β and, transgenic mice, 5564
- MGMT* gene knockout mice, 2415
- neurokinin midline and pleiotrophin role, 1814
- src*-induced
 - suppression by SSeCKS, 2304
- Wilms'
 - H1G* gene inactivation, 4469

Tumorigenicity

- Burkitt's lymphoma
 - p53 role, 2508
- fibroblasts
 - PLC- γ 1 overexpression and, rat 3Y1 cells, 5465
- phenotypes
 - pp60^{c-src} mutational activation and, preneoplastic Syrian hamster embryo cells, 1962
- prostate epithelial cell, FGFR1 and FGFR2 and, 5369

Tumor immunity

- CD40/CD154 interactions and, 2569
- induction by anti-idiotypic antibody, 728

Tumor-infiltrating lymphocytes

- MART-1 peptide-stimulated
 - T-cell receptor repertoire, 5320
- ζ -chain expression, renal cell carcinoma, 3517

Tumor necrosis factor

- and parathyroid hormone-related protein
 - bone effects, 3194
- receptor-interacting protein RIP
 - adaptor molecule CRADD, 615

Tumor necrosis factor α

- biotinylated
 - three-step tumor targeting, 1922
- expression
 - regulatable, adenovirus, 3339
- resistance
 - MnSOD and, 1991
 - prostatic carcinoma cells, 3941
- 3'-untranslated region
 - protein expression regulation, epithelial carcinoma cells, 5426

Tumor progression

- BRCA1* and *BRCA2* mutation carriers, 1222
- hypoxia-inducible factor 1, 5328
- modulation by dietary restriction, p53-deficient mice, 4667
- PACE4* expression and, 5226

Tumors: see also Lesions; Neoplasia; specific sites, tumors

- AD12-induced hamster tumors
 - clonal origin, 3001
- angiogenic
 - induction, ODC-overexpressing cells, 3016
- in vivo* model, 3847

- astrocytic
 - Id* gene expression, 215
- cholecystokinin-A and cholecystokinin-B/gastrin receptors, 1377
- combination
 - uterine carcinosarcoma, molecular evidence, 5379
- hypoxia
 - SR-4554 probe, preclinical evaluation, 3314
 - tirapazamine-induced DNA damage and, 2922
- minimal residual disease
 - metastatic phenotypes, 1394
- MMAC1/PTEN* mutations, 5221
- multicellular spheroids, ovarian carcinoma
 - Taxol resistance, 2388
- radiosensitization
 - p21^{Waf1/Cip1} and, 4703
- rhabdoid
 - GOK* gene involvement, 4493
- solid
 - advanced, magnetic drug targeting, 3063
 - combined radioimmunotherapy and radiotherapy, timing effects, 1312
 - extracellular fluid adenosine, 2602
 - humanized anti-VEGF MAb therapy, 4593
 - malignant, chromosomal imbalance maps, 2765
 - multidrug resistant, combination liposomal doxorubicin and PSC 833 therapy, 5246
- stromal interactions
 - HGF-mediated, analysis, 3305
- T-cell migration, IL-12-induced, 2216
- vascular endothelium
 - mAb to PSMA extracellular domain and, 3629
- vasculature
 - combretastatin A-4 toxicity, 1829

Tumor suppression

- anti-Ras
 - GTPase and Rho GAP p190 domains, 2478
- pathways, pancreatic carcinoma, 1731

Tumor suppressor genes: see also specific genes

- chromosome 3q
 - osteosarcoma, mapping, 106
- chromosome 11
 - organotypic raft culture localization, 1157

Tumor vaccine

- adjuvants
 - cytokine-secreting fibroblasts, 3230

Tunicamycin

- apoptosis induction, 543

Tuscany

- gastric cancer
 - microsatellite instability, 4523

Tyrosinase

- expression, melanoma, 3223

Tyrphostins

- AG17
 - apoptosis and cdk2 inhibition, lymphoma cells, 2434, 5610
- apoptosis induction, small cell lung cancer, 2203
- HPV 16-immortalized keratinocyte suppression, 3741

U

- UCN-01: see 7-Hydroxystaurosporine
- UDP-N-acetyl- α -D-galactosamine:polypeptide GalNAc N-acetylgalactosaminyltransferases
 - expression, adenocarcinoma cells, 4744
- UDP-glucuronosyltransferase
 - UGT1A

- expression, liver tumors, 2979
- Ulcerative hemorrhagic cystitis**
cyclophosphamide-induced
amelioration by keratinocyte growth factor, 472
- Ultraviolet A radiation**
apoptosis
inhibition by bcl-2 overexpression, rat 6 fibroblasts, 1405
cutaneous melanoma, *Monodelphis domestica*, 3682
skin tumors
p53 mutations, mice, 1238
- Ultraviolet B radiation**
keratosis induction, 2081
skin carcinogenesis, 2081
tea, decaffeinated tea, and caffeine and, 2623
XPA knockout mice, 581
transcription effects, RNA fingerprinting, 3554
- Ultraviolet radiation**
G₁ arrest, human skin fibroblasts, 3390
hypermutability, familial melanoma, 4637
light
associated telomerase activity, skin, 370
sensitivity
p53-null cells, caffeine and, 5434
- UM-UC-2 cells**
growth suppression by β 4 integrin, 38
- Urine**
tumor-associated hyaluronic acid, bladder carcinoma, 773
tumor-derived hyaluronidase levels, bladder cancer, 778
- Urokinase**
inhibitors
prostate cancer size reduction, xenografts, 559
- Urokinase-type plasminogen activator**
receptor
blockade, prostate cancer angiogenesis and growth inhibition, 3594
integrin interactions, fibrosarcoma, 1682
minimal residual cancer, 1394
- Uterine carcinosarcoma**
combination tumors, molecular evidence, 5379
- Uterine cervical carcinoma: see Cervical carcinoma**
- Uterine endometrial carcinoma: see Endometrial carcinoma**
- Uterus**
endometrial hyperplasia/apoptosis
neonatal diethylstilbestrol exposure and, hamster, 1903
estrogen-responsive lactoferrin gene demethylation, diethylstilbestrol exposure and, 4356
tamoxifen- and toremifene-induced DNA adducts, rat, 1438
- V**
- Vaccination**
anti-idiotypic
bsAb-producing cells, 2346
trioma-based, B-cell lymphoma, 2346
- Vaccines**
against EGFRvIII, 1419
GM-CSF-transduced renal cell carcinoma, bioactivity, 1537
tumor
adjuvant cytokine-secreting fibroblasts, 3230
- Vascular endothelial cells**
human
- FLT-1 upregulation by VEGF, 5421
- Vascular endothelial growth factor**
anti-VEGF MAb
humanization, solid tumor therapy, 4593
down-regulation by androgen ablation, prostatic cancers, 1054
endothelial cell migration
inhibition by ETS1 antisense oligonucleotides, 2013
expression
breast cancer, 956
superficial bladder cancer, 5281
up-regulation, rat glioma, 3860
FLT-1 upregulation, HUVECs, 5421
initial tumor growth, breast carcinoma cells, 3924
neovasculature
fenestration, 765
receptor 2
ligand-induced up-regulation, cerebral system, 3852
transcription
activation by V-SRC, 5328
repression by p53, 4474
upregulation by FGF-4, 5590
- Vascular endothelium**
tumor
mAb to PSMA extracellular domain and, 3629
- Vasoactive intestinal peptide**
receptors, pancreatic adenocarcinoma, 1475
- Venous blood**
disseminated tumor cells
detection by RT-PCR, gastrointestinal cancer, 3106
- Very late antigen 4**
T-cell migration, IL-12-induced, 2216
- Very late antigen 6**
cell migration and extravasation, liver, 3812
- v-Ha-ras**
MMTV-ras mice
tumor properties, 600
- Vinyl chloride**
hepatic angiosarcoma
connexin 37 mutations, rat, 375
p53 gene mutations, rat, 1695
- Viruses: see also specific viruses**
enhanced reactivation
and cancer proneness, 4384
- Vitamin C**
uptake by melanoma cells and melanocytes, 2529
- Vitamin D**
combined with cisplatin
antitumor activity, murine squamous cell carcinoma model, 3759
- Vitamin D₃**
19-nor-hexafluoride analogue
proliferation inhibition, breast cells, 4545
- Vitamin D-binding protein**
-derived macrophage activating factor
antitumor activity, Ehrlich ascites tumor, 2187
- Vitamin E**
iron cancer inhibition, 2410
- Vitamin E succinate**
apoptosis induction, breast cancer cells, 881
cell proliferation inhibition, breast cancer, 2668
- VLA: see Very late antigen**
- Von Hippel-Lindau tumor**
VHL gene
mutations, glial tumors, 1035
- Vorzole**
intratumoral aromatase inhibition, breast cancer tissue, 2109
- VP-16: see Etoposide**
- v-ras^{Ha}**
-mediated keratinocyte neoplasia
epidermal growth factor receptor role, 3180
- v-src**
HIF-1 induction, 5328
transformation
suppression by SSeCKS, 2304
- W**
- 1400W**
tumor growth inhibition, 3300
- Werner syndrome**
mismatch repair, 2956
- Western lifestyle**
and colorectal cancer, 4787
- Wild-type p53**
G₂ to M transition, 818
mdm2 expression
translational enhancement, 3562
- Wilms' tumor**
familial
genetic heterogeneity, 1855
1-KTS isoforms
apoptosis induction, hepatoma cells, 1353
WT1 gene
p21 induction, 1429
- Wilms' tumorigenesis**
H1G gene inactivation, 4469
- X**
- X antigen**
hepatitis B virus-encoded
hepatocellular carcinoma, p53 integrity, 426
- Xenobiotics**
release from fat, mice, 865
- Xenografts**
colon carcinoma
inhibition by FMdC, mouse xenografts, 4023
colon carcinoma, mixed
BCNU effects, 4817
glioma
SarCNU antitumor activity, xenografts, 3895
MCF-7
hypoxia induction by tamoxifen, 5155
oral squamous carcinoma
ALRT1550 antitumor activity, nude mice, 162
prostate cancer
size reduction by urokinase inhibitors, SCID mice, 559
renal cell carcinoma
inhibition by BCH-4556, 4803
- Xeroderma pigmentosum**
XPA knockout mice
UVB-induced skin cancer, 581
- Y**
- Yeast**
estrogen receptor, functional assay, 3478
- Yeast artificial chromosomes**
human
DNA destabilization by persistent double-strand breaks, 1970
- Z**
- Zidovudine**
growth inhibitory activity, breast cancer and mammary tumors, 2341



